<SEC-DOCUMENT>0001178913-22-002918.txt : 20241204
<SEC-HEADER>0001178913-22-002918.hdr.sgml : 20241204
<ACCEPTANCE-DATETIME>20220804070049
ACCESSION NUMBER:		0001178913-22-002918
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		40
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		221134567

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2228202.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:cgen="http://cgen.com/20220630"  ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>COMPUGEN LTD - 1119774 - 2022</title></head><body>
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20220101to20220630"  id="FFact_306" >0001119774</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="C_20220101to20220630"  id="FFact_307" >--12-31</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20220101to20220630"  id="FFact_309" >false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20220101to20220630"  id="Fdei_DocumentFiscalPeriodFocus20220803133013452" >Q2</ix:nonNumeric><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="C_20220101to20220630"  id="Fdei_DocumentPeriodEndDate20220803135349061" >2022-06-30</ix:nonNumeric></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cgen-20220630.xsd"/>
        </ix:references></ix:header></div><div>
  <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" />
  <div>&#160;</div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNITED STATES</span></span></div>
  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif">SECURITIES AND EXCHANGE COMMISSION</span></span></div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif;margin-bottom:0pt">Washington, D.C. 20549</span></span></div>
  <div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:14pt"><span><span style="font-family:Times New Roman,Times,serif;margin-top:0pt">Form <ix:nonNumeric id="Fxbrl_20220803132217335" name="dei:DocumentType" contextRef="C_20220101to20220630">6-K</ix:nonNumeric></span></span></span></div>
  <div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</span></span></div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNDER THE SECURITIES EXCHANGE ACT OF 1934</span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>For the month of August <ix:nonNumeric id="Fxbrl_20220803135229207" name="dei:DocumentFiscalYearFocus" contextRef="C_20220101to20220630">2022</ix:nonNumeric></span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Commission File Number <ix:nonNumeric id="Fxbrl_20220803132624667" name="dei:EntityFileNumber" contextRef="C_20220101to20220630">000-30902</ix:nonNumeric></span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:16pt;font-weight:bold"><span style="font-size:16pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220803132653437" name="dei:EntityRegistrantName" contextRef="C_20220101to20220630">COMPUGEN LTD.</ix:nonNumeric></span></span></div>
  <div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(Translation of registrant&#8217;s name into English)</span></span></span></div>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

      <tr>
        <td style="width:100%;vertical-align:middle">
          <div style="line-height:1.25">&#160;</div>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20220803132710165" name="dei:EntityAddressAddressLine1" contextRef="C_20220101to20220630">26 Harokmim Street</ix:nonNumeric></span></span></span></div>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20220803132729395" name="dei:EntityAddressCityOrTown" contextRef="C_20220101to20220630">Holon</ix:nonNumeric> <ix:nonNumeric id="Fxbrl_20220803132743972" name="dei:EntityAddressPostalZipCode" contextRef="C_20220101to20220630">5885849</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20220803132757086" name="dei:EntityAddressCountry" contextRef="C_20220101to20220630" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></span></div>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(Address of Principal Executive Offices) </span></span></span></div>
        </td>
      </tr>

  </table>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:<br />&#160;</span></span></span></div>
  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Form 20-F &#9746;&#160; &#160; &#160; &#160; &#160; Form 40-F &#9744;</span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160; &#160; &#160; &#160;&#9744;</span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160; &#160; &#160; &#160;&#9744;</span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
    <div style="page-break-after:always">
      <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
    </div>
  </div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Compugen Ltd.</span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25">
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On August 4, 2022, Compugen Ltd. (the &#8220;<span style="font-weight:bold">Company</span>&#8221;) issued a press release, a copy of which is furnished as Exhibit 99.1 to this Report on Form 6-K and, excluding the 1<sup style="vertical-align:text-top;line-height:1;font-size:smaller">st</sup>, 2<sup style="vertical-align:text-top;line-height:1;font-size:smaller">nd, </sup>3<sup style="vertical-align:text-top;line-height:1;font-size:smaller">rd</sup> and 4<sup style="vertical-align:text-top;line-height:1;font-size:smaller">th</sup> paragraphs under the heading &#8220;Corporate Update&#8221; and the sections titled &#8220;Conference call and webcast information&#8221; and &#8220;Forward-Looking Statement,&#8221; is incorporated by reference herein.</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
    <div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Second Quarter 2022 Financial Results</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
  </div>
  <div style="line-height:1.25">
    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The unaudited interim consolidated financial statements of the Company and its subsidiary as of June 30, 2022 and December 31, 2021 and for the six&#160;months ended June 30, 2022 and 2021 are furnished as Exhibit 99.2 to this Report on Form 6-K and incorporated by reference herein. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition of the Company as of and for the six months ended June 30, 2022 are furnished as Exhibit 99.3 to this Report on Form 6-K and incorporated by reference herein.</span></span></span></div>
  </div>
  <div style="line-height:1.25">
    <div style="line-height:1.25">&#160;</div>
    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The information contained in this Report on Form 6-K is hereby incorporated by reference into the Company&#8217;s Registration Statement on Form F-3, File No. 333-240183.</span></span></span></div>
    <div style="line-height:1.25">&#160;</div>
  </div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Exhibits</span></span></span></div>
  <div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>
  <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Exhibit</span></span></span></div>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

      <tr>
        <td style="width:72pt;vertical-align:top;align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold;text-decoration:underline">Number</span></span></span></span></td>
        <td style="width:auto;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="font-weight:bold;text-decoration:underline">Description of Exhibit</span></span></span></span></td>
      </tr>

  </table>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

      <tr>
        <td style="width:72pt;vertical-align:top;align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-1.htm">99.1</a></span></span></span></td>
        <td style="width:auto;vertical-align:top">
          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-1.htm">Press Release dated August 4, 2022.</a></span></span></span></div>
        </td>
      </tr>

  </table>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

      <tr>
        <td style="width:72pt;vertical-align:top;align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-2.htm">99.2</a></span></span></span></td>
        <td style="width:auto;vertical-align:top">
          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-2.htm">Unaudited interim consolidated financial statements as of June 30, 2022 and December 31, 2021 and for the&#160;six months ended June 30, 2022 and 2021.</a></span></span></span></div>
        </td>
      </tr>

  </table>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

      <tr>
        <td style="width:72pt;vertical-align:top;align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-3.htm">99.3</a></span></span></span></td>
        <td style="width:auto;vertical-align:top">
          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="exhibit_99-3.htm">Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition of the Company as of and for the six months ended June 30, 2022.</a></span></span></span></div>
        </td>
      </tr>

  </table>
  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

      <tr>
        <td style="width:72pt;vertical-align:top;align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>101</span></span></span></td>
        <td style="width:auto;vertical-align:top">
          <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The following financial information from Compugen Ltd.&#8217;s Report on Form 6-K, formatted in Inline XBRL (ieXtensible Business Reporting Language): (i) consolidated balance sheets as of June 30, 2022 and December 31, 2021; (ii) consolidated statements of comprehensive loss for the six months ended June 30, 2022 and 2021; (iii) consolidated statements of changes in shareholders&#8217; equity for the six months ended June 30, 2022 and 2021; (iv) consolidated statements of cash flows for the six months ended June 30, 2022 and 2021; and (v) notes to the consolidated financial statements.</span></span></span></div>
        </td>
      </tr>

  </table>
  <div style="line-height:1.25">&#160;</div>
  <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
    <div style="page-break-after:always">
      <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
    </div>
  </div>
  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Signatures</span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></span></span></div>
  <div style="line-height:1.25">&#160;</div>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000" width="100%">

      <tr>
        <td style="vertical-align:bottom">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td colspan="3" style="vertical-align:bottom">
          <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>COMPUGEN LTD.</span></span></span></div>
        </td>
      </tr>
      <tr>
        <td colspan="4" style="vertical-align:middle">
          <div style="line-height:1.25">&#160;</div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:50%">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Date: August 4, 2022</span></span></span></div>
        </td>
        <td style="vertical-align:bottom;width:3%">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>By: </span></span></span></div>
        </td>
        <td style="vertical-align:bottom;width:35%">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="text-decoration:underline">/s/ Eran Ben Dor</span></span></span></span></div>
        </td>
        <td style="vertical-align:bottom;width:12%">
          <div style="text-align:center;line-height:1.25">&#160;</div>
        </td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;width:50%">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td style="vertical-align:bottom;width:3%">
          <div style="line-height:1.25">&#160;</div>
        </td>
        <td style="vertical-align:bottom;width:35%">
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Eran Ben Dor</span></span></span></div>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>General Counsel</span></span></span></div>
        </td>
        <td style="vertical-align:bottom;width:12%">
          <div style="text-align:center;line-height:1.25">&#160;</div>
        </td>
      </tr>

  </table>
  <div style="line-height:1.25">&#160;</div>
  <div>
    <hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" />
  </div>
</div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;"> Exhibit 99.1</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="line-height: 1.25;"><img width="128" height="53" src="image00001.jpg"></div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">FOR IMMEDIATE RELEASE:</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Compugen Reports Second Quarter 2022 Results</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zb441ed521f1544f29f7ebda6349e7388" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 17.85pt; vertical-align: top; align: right;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="line-height: 1.25;">Prioritized two indications, MSS-CRC and NSCLC, utilizing fully owned assets, COM701 and COM902</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z872fce2a31344e8cae7eb41dbcf7a538" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 17.85pt; vertical-align: top; align: right;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="line-height: 1.25;">Focus on MSS-CRC and NSCLC expected to provide highest probability of success and support future path to registration</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zb3796c8cec1c452c9411a5a2dfa00684" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 17.85pt; vertical-align: top; align: right;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="line-height: 1.25;">Focused development plan results in strategic decision to wind down Phase 1 cohort expansion studies resulting in the
                  conclusion of collaboration with Bristol Myers Squibb</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zeb4b1605acee41deb16fa8bd397a4cc5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 17.85pt; vertical-align: top; align: right;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="line-height: 1.25;">Most advanced preclinical program with first-in-class potential entering pre-IND enabling studies</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zee774da89bcd4c2bb26b8ac8565df8cc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 17.85pt; vertical-align: top; align: right;">
                <div style="line-height: 1.25;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="line-height: 1.25;">Extended cash runway expected to last through the end of 2024</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">HOLON, ISRAEL, August 4, 2022 &#8211;&#8211; <u>Compugen Ltd.</u>
        (Nasdaq: CGEN),<font style="font-weight: bold;">&#160;</font>a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, provided a corporate update and
        announced financial results for the second quarter ended June 30, 2022.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Corporate Update</div>
      <div style="line-height: 1.25;">&#8220;Adapting to challenging market conditions, we have taken a strategic decision to focus on two prioritized indications, microsatellite
        stable-colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC), and wind down our broad Phase 1 cohort expansion program resulting in the conclusion of our collaboration with Bristol Myers Squibb,&#8221; said Anat Cohen-Dayag, Ph.D.,
        President, and Chief Executive Officer of Compugen. &#8220;I would like to thank Bristol Myers Squibb for our productive interactions and for their support in providing nivolumab and their anti-TIGIT, BMS-986207, enabling us to initiate the triple and
        dual combination studies to evaluate our DNAM-1 axis hypothesis at a time when our own differentiated anti-TIGIT, COM902 had not yet reached the clinic. Additionally, my sincere thanks to the investigators, their staff, and the patients for
        participating in these studies. This strategic decision allows us to extend our cash runway into the end of 2024, execute on our strong belief in COM701 and gives us the freedom to switch to and develop our own differentiated anti-TIGIT antibody,
        COM902. Concluding the collaboration with Bristol Myers Squibb provides us with what is expected to be the greatest opportunity to advance and partner our clinical assets
          and support a future path to registration.&#8221;</div>
      <div style="line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">Dr. Cohen-Dayag continued, &#8220;Our clinical data from the COM701/nivolumab dose escalation and cohort expansion study in a small number of
          MSS-CRC patients, show a modestly higher response rate compared to what has been reported for standard of care. We believe that this initial data, along with the translational package showing a COM701 driven mechanism, supports the evaluation of
          COM701 triple combination in a single arm study. The full data from the COM701/nivolumab cohort expansion study in MSS-CRC and details of the new study design along with timelines is expected to be presented once finalized in the fourth quarter
          of this year. The second indication we have prioritized is NSCLC in anti-PD-(L)1 treated patients. As an inflamed tumor type sensitive to PD-1 and possibly TIGIT checkpoints, NSCLC was selected as a tumor type with increased probability of
          responding to our triplet combination. We also plan to evaluate the blockade of PVRIG and TIGIT in combination with standard of care in this indication, to build
          an additional path to randomized studies. The design and timelines of the NSCLC program will be presented once finalized in the fourth quarter of this year. We believe focusing on these indications provides us with the highest probability of
          success, and we plan to share the progress and initial findings from these studies during 2023.&#8221;</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">Dr. Cohen-Dayag added, &#8220;I am also extremely proud of
            the progress we have made in our preclinical portfolio. Several early-stage programs from our computational discovery platform are advancing in our pipeline with the most advanced program about to enter pre-IND enabling studies with
            first-in-class potential. We are very excited about this program, which is
            targeting a soluble immune checkpoint upregulated in the tumor microenvironment in response to IFN-&#947;. We developed a very high affinity antibody, COM503, to block this soluble immune checkpoint pathway and we believe we are the first to do so. The antibody has demonstrated preclinical&#160;<font style="font-style: italic;">in-vitro</font>&#160;and&#160;<font style="font-style: italic;">in-vivo</font>&#160;activity as monotherapy and in combination with other checkpoint inhibitors across various models and systems. We intend to share details on this program in the fourth quarter of this year.&#8221;</div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Dr. Cohen-Dayag concluded, &#8220;With the decisive actions we have taken, we are being cash efficient and may be better positioned to bring
        value to our stakeholders. I am excited with what we have achieved and look forward to continuing to focus on execution and delivering value to our shareholders and patients.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Financial Results</div>
      <div style="text-align: justify; line-height: 1.25;">As of June 30, 2022, cash, cash equivalents, short-term bank deposits and restricted cash totaled approximately $97 million, compared
        with approximately $118 million as of December 31, 2021. As a result of the Company&#8217;s strategic decision to end its Phase 1 program early and focus on two prioritized indications, the Company expects its existing cash and cash related balances to be sufficient to fund its operating plan into the end of 2024, without taking
          into consideration any cash inflows. Compugen does not have any debt.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">R&amp;D expenses for the second quarter ended June 30, 2022, were approximately $6.8 million, no change from the comparable period in
        2021. Going into the second half of 2022, the reduction in R&amp;D expenses is expected to be limited and will reflect winding down expenses of the current ongoing studies as well as preparation for the planned prioritized clinical studies. We
        expect that the full effect of the reduction in expenses will be reflected in 2023.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">General and administrative expenses for the second quarter ended June 30, 2022, were approximately $2.6 million compared with
        approximately $2.7 million for the comparable period in 2021.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Cash balance at the end of 2022 is expected to be approximately $72-$74 million.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Net loss for the second quarter ended June 30, 2022, was approximately $9.1 million, or $0.11 per basic and diluted share, compared with
        a net loss of approximately $9.5 million, or $0.11 per basic and diluted share, in the comparable period of 2021.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Full financial tables are included below</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Conference call and webcast information</div>
      <div style="line-height: 1.25;">The Company will hold a conference call today, August 4,
          2022, at 8:30 AM ET to review its second quarter 2022 results. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through
          Compugen&#8217;s website, located at the following <u>link.</u> Following the live
          audio webcast, a replay will be available on the Company's website.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">About&#160;Compugen</div>
      <div style="line-height: 1.25;">Compugen&#160;is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies.&#160;Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902,&#160;a
          potential best-in-class monoclonal antibody targeting TIGIT for the treatment of solid tumors. Partnered programs include bapotulimab, an antibody targeting ILDR2, in Phase 1 development, licensed to Bayer under a research and discovery
          collaboration and license agreement, and a TIGIT/PD-1 bispecific derived from COM902 (AZD2936) in Phase 1/2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies.&#160;In addition, the
          Company&#8217;s therapeutic pipeline of early-stage&#160;immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. Compugen&#160;is headquartered in Israel, with offices in South San Francisco, CA.&#160;Compugen&#8217;s&#160;shares are listed on Nasdaq and the Tel Aviv&#160;Stock Exchange under the ticker symbol CGEN.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Forward-Looking Statement</div>
      <div style="line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221;
          within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current
          beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221;
          &#8220;confident,&#8221; and &#8220;intends,&#8221; and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to,
          statements regarding our expectations that the conclusion of the collaboration with Bristol Myers Squibb provides Compugen with the greatest opportunity to
          advance and partner its clinical assets and support a future path to registration; our belief that the initial clinical data from the COM701/nivolumab cohort
          expansion study in a small number of MSS-CRC patients,&#160;along with the translational package showing a COM701 driven mechanism, supports further evaluation of
          COM701 triple combination in a single arm study; statements regarding the increased probability of NSCLC to respond to our triplet combination; statements regarding our expectations that our focus on MSS-CRC and NSCLC indications is
        expected to provide highest probability of success to support a future path to registration; statements regarding the potential of our most advanced preclinical program
          to be first-in-class; our expectation that existing cash and cash related balances will be sufficient to fund our operating plan through the end of 2024; and our expectations regarding the timing for disclosure of the new studies design and data.  These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or
          achievements expressed or implied by such forward-looking statements. Among these risks: In the near term, Compugen is highly dependent on the success of COM701 and of COM902; Compugen may not be able to advance its internal clinical stage
          programs through clinical development or manufacturing or successfully partner or commercialize them, or obtain marketing approval, either alone or with a collaborator, or may experience significant delays in doing so; Clinical development
          involves a lengthy and expensive process, with an uncertain outcome and Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific product or may not be able to conduct or complete its trials on the
          timelines it expects; Compugen has limited experience in the development of therapeutic product candidates, and it may be unable to implement its business strategy. These risks and other risks are more fully discussed in the &#8220;Risk Factors&#8221;
          section of Compugen&#8217;s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any
          forward-looking statements represent Compugen&#8217;s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking
          statements unless required by law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">Company contact:</font><br>
        Yvonne Naughton, Ph.D.</div>
      <div style="line-height: 1.25;">Head of Investor Relations and Corporate Communications Compugen Ltd.</div>
      <div style="line-height: 1.25;">Email: <u>ir@cgen.com</u></div>
      <div style="line-height: 1.25;">Tel: +1 (628) 241-0071</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z4bf4b4cf930a44fcbebf3ad38257f76c" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: top;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except for share and per share amounts)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z519f959f11ac4125b03099014dd9b97d" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Three Months Ended</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Six Months Ended,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> June 30,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">June 30,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2022</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2022</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Operating expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 52%;">
              <div style="line-height: 1.25;">Research and development expenses</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">6,812</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">6,797</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">13,982</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">14,123</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%;">
              <div style="line-height: 1.25;">Marketing and business development expenses</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">255</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">241</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">478</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">465</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">General and administrative expenses</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,570</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,659</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">5,173</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">5,373</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%; padding-bottom: 2px;">
              <div style="line-height: 1.25; font-weight: bold;">Total operating expenses</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">9,637</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">9,697</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">19,633</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">19,961</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Financial and other income, net</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">493</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">200</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">779</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">559</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%;">
              <div style="line-height: 1.25; font-weight: bold;">Loss before taxes on income</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(9,144</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(9,497</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(18,854</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(19,402</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Taxes on income</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%; padding-bottom: 4px;">
              <div style="line-height: 1.25; font-weight: bold;">Net loss</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(9,144</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(9,497</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(18,854</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">(19,402</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25; font-weight: bold;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 52%;">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; background-color: rgb(204, 238, 255); width: 52%;">
              <div style="line-height: 1.25;">Basic and diluted net loss per ordinary share</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">(0.11</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">(0.11</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">(0.22</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">(0.23</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="line-height: 1.25;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; width: 52%;">
              <div style="line-height: 1.25;">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">86,518,714</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">83,799,634</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">86,486,612</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">83,739,983</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z2947a97d74544e3ba3c06cbd1524db85" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONDENSED CONSOLIDATED BALANCE SHEETS DATA</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">(U.S. dollars, in thousands)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z23b9fe21fe364c05a4507b64ff7a4dec" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> June 30,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2022</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Unaudited</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">ASSETS</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Cash, cash equivalents, short-term bank deposits and restricted cash</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">97,288</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">117,762</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Other accounts receivable and prepaid expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">4,696</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">5,460</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25; font-weight: bold;">Total current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">101,984</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">123,222</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; font-weight: bold;">Non-current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Long-term prepaid expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,906</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,911</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Severance pay fund</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,866</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">3,125</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Operating lease right to use asset</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,952</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,247</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Property and equipment, net</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,604</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,658</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total non-current assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">8,328</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">8,941</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total assets</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">110,312</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">132,163</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">LIABILITIES AND SHAREHOLDERS EQUITY</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Other accounts payable, accrued expenses and trade payables</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">10,474</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">12,699</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Current maturity of operating lease liability</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">615</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">768</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Short-term deferred participation in R&amp;D expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,906</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">3,629</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">13,995</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">17,096</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Non-current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Long-term deferred participation in R&amp;D expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,051</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">2,715</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Long-term operating lease liability</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,491</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">1,982</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Accrued severance pay</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">3,394</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">3,677</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total non-current liabilities</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">5,936</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">8,374</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total shareholders' equity</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">90,381</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">106,693</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">Total liabilities and shareholders' equity</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">110,312</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25; font-weight: bold;">132,163</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>exhibit_99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:cgen="http://cgen.com/20220630"  ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>COMPUGEN LTD - 1119774 - 2022</title></head><body>
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"  id="Fxbrl_20220727222920490" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"  id="Fxbrl_20220727223630806" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:nonFraction name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"  id="Fxbrl_20220727223653597" unitRef="usd"  xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"  id="Fxbrl_20220727223710614" unitRef="usd"  xsi:nil="true"></ix:nonFraction></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cgen-20220630.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20220101to20220630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210630_usgaapSupplyCommitmentAxis_cgenCollaborationAgreementWithUSAntibodyCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">cgen:CollaborationAgreementWithUSAntibodyCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapSupplyCommitmentAxis_cgenCollaborationAgreementWithUSAntibodyCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">cgen:CollaborationAgreementWithUSAntibodyCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:CommercialLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-01-05</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-06-14</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-14</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210630_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210630_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-10-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-03-01</xbrli:startDate>
        <xbrli:endDate>2020-03-16</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-14</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210630_srtRangeAxis_srtMinimumMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210630_srtRangeAxis_srtMaximumMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130801to20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2013-08-01</xbrli:startDate>
        <xbrli:endDate>2013-08-05</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2013-08-05</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180301to20180330"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180330"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-03-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211130"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:unit id="ILSPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<ix:relationship fromRefs="Fxbrl_20220727222920490" toRefs="FN20220727223934071"/><ix:relationship fromRefs="Fxbrl_20220727223630806" toRefs="FN20220727223934071"/><ix:relationship fromRefs="Fxbrl_20220727223653597" toRefs="FN20220727223934071"/><ix:relationship fromRefs="Fxbrl_20220727223710614" toRefs="FN20220727223934071"/><ix:relationship fromRefs="FFact_298" toRefs="FN20220720121444312"/><ix:relationship fromRefs="FFact_299" toRefs="FN20220720121444312"/><ix:relationship fromRefs="FFact_300" toRefs="FN20220720121444312"/><ix:relationship fromRefs="FFact_301" toRefs="FN20220720121444312"/></ix:resources></ix:header></div><div><div><div><hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" /></div><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="text-decoration:underline"><strong>Exhibit 99.2</strong></span></p><div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INTERIM CONSOLIDATED FINANCIAL STATEMENTS</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AS OF JUNE 30, 2022</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. DOLLARS IN THOUSANDS</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INDEX</span></span></div><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><div style="line-height:1.25"><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div></div></td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#BALANCESHEETS">Consolidated Balance Sheets</a></span></span></div></td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-2 - F-3</span></span></div></td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#COMPREHENSIVELOSS">Consolidated Statements of Comprehensive Loss</a></span></span></div></td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-4</span></span></div></td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#SHAREHOLDERSEQUITY">Consolidated Statements of Changes in Shareholders' Equity</a></span></span></div></td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-5</span></span></div></td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CASHFLOWS">Consolidated Statements of Cash Flows</a></span></span></div></td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-6</span></span></div></td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif">&#160;</td></tr><tr><td style="width:85.36%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#FINANCIALSTATEMENTS">Notes to Consolidated Financial Statements</a></span></span></div></td><td style="width:14.64%;vertical-align:bottom;font-family:'Times New Roman',Times,serif"><div style="text-align:center;margin-left:2.85pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>F-7 - F-14</span></span></span></span></div></td></tr></table><div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">- - - - - - - - - - - - -</span></span></div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div></div></div>
  <div>
    <div style="font-family:'Times New Roman',Times,serif">
      <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><a id="BALANCESHEETS"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED BALANCE SHEETS</span></span>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASSETS</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT ASSETS:</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,008</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,801</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">363</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_4" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">713</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term bank deposits</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_5" name="us-gaap:OtherShortTermInvestments" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,917</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_6" name="us-gaap:OtherShortTermInvestments" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,248</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other accounts receivable and prepaid expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,696</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_10" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,460</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> current assets</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_11" name="us-gaap:AssetsCurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,984</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_12" name="us-gaap:AssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,222</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT ASSETS:</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term prepaid expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_13" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,906</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_14" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,911</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Severance pay fund</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_15" name="cgen:SeverancePayFundNonCurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,866</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_16" name="cgen:SeverancePayFundNonCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,125</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right to use asset</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_17" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,952</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_18" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,247</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment, net</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_19" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,604</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_20" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,658</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> non-current assets</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_21" name="us-gaap:AssetsNoncurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,328</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_22" name="us-gaap:AssetsNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,941</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> assets</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_23" name="us-gaap:Assets" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,312</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_24" name="us-gaap:Assets" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,163</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>

    </table>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">F - 2</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div>
        <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
      </div>
    </div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED BALANCE SHEETS</span></span>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share data)</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LIABILITIES AND SHAREHOLDERS' EQUITY</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT LIABILITIES:</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="F20220719213713620_0" name="us-gaap:AccountsPayableCurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,154</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="F20220719213713621_1" name="us-gaap:AccountsPayableCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,621</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term deferred participation in R&#38;D expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713621_2" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,906</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713622_3" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,629</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current maturity of operating lease liability</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713622_4" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">615</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713622_5" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other accounts payable and accrued expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713623_6" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,320</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713623_7" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,078</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> current liabilities</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713623_8" name="us-gaap:LiabilitiesCurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,995</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713623_9" name="us-gaap:LiabilitiesCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,096</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON- CURRENT LIABILITIES:</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term deferred participation in R&#38;D expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713624_10" name="cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,051</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713624_11" name="cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,715</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long term operating lease liability</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713624_12" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713625_13" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,982</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued severance pay</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713625_14" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,394</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713625_15" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,677</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> non-current liabilities</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713627_16" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,936</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713627_17" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,374</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><ix:nonFraction id="Fxbrl_20220720111940687_20220719213713627_16" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20220630" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"><ix:nonFraction id="Fxbrl_20220720111940687_20220719213713627_17" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20211231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS' EQUITY:</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share capital:</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-indent:0px;margin-left:25.5pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares of NIS <ix:nonFraction id="Fxbrl_20220719214834949" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20211231" unitRef="ILSPerShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713628_18" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20220630" unitRef="ILSPerShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="Fxbrl_20220719214917721" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713628_20" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20220630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized on June 30, 2022, and December 31, 2021; <ix:nonFraction id="Fxbrl_20220719215055193" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20220630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713629_22" name="us-gaap:CommonStockSharesIssued" contextRef="C_20220630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="Fxbrl_20220719215111705" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20220719213713629_24" name="us-gaap:CommonStockSharesIssued" contextRef="C_20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,433,432</ix:nonFraction></ix:nonFraction> shares issued and&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">outstanding on June 30, 2022, and December 31, 2021, respectively</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713630_26" name="us-gaap:CommonStockValue" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713630_27" name="us-gaap:CommonStockValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in capital</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713630_28" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">531,074</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713631_29" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">528,533</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated deficit</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20220719213713631_30" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">440,933</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20220719213713632_31" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">422,079</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> shareholders' equity</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713632_32" name="us-gaap:StockholdersEquity" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,381</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713632_33" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,693</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:76%;padding-bottom:4px" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> liabilities and shareholders' equity</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713633_34" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,312</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20220719213713633_35" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,163</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>

    </table>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">F - 3</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
  </div>

  <div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div>
        <div style="text-align:right;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><a id="COMPREHENSIVELOSS"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></span>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses:</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses, net</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_61" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,982</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_62" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,123</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_63" name="us-gaap:BusinessDevelopment" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">478</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_64" name="us-gaap:BusinessDevelopment" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">465</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
            <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_65" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,173</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_66" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,373</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:76%;padding-bottom:2px" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> operating expenses</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_67" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,633</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_68" name="us-gaap:OperatingExpenses" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,961</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_69" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">779</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_70" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">559</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes on income</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_71" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_72" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19,402</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719215810562_Fact_71" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719215810562_Fact_72" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_75" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_76" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19,402</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted net loss per share</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20220719220126329" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20220630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_77" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20220630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">0.22</ix:nonFraction></ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20220719220147427" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20210101to20210630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_78" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210101to20210630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">0.23</ix:nonFraction></ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span> comprehensive loss</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_79" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_80" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19,402</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720012025614" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20220630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_81" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20220630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,486,612</ix:nonFraction></ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720012118943" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20210630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_82" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20210630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">83,739,983</ix:nonFraction></ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>

    </table>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">F - 4</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
  </div>

      <div style="margin-top:10pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></strong></span></span></div>
      <div>
        <div>
          <div style="font-family:'Times New Roman',Times,serif">
            <div style="text-align:right;line-height:1.25;font-weight:bold">&#160;</div>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><a id="SHAREHOLDERSEQUITY"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</span></span></span></span>
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>U.S. dollars in thousands (except share data)</span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%" width="100%">

              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-family:Arial;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Ordinary</span><span>&#160;<span style="font-weight:bold">shares</span></span></span></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Additional&#160;</span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>paid-in</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accumulated</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total&#160;</span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>shareholders'</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Amount</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>capital</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>deficit</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>equity</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance as of January 1, 2021</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823737_Fact_109" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">83,675,856</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823737_Fact_110" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823737_Fact_111" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">507,427</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220727222823737_Fact_112" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">387,876</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823737_Fact_113" name="us-gaap:StockholdersEquity" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,782</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:38%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:11%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Options exercised</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823694_Fact_88" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">115,877</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20220727222920490">*</span></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823694_Fact_90" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823694_xbrl_20220720104827763" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823694_Fact_91" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Warrants exercised</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823702_Fact_92" name="cgen:NumberOfWarrantsExercised" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,557</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20220727223653597">*</span></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823702_Fact_94" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823702_xbrl_20220720104840927" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823702_Fact_95" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of ESPP shares</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223504334_Fact_96" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">36,639</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20220727223710614">*</span></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223504334_Fact_98" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223504334_xbrl_20220720104851290" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223504334_Fact_99" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Stock-based compensation issued to employees, directors and non-employees</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223514966_xbrl_20220720105139483" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223514966_Fact_100" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,916</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223514966_xbrl_20220720104928823" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223514966_Fact_101" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,916</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;background-color:rgb(204, 238, 255);width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823722_xbrl_20220720105158469" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:11%" valign="bottom">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="Fxbrl_20220727222823722_xbrl_20220720105155026" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></div>
                  </div>
                </td>
                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220727222823722_Fact_102" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19,402</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220727222823722_Fact_103" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19,402</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:38%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:11%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance as of June 30, 2021 (unaudited)</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823729_Fact_104" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">83,917,929</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823729_Fact_105" name="us-gaap:StockholdersEquity" contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823729_Fact_106" name="us-gaap:StockholdersEquity" contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">510,468</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220727222823729_Fact_107" name="us-gaap:StockholdersEquity" contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">407,278</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823729_Fact_108" name="us-gaap:StockholdersEquity" contextRef="C_20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,421</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:38%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:11%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance as of January 1, 2022</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223132738_Fact_109" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,433,432</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223132738_Fact_110" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223132738_Fact_111" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">528,533</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220727223132738_Fact_112" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">422,079</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223132738_Fact_113" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,693</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:38%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:11%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Options exercised</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823749_Fact_114" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">33,186</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20220727223630806">*</span></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823749_Fact_116" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823749_xbrl_20220720104943489" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823749_Fact_117" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of ESPP shares</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223329630_Fact_122" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">158,025</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223329630_xbrl_20220719224804137" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223329630_Fact_124" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">248</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223329630_xbrl_20220720104955752" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223329630_Fact_125" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">249</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Stock-based compensation issued to employees, directors and non-employees</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223450181_xbrl_20220720105058426" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223450181_Fact_126" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,189</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223450181_xbrl_20220720105006668" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727223450181_Fact_127" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,189</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823775_xbrl_20220720105044504" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823775_xbrl_20220720105025339" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220727222823775_Fact_128" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220727222823775_Fact_129" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:38%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:11%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:38%" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance as of June 30, 2022 (unaudited)</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823781_Fact_130" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823781_Fact_131" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:11%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823781_Fact_132" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">531,074</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220727222823781_Fact_133" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">440,933</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220727222823781_Fact_134" name="us-gaap:StockholdersEquity" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,381</ix:nonFraction></span></span></span></span></div>
                </td>
                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>* <ix:footnote id="FN20220727223934071" xml:lang="en-US">Represents an amount lower than $ 1.</ix:footnote></span></span></span></span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The accompanying notes are an integral part of the consolidated financial statements.</span></span></span></span></div>
          <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
            <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 5</span></span></span></span></span></div>
            <div style="page-break-after:always">
              <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
            </div>
          </div>
        </div>
      </div>

  <div>
    <div>
      <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
      <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="text-align:justify;line-height:1.25;font-weight:bold"><a id="CASHFLOWS"></a> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
            <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from operating activities:</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_135" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,854</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_136" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19,402</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-indent:-8.8pt;margin-left:25.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments required to reconcile net loss to net cash used in operating activities:</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-8.8pt;margin-left:25.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_137" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,189</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_138" name="us-gaap:ShareBasedCompensation" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,916</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_139" name="us-gaap:Depreciation" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">232</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_140" name="us-gaap:Depreciation" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in severance pay, net</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_141" name="cgen:SeverancePayNet" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220719231801817" name="cgen:SeverancePayNet" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">64</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain from property and equipment disposal</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_143" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220720144058011" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in operating lease right of use asset</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_145" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">295</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_146" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">357</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in interest receivables from short-term bank deposits</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220719231852648" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_148" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">403</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in trade receivables</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_149" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719231907400" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,000</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in other accounts receivable and prepaid expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_151" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">764</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_152" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">212</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in long-term prepaid expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_153" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_154" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in trade payables</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220719232044563" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,387</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_156" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">361</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase in other accounts payable and accrued expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_157" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">242</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_158" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">872</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in operating lease liability</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_159" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">644</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_160" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">319</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
            <div style="text-indent:-8.5pt;margin-left:25.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in deferred participation in R&#38;D expenses</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_161" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,387</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_162" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">178</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash used in operating activities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_163" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,683</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_164" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,629</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from investing activities:</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from maturity of short-term bank deposits</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_165" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,945</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_166" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,100</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in short-term bank deposits</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_167" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,500</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_168" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,445</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_169" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_170" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">218</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
            <div style="text-indent:-8.5pt;margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from sales of property and equipment</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_171" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220719232155049" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by investing activities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_173" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,187</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_174" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,438</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from financing activities:</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from issuance of ordinary shares, net</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_175" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">249</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_176" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from exercise of warrants</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_177" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_178" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:14.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from exercise of options</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_179" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_180" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by financing activities</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_181" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_182" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">909</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in cash, cash equivalents and restricted cash</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220719232250681" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">143</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_184" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">718</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
            <div style="text-indent:-5.65pt;margin-left:8.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at the beginning of the period</span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_185" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,514</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_186" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,810</ix:nonFraction></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at the end of the period</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_187" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,371</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_188" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,528</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Supplemental disclosure of non-cash investing and financing activities:</span></span></span></div>
          </td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20220720191345976" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">80</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20220720191351930" name="cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Receivables on account of shares</span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_191" name="cgen:ReceivablesOnAccountOfShares" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_192" name="cgen:ReceivablesOnAccountOfShares" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></span></span></div>
          </td>
          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>

    </table>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">F - 6</span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
  </div>

  <div style="margin-top:0pt;margin-bottom:8pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>COMPUGEN LTD. AND ITS SUBSIDIARY</strong></span></div>
  <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</div>
  <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">
    <div style="display:inline"><a id="FINANCIALSTATEMENTS"></a>
      <div>
        <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></span></div>
      </div>
    </div>
  </div>
  <hr style="border-top:2px solid black;text-align:center" />
  <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>U.S. dollars in thousands (except share and per share data)</strong></span></div>
  <div style="margin:0pt">&#160;</div>
  <ix:nonNumeric id="FFact_200" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="C_20220101to20220630" escape="true">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 1:-</span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">GENERAL</span></span></strong></p>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:26.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">a.</span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div>
                    <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Compugen (the &#8220;Company&#8221;) is a clinical-stage, therapeutic discovery and development company utilizing its proprietary computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company&#8217;s innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the Company discovered computationally, COM701, COM902, bapotulimab (formerly known as BAY 1905254) and AZD2936. The Company&#8217;s therapeutic pipeline also includes early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The innovative immuno-oncology pipeline, the strategic collaborations and the Company&#8217;s computational discovery engine serves as the three key corporate building blocks.</span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">b.</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Company is headquartered in Holon, Israel. Its clinical development activities operate from its U.S. subsidiary in South San Francisco, California.</span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">c.</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint regulators.</span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $<ix:nonFraction id="FFact_193" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20130801to20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction>, and, following the return of the CGEN 15022 program in 2017 to the Company, the Company is eligible to receive an aggregate of over $<ix:nonFraction id="FFact_194" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">250,000</ix:nonFraction> in potential milestone payments, not including aggregate milestone payments of approximately $<ix:nonFraction id="FFact_195" name="cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" contextRef="C_20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,000</ix:nonFraction> received to date. Additionally, the Company is eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.</span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Pursuant to the terms of Bayer Agreement, bapotulimab program was transferred to Bayer&#8217;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing licenses from Compugen.</span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.8pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">d.</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development and commercial activities under the agreement. Compugen received a $<ix:nonFraction id="FFact_196" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20180301to20180330" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction> upfront payment and $<ix:nonFraction id="Fxbrl_20220720020744651" name="cgen:AccruedMilestonePayment" contextRef="C_20180301to20180330" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,000</ix:nonFraction> milestone payment out of up to $<ix:nonFraction id="FFact_198" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20180330" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction> that the Company is eligible to receive in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></div>
              </td>
            </tr>

        </table>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <div style="margin:0pt">&#160;</div>
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 7</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:8pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:3pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p></div>
          </div>
          <div style="text-align:justify;line-height:1.25">
            <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 1:-</span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><strong><span style="font-family:Times New Roman, Times, serif;font-size:10pt">GENERAL (Cont.)</span></strong></p>
                  </td>
                </tr>

            </table>
          </div>
        </ix:exclude></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">e.</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol-Myers Squibb Company (&#8220;Bristol-Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. Pursuant to the Master Clinical Agreement, Compugen is responsible for and will continue sponsoring the ongoing two-part Phase 1 trial, which includes the evaluation of the combination of COM701 and Opdivo&#174;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplies its own compound(s) for the studies, and otherwise each party is responsible for all costs associated with the study that it is conducting.<br />&#160;<br />In conjunction with the signing of the Master Clinical Agreement, Bristol-Myers Squibb made a $<ix:nonFraction id="FFact_199" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> investment in Compugen, see Note 5a.</span></div>
              </td>
            </tr>
            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
            </tr>
            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On February 14, 2020, the Master Clinical Agreement with Bristol-Myers Squibb was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol-Myers Squibb&#8217;s antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#174;.</span></div>
                <div style="margin:0pt">&#160;</div>
                <div style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Pursuant to the Master Clinical Agreement, as amended, the Company sponsors the two-part Phase 1/2 trial, which includes the evaluation of the triple combination of COM701, Opdivo&#174; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provides Opdivo&#174; and BMS-986207 at no cost to the Company.</span></div>
                <div style="margin:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">As part of the said amendment, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo&#174; under the Phase 1 study and will not continue the expansion cohorts of the dual combination.</span></div>
                <div style="margin:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On February 19, 2021, the Master Clinical Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced solid tumors, where Compugen is responsible for and sponsors the expansion cohort and Bristol-Myers Squibb provides Opdivo&#174; at no cost to us for this study.</span></div>
                <div style="margin:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration.</span></div>
                <div style="margin:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $<ix:nonFraction id="Fxbrl_20220728112859416" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20211130" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in Compugen, see Note 5a.</span></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  </ix:nonNumeric>
  <div>
    <div style="width:100%;clear:both">
      <div style="margin:0pt">&#160;</div>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 8</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:8pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:3pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p></div>
    </div>
  </div>

  <ix:nonNumeric id="FFact_201" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20220101to20220630" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 2:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNIFICANT ACCOUNTING POLICIES</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
            </tr>
            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2021. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2021, are applied consistently in these interim consolidated financial statements.</span></p>
              </td>
            </tr>

        </table>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="FFact_202" name="cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock" contextRef="C_20220101to20220630" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Operating results for the six-month period ended June 30, 2022, are not necessarily indicative of the results that may be expected for the year ended December 31, 2022.</span></span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="FFact_217" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20220101to20220630" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS AND CONTINGENCIES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company provided bank guarantees in the amount of $<ix:nonFraction id="Fxbrl_20220720103610231" name="us-gaap:GuaranteeObligationsMaximumExposure" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">320</ix:nonFraction> in favor of its offices in Israel, car leases in Israel and credit card security for its U.S. subsidiary.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company received in the past grants from the office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist, (&#8220;IIA&#8221;). The Company is not obligated to repay any amounts received from the IIA if it does not generate any income from products which incorporate technologies which were funded by such research program(s).</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If income is generated from products which incorporate technologies which were funded by a research program, the Company is committed to pay royalties at a rate of between <ix:nonFraction id="Fxbrl_20220720062450451" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20220101to20220630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% to <ix:nonFraction id="Fxbrl_20220720062556413" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20220101to20220630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of future revenue generated from products that incorporate technologies that were funded by such research program(s), up to a maximum of <ix:nonFraction id="Fxbrl_20220720062648820" name="cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived" contextRef="C_20220101to20220630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum amount to be repaid is 100% plus interest at LIBOR).</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2022, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled $<ix:nonFraction id="Fxbrl_20220720062746091" name="cgen:RoyaltyContingentObligations" contextRef="C_20220630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,867</ix:nonFraction>.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div>
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company is entitled to certain royalties that could be eliminated upon payment of certain one-time fees (all milestone and royalties payments referred together as &#8220;Contingent Fees&#8221;). For the six-month periods ended June 30, 2022 and 2021, the Company did not incur Contingent Fees.</span></span></div>
                  </div>
                </td>
              </tr>

          </table>
        </div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <div style="line-height:1.25">
              <p style="margin:0pt">&#160;</p>
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 9</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:8pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:3pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p></div>
            </div>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMMITMENTS AND CONTINGENCIES </span><strong><span>(Cont.)</span></strong></span></span></div>
                </td>
              </tr>

          </table>
        </ix:exclude></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On <ix:nonNumeric id="Fxbrl_20220720063011170" name="cgen:AgreementStartDate" contextRef="C_20220101to20220630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember" format="ixt:date-monthname-day-year-en">May 9, 2012</ix:nonNumeric>, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates. Under the agreement the Advisor shall be entitled to <ix:nonFraction id="Fxbrl_20220727214951426" name="cgen:ParticipationRights" contextRef="C_20220101to20220630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the cash considerations that may be received under such transactions. <ix:nonNumeric id="Fxbrl_20220720063144707" name="cgen:AgreementTerminationDescription" contextRef="C_20220101to20220630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</ix:nonNumeric></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months ended June 30, 2022 and 2021, the Company had not paid nor accrued any expenses related to this agreement.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (&#8220;CLA&#8221;) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and <ix:nonFraction id="Fxbrl_20220720063310237" name="cgen:PercentageOfRoyaltiesOnNetSales" contextRef="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction>% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the six-month periods ended June 30, 2022 and 2021, the Company did not incur milestone payments.<br />&#160;</span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the six-month periods ended June 30, 2022 and 2021 the Company incurred milestone payments in the amounts of $<ix:nonFraction id="Fxbrl_20220720025255942" name="cgen:AmountIncurredMilestonePayments" contextRef="C_20220101to20220630_usgaapSupplyCommitmentAxis_cgenCollaborationAgreementWithUSAntibodyCompanyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction id="FFact_216" name="cgen:AmountIncurredMilestonePayments" contextRef="C_20210101to20210630_usgaapSupplyCommitmentAxis_cgenCollaborationAgreementWithUSAntibodyCompanyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction>.</span></span></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  </ix:nonNumeric>
  <div>
    <div style="width:100%;clear:both">
      <p style="margin:0pt">&#160;</p>
    </div>
  </div>

  <ix:nonNumeric id="FFact_289" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_20220101to20220630" escape="true">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 5:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS' EQUITY</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of Shares:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 14, 2018, the Company entered into agreements in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of <ix:nonFraction id="FFact_223" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">5,316,457</ix:nonFraction> Ordinary Shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $<ix:nonFraction id="FFact_224" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">3.95</ix:nonFraction> per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to <ix:nonFraction id="FFact_225" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">4,253,165</ix:nonFraction> additional Ordinary Shares (the &#8220;Warrants&#8221;). The Warrants are exercisable at a price of $<ix:nonFraction id="FFact_226" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">4.74</ix:nonFraction> per Ordinary Share and have a term of <ix:nonNumeric id="FFact_227" name="cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $<ix:nonFraction id="FFact_228" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,767</ix:nonFraction> (net of $<ix:nonFraction id="FFact_229" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction> issuance expenses).</span></span></div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="margin:0pt">&#160;</p>
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 10</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:8pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:3pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p></div>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 5:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS&#8217; EQUITY (Cont.)</span></span></div>
                </td>
              </tr>

          </table>
        </ix:exclude></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six-month periods ended June 30, 2022 and 2021, warrants to purchase an aggregate of <ix:nonFraction id="Fxbrl_20220720033721852" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20220630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction> and <ix:nonFraction id="FFact_230" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20210630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,557</ix:nonFraction> Ordinary Shares were exercised with proceeds of approximately $<ix:nonFraction id="FFact_232" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20220101to20220630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction id="FFact_233" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20210101to20210630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction>, respectively, and warrants to purchase up to <ix:nonFraction id="FFact_234" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20220630_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">297,469</ix:nonFraction> Ordinary Shares remain outstanding as of June 30, 2022.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $<ix:nonFraction id="FFact_235" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> equity investment in the Company.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased <ix:nonFraction id="FFact_236" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,424,243</ix:nonFraction> ordinary shares of the Company at a purchase price of $<ix:nonFraction id="FFact_237" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">4.95</ix:nonFraction> per share. The share price represents a <ix:nonFraction id="FFact_238" name="cgen:PercentageOfClosingPrice" contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the average closing price of Compugen&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $<ix:nonFraction id="FFact_239" name="cgen:RelativeFairValueOfDeferredParticipation" contextRef="C_20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction> represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&#38;D expenses which are amortized over the period of the clinical trial based on the progress in the R&#38;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221; and $<ix:nonFraction id="FFact_240" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,788</ix:nonFraction> (net of $<ix:nonFraction id="FFact_241" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $<ix:nonFraction id="Fxbrl_20220720034631668" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in the Company, purchasing <ix:nonFraction id="Fxbrl_20220720034743180" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,332,815</ix:nonFraction> ordinary shares of the Company at a purchase price of $<ix:nonFraction id="Fxbrl_20220720034904580" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="USDPerShare" scale="0" decimals="5" format="ixt:num-dot-decimal">8.57333</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="Fxbrl_20220720034949299" name="cgen:PercentageOfClosingPrice" contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $<ix:nonFraction id="Fxbrl_20220720035100582" name="cgen:RelativeFairValueOfDeferredParticipation" contextRef="C_20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&#38;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&#38;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;) and $<ix:nonFraction id="Fxbrl_20220720035407188" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,958</ix:nonFraction> (net of $<ix:nonFraction id="Fxbrl_20220720035509163" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &#38; Company, Incorporated, as representatives of the several underwriters relating to the issuance and sale in a public offering of <ix:nonFraction id="FFact_242" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,333,334</ix:nonFraction> of the Company&#8217;s ordinary shares at a price to the public of $<ix:nonFraction id="FFact_243" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="USDPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.00</ix:nonFraction> per share (and a price of $<ix:nonFraction id="FFact_244" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="USDPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.46</ix:nonFraction> per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement an additional <ix:nonFraction id="FFact_245" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">483,005</ix:nonFraction> ordinary shares pursuant to the underwriters&#8217; option specified above. The Company sold a total of <ix:nonFraction id="FFact_246" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,816,339</ix:nonFraction> ordinary shares in the offering with proceeds of $<ix:nonFraction id="FFact_247" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,147</ix:nonFraction> (net of $<ix:nonFraction id="FFact_248" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction> issuance expenses).</span></span></div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="margin:0pt">&#160;</p>
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 11</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:8pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:3pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p></div>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 5:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS&#8217; EQUITY (Cont.)</span></span></div>
                </td>
              </tr>

          </table>
        </ix:exclude></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock option plan:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six-month period ended June 30, 2022, the Company&#8217;s Board of Directors granted <ix:nonFraction id="Fxbrl_20220720040533152" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="C_20220101to20220630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,497,500</ix:nonFraction> options to purchase ordinary shares of the Company to employees, directors and non-employees. The exercise prices for such options range from $<ix:nonFraction id="Fxbrl_20220720040558485" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="C_20220101to20220630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">1.90</ix:nonFraction> to $<ix:nonFraction id="FFact_251" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="C_20220101to20220630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">5.00</ix:nonFraction> per share, with vesting to occur in up to <ix:nonNumeric id="FFact_252" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20220101to20220630" format="ixt-sec:durwordsen">four years</ix:nonNumeric>.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents the assumptions used to estimate the fair value of the options granted in the periods presented:</span></span></div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:84.45pt">
          <ix:nonNumeric id="Fxbrl_20220728002533924" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20220101to20220630" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222002683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20220101to20220630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">69</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727222015231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20220101to20220630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">72</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222026940" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20210101to20210630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">66</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727222103489" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20210101to20210630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">67</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727222244528" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20220101to20220630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.5</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727233307366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20220101to20220630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727233317706" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20210101to20210630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220727235651276" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20210101to20210630" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727235701651" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20220630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220727235716123" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20210101to20210630" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220727235725275" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20220630_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.0</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20220727235734670" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20220630_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">5.4</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220727235745019" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20210630" format="ixt-sec:duryear">5.1</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
      </div>
    </div>
    <div>
      <div>
        <div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average fair value of options granted during the six-month periods ended June 30, 2022 and 2021 were $<ix:nonFraction id="FFact_267" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20220101to20220630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">1.94</ix:nonFraction> and $<ix:nonFraction id="FFact_268" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20210101to20210630" unitRef="USDPerShare" decimals="INF" format="ixt:num-dot-decimal">5.54</ix:nonFraction>, respectively.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six-month periods ended June 30, 2022 and 2021, the Company recorded share based compensation related to stock options in a total amount of $<ix:nonFraction id="FFact_269" name="us-gaap:StockOptionPlanExpense" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,092</ix:nonFraction> and $<ix:nonFraction id="FFact_270" name="us-gaap:StockOptionPlanExpense" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,805</ix:nonFraction>, respectively.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2022, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $<ix:nonFraction id="FFact_271" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,614</ix:nonFraction> which is expected to be recognized over a weighted average period of approximately<span style="font-weight:bold">&#160;</span><ix:nonNumeric id="FFact_272" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20220101to20220630" format="ixt-sec:duryear">2.85</ix:nonNumeric> years.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months ended June 30, 2022 and 2021, the total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were <ix:nonFraction id="Fxbrl_20220720041818515" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20220630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,504,958</ix:nonFraction> and <ix:nonFraction id="FFact_274" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20210101to20210630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">6,242,283</ix:nonFraction>, respectively.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee Stock Purchase Plan:</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its stock-option awards and Employee Stock Purchase Plan (&#8220;ESPP&#8221;).</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2022 and since its adoption, <ix:nonFraction id="FFact_275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">275,854</ix:nonFraction> Ordinary Shares had been purchased under the ESPP and <ix:nonFraction id="FFact_276" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">324,146</ix:nonFraction> Ordinary Shares were available for future issuance under the ESPP.</span></span></div>
          <div><ix:exclude>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
              <p style="margin:0pt">&#160;</p>
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 12</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:8pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:3pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p></div>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 5:-</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                    <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS&#8217; EQUITY (Cont.)</span></span></div>
                  </td>
                </tr>

            </table>
          </ix:exclude></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div>
            <div style="margin-left:56.7pt">
              <ix:nonNumeric id="Fxbrl_20220728002557752" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" escape="true">
                <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_277" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">65</ix:nonFraction>%-<ix:nonFraction id="FFact_278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720042810087" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">64</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220720042816078" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_280" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction>%-<ix:nonFraction id="FFact_281" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720042753766" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20220720042801271" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_283" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720042946790" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_286" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" format="ixt-sec:duryear">0.5</ix:nonNumeric></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220720042710462" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20210630_srtRangeAxis_srtMinimumMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" format="ixt-sec:duryear">0.4</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20220720042714542" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20210630_srtRangeAxis_srtMaximumMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" format="ixt-sec:duryear">0.5</ix:nonNumeric></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>

                </table>
              </ix:nonNumeric>
            </div>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six-month periods ended June 30, 2022 and 2021, the Company recorded ESPP compensation in a total amount of $<ix:nonFraction id="Fxbrl_20220720043008949" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction> and $<ix:nonFraction id="FFact_288" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction>.</span></span></div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <div>
    <div>
      <ix:nonNumeric id="Fxbrl_20220727231501241" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" contextRef="C_20220101to20220630" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 6:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">FINANCIAL AND OTHER INCOME, NET</span></p>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
          <div>
            <div style="margin-left:56.7pt">
              <ix:nonNumeric id="Fxbrl_20220727231515518" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="C_20220101to20220630" escape="true">
                <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_290" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">463</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_291" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">528</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences and other</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220720002002984" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_293" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_294" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">779</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_295" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">559</ix:nonFraction></span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>

                </table>
              </ix:nonNumeric>
            </div>
          </div>
        </div>
      </ix:nonNumeric>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
    </div>
  </div>

      <div>
        <div>
          <ix:nonNumeric id="Fxbrl_20220727224715083" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20220101to20220630" escape="true">
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7:-</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>RELATED PARTY BALANCES AND TRANSACTIONS</strong></span></p>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <ix:nonNumeric id="Fxbrl_20220728112628625" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20220101to20220630" escape="true">
                <div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Balances with related parties:</span></span></span></div>
                  <div>
                    <div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>June 30,</span></strong></span></span></div>
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2022</span></strong></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>December&#160;31,<br />2021</span></strong></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
                                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                              </td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;Trade and other payables (a)</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_298" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="C_20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_299" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                            </tr>

                        </table>
                      </div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                      <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Related parties' expenses:</span></span></span></div>
                      <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <div>
                          <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Six months ended</span></strong></span></span></div>
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>June 30,</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2022</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2021</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Amounts charged to:</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development expenses (a)</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_300" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20220101to20220630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_301" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20210101to20210630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              </tr>

                          </table>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;width:56.7pt">&#160;</td>
                        <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:32pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(a)</span></span></span></td>
                        <td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif">
                          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:footnote id="FN20220720121444312" xml:lang="en-US">The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</ix:footnote></span></span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>
              </ix:nonNumeric>
            </div>
          </ix:nonNumeric>
          <div>
            <p style="margin:0pt">&#160;</p>
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:3pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 13</span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></div></div><div><p style="margin-top:8pt;margin-bottom:0pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p><p style="margin-top:0pt;margin-bottom:3pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></p><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:0pt;margin-bottom:0pt" /><p style="margin-top:6pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></p><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p></div>
          </div>
        </div>
      </div>

  <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">
    <ix:nonNumeric id="Fxbrl_20220728193545297" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20220101to20220630" escape="true">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>NOTE 8:-</span></span></span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>SUBSEQUENT EVENTS</span></span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>On August 3, 2022, the Company and Bristol-Myers Squibb entered into a letter agreement pursuant to which the Master Clinical Agreement, as amended thereafter, is terminated as of such date. Such termination also includes termination of the right of first negotiation and the exclusivity right granted to BMS thereunder.</span></span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The parties shall use reasonable efforts to wind down activities under the Master Clinical Agreement with respect to the dual combination study of COM701 with nivolumab and the triple combination study of COM701 with nivolumab and BMS- 986207 and will create a sub-team of the parties to oversee such wind-down activities.</span></span></span></span></span></div>
      </div>
    </ix:nonNumeric>
    <div style="text-align:justify;margin-left:56.9pt;line-height:1.25">&#160;</div>
  </div>
  <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F - 14</span></span></span></span></span></span>
    <hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;width:100%;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" />
  </div>
</div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>exhibit_99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; margin-right: 5.35pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><u>Exhibit 99.3</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FINANCIAL CONDITION</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">RESULTS OF OPERATIONS</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Six months ended June 30, 2022 and 2021</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Research and Development Expenses</font>. Research and development, or R&amp;D, expenses decreased by approximately 1% to approximately
        $14.0 million for the first six months of 2022 from approximately $14.1 million for the comparable period of 2021. The decrease is mainly due to higher amortization of the deferred participation in R&amp;D expenses following the November 2021
        Bristol Myers Squibb investment in our Company and a decrease in expenses associated with COM701 and COM902 manufacturing, offset by an increase in clinical trial expenses and an increase in headcount mainly to support the expansion of the various
        ongoing clinical trials we are conducting. R&amp;D expenses, as a percentage of total operating expenses, were 71% for the first six months of 2022 and 2021.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Marketing and Business Development Expenses</font>. Marketing and business development expenses were approximately $0.5 million for the
        first six months of 2022 and for the comparable period of 2021. Marketing and business development expenses, as a percentage of total operating expenses, were 2% for the first six months of 2022 and 2021.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">General and Administrative Expenses</font>. General and administrative expenses decreased by approximately 4% to approximately $5.2 million
        for the first six months of 2022 from approximately $5.4 million for the comparable period of 2021. The decrease is attributable mainly to various corporate related expenses. General and administrative expenses, as a percentage of total operating
        expenses, decreased to 26% for the first six months of 2022 from 27% for the comparable period of 2021.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Financial and other Income, Net</font>. Financial and other income, net, were approximately $0.8 million for the first six months of 2022
        compared with approximately $0.6 million for the comparable period of 2021. The increase is attributable to currency exchange differences.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">LIQUIDITY AND CAPITAL RESOURCES</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Net Cash Used in Operating Activities. </font>Net cash used in operating activities was approximately $20.7 million in the first six months
        of 2022 compared with approximately $13.6 million in the comparable period of 2021. The higher net cash used during the first six months of 2022 reflects mainly the higher level of cash expenses related to clinical, CMC, other R&amp;D, and
        headcount in the first six months of 2022 and the collection of the 2.0 million preclinical milestone pursuant to the license agreement with AstraZeneca PLC during the comparable period of 2021. </div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Net Cash Provided by Investing Activities. </font>Net cash provided by investing activities during the first six months of 2022 was
        approximately $20.2 million compared with approximately $13.4 million in the comparable period of 2021. Changes in net cash during the periods are affected by the level of cash in the Company over the periods which is deposited or withdrawn from
        bank deposits based on fund raisings and the cash needs to fund our operating activities. During the first six months of 2022, cash provided by investing activities was higher than the comparable period of 2021 as a result of higher cash expenses
        in the first six months of 2022.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Net Cash Provided by Financing Activities. </font>Net cash provided by financing activities was $0.4 million in the first six months of
        2022 compared with $0.9 million in the comparable period of 2021. The lower net cash provided in the first six months of 2022 is due to lower proceeds received from exercise of employee share options compared to the comparable period of 2021 and no
        exercises of outstanding warrants in the first six months of 2022.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-style: italic;">Net Liquidity. </font>Liquidity refers to liquid financial assets available to fund the Company&#8217;s business operations and pay for near-term
        obligations. These liquid financial assets mostly consist of cash and cash equivalents, as well as short-term bank deposits. As of June 30, 2022, the Company had total cash, cash equivalents, restricted cash and short- term bank deposits of
        approximately $97.3 million.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div> <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cgen-20220630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cgen="http://cgen.com/20220630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" targetNamespace="http://cgen.com/20220630" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cgen.com/role/cgen-daei1" id="cgen-daei1">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cbs" id="cgen-cbs">
        <link:definition>0002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cbsp" id="cgen-cbsp">
        <link:definition>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-csocl" id="cgen-csocl">
        <link:definition>0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-socise1" id="cgen-socise1">
        <link:definition>0005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-g" id="cgen-g">
        <link:definition>0007 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sap1" id="cgen-sap1">
        <link:definition>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements" id="UnauditedInterimConsolidatedFinancialStatements">
        <link:definition>0009 - Disclosure - UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cac" id="cgen-cac">
        <link:definition>0010 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-se1" id="cgen-se1">
        <link:definition>0011 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/TaxesOnIncome" id="TaxesOnIncome">
        <link:definition>0012 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-fin" id="cgen-fin">
        <link:definition>0013 - Disclosure - FINANCIAL AND OTHER INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-rpbat" id="cgen-rpbat">
        <link:definition>0014 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SUBSEQUENTEVENTS" id="SUBSEQUENTEVENTS">
        <link:definition>0015 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies" id="Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-set" id="cgen-set">
        <link:definition>0017 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-fint" id="cgen-fint">
        <link:definition>0018 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
        <link:definition>0019 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-gd1" id="cgen-gd1">
        <link:definition>0020 - Disclosure - GENERAL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>0021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails" id="ShareholdersEquityIssuanceOfSharesDetails">
        <link:definition>0022 - Disclosure - SHAREHOLDERS' EQUITY (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails" id="ShareholdersEquityScheduleOfStock-basedCompensationDetails">
        <link:definition>0023 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-find" id="cgen-find">
        <link:definition>0024 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-rpbatd" id="cgen-rpbatd">
        <link:definition>0025 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccruedMilestonePayment" id="cgen_AccruedMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AgreementMember" id="cgen_AgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementStartDate" id="cgen_AgreementStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementTerminationDescription" id="cgen_AgreementTerminationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmountIncurredMilestonePayments" id="cgen_AmountIncurredMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AtMarketOfferingProgramMember" id="cgen_AtMarketOfferingProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" id="cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborationAgreementWithUSAntibodyCompanyMember" id="cgen_CollaborationAgreementWithUSAntibodyCompanyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsMember" id="cgen_CollaborativeArrangementsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsTwoMember" id="cgen_CollaborativeArrangementsTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommercialLicenseAgreementMember" id="cgen_CommercialLicenseAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentFees" id="cgen_ContingentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredParticipationOfBmsInRdExpenses" id="cgen_DeferredParticipationOfBmsInRdExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DevelopmentRegulatoryAndCommercialMilestonesCompensation" id="cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DocumentAndEntityInformationAbstract" id="cgen_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialIncomeExpenseNet" id="cgen_FinancialIncomeExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GovernmentAndOtherGrantsAxis" id="cgen_GovernmentAndOtherGrantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="GovernmentAndOtherGrantsDomain" id="cgen_GovernmentAndOtherGrantsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsLineItems" id="cgen_GovernmentAndOtherGrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsMember" id="cgen_GovernmentAndOtherGrantsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAndOtherGrantsTable" id="cgen_GovernmentAndOtherGrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" id="cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LongTermDeferredParticipationinResearchAndDevelopmentExpenses" id="cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MasterClinicalAgreementMember" id="cgen_MasterClinicalAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumAuthorizedProceedsFromIssuanceOfCommonStock" id="cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MaximumRoyaltyRepaidAsPercentageOfGrantReceived" id="cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="May2012AgreementMember" id="cgen_May2012AgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" id="cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercised" id="cgen_NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ParticipationRights" id="cgen_ParticipationRights" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfClosingPrice" id="cgen_PercentageOfClosingPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltiesOnNetSales" id="cgen_PercentageOfRoyaltiesOnNetSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseOfPropertyAndEquipmentAsNonCashTransaction" id="cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReceivablesOnAccountOfShares" id="cgen_ReceivablesOnAccountOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RegisteredDirectOfferingMember" id="cgen_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyBalancesAndTransactionsAbstract" id="cgen_RelatedPartyBalancesAndTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelativeFairValueOfDeferredParticipation" id="cgen_RelativeFairValueOfDeferredParticipation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentGrantOneMember" id="cgen_ResearchAndDevelopmentGrantOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RetainerFee" id="cgen_RetainerFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RoyaltyContingentObligations" id="cgen_RoyaltyContingentObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RoyaltyPercentageBasedOnFutureRevenues" id="cgen_RoyaltyPercentageBasedOnFutureRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeverancePayFundNonCurrent" id="cgen_SeverancePayFundNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SeverancePayNet" id="cgen_SeverancePayNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" id="cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueWarrantsExercised" id="cgen_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SvbLeerinkLlcAndStifelNicolausAndCompanyMember" id="cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnauditedInterimConsolidatedFinancialStatementsAbstract" id="cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnauditedInterimConsolidatedFinancialStatementsTextBlock" id="cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnderwritersMember" id="cgen_UnderwritersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cgen-20220630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-cbs" roleURI="http://cgen.com/role/cgen-cbs"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-find" roleURI="http://cgen.com/role/cgen-find"/>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbs">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_7" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_7" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_7" xlink:to="loc_cgen_SeverancePayFundNonCurrent_8" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_13" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_13" xlink:to="loc_us-gaap_AccountsPayableCurrent_13" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_13" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_14" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_13" xlink:to="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_15" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_13" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_16" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_12" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_18" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_18" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_18" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_18" xlink:to="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_20" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_12" xlink:to="loc_us-gaap_StockholdersEquity_22" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_CommonStockValue_22" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_OperatingExpenses_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1" xlink:to="loc_us-gaap_BusinessDevelopment_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_cgen_FinancialIncomeExpenseNet_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_23"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_SeverancePayNet_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_5" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6" order="50" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_10" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_11" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_12" order="110" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_13" order="120" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_14" order="130" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_16" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_17" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_18" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_19" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_23" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-find">
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2" order="10" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cgen-20220630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-socise1" roleURI="http://cgen.com/role/cgen-socise1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-set" roleURI="http://cgen.com/role/cgen-set"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#ShareholdersEquityIssuanceOfSharesDetails" roleURI="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#ShareholdersEquityScheduleOfStock-basedCompensationDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-socise1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NumberOfWarrantsExercised_13" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_14" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_15" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_16" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_17" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-set">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_EmployeeStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="loc_us-gaap_PropertyLeaseGuaranteeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_37"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_39"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_GovernmentAndOtherGrantsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_1" xlink:to="loc_us-gaap_PropertyLeaseGuaranteeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_StatementGeographicalAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_IL_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_9" xlink:to="loc_us-gaap_GainContingencyNatureDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_9" xlink:to="loc_cgen_GovernmentAndOtherGrantsMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_9" xlink:to="loc_us-gaap_GainContingencyNatureDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_RangeAxis_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MinimumMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_18" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_18" xlink:to="loc_cgen_May2012AgreementMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_18" xlink:to="loc_cgen_CommercialLicenseAgreementMember_19" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_18" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_SupplyCommitmentAxis_23" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_23" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_23" xlink:to="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_23" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_28" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_29" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_30" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_RoyaltyContingentObligations_31" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_ContingentFees_32" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_ParticipationRights_33" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_RetainerFee_34" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_35" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_AgreementStartDate_36" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_AgreementTerminationDescription_37" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_PercentageOfRoyaltiesOnNetSales_38" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_0" xlink:to="loc_cgen_AmountIncurredMilestonePayments_39" order="120" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_51"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AtMarketOfferingProgramMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_RegisteredDirectOfferingMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_UnderwritersMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_WarrantMember_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" xlink:to="loc_us-gaap_EmployeeStockMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_22" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_24" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_25" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_26" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_28" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_30" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_31" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_PercentageOfClosingPrice_32" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DeferredParticipationOfBmsInRdExpenses_33" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_RelativeFairValueOfDeferredParticipation_34" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_35" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_36" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_38" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_39" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_40" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_41" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_42" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockOptionPlanExpense_44" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_45" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_48" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_49" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_50" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_51" order="310" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_EmployeeStockMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_16" order="60" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cgen-20220630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation" xlink:label="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation" xlink:label="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_DocumentAndEntityInformationAbstract" xlink:label="loc_cgen_DocumentAndEntityInformationAbstract_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_DocumentAndEntityInformationAbstract" xlink:label="loc_cgen_DocumentAndEntityInformationAbstract_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_37"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_40"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_41"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_42"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_43"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_44"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_45"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_46"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_47"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_49"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_50"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_51"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_52"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_53"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_54"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_55"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_56"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_57"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_58"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_59"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_60"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_61"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_62"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_63"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_64"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_65"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_66"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_67"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_68"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_69"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_70"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_71"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_72"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_73"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_74"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_75"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_76"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_77"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_78"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_79"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_80"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_81"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_82"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_83"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_84"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_85"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_86"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_87"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_88"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_89"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_90"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_91"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_92"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_93"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_94"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_95"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_96"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_97"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_98"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_99"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_100"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_101"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_102"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_103"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_104"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_105"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_106"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_107"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_108"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_109"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_110"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_111"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_112"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_113"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_114"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_115"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_116"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_117"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_118"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_119"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_120"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_121"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_122"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_123"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_124"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_125"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_126"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_127"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_128"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_129"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_130"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_131"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_132"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_133"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_134"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_135"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_136"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_137"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_138"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_139"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_141"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_142"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_143"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_144"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_145"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_146"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_147"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_148"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_149"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_151"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_152"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_153"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_154"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_155"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_156"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_157"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_158"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_159"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_161"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_162"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_163"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_164"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_165"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_166"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_167"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_168"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_169"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_171"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_172"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_173"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_174"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_175"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_176"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_177"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_178"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_179"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_181"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_182"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_183"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_184"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_185"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_186"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_187"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_188"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_189"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_190"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_191"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RelatedPartyBalancesAndTransactionsAbstract" xlink:label="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_192"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_193"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_194"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_195"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_196"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_197"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_198"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_199"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_201"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_202"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_203"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_204"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_205"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_206"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_207"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_208"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_209"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_210"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_211"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_212"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_213"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_214"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_215"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_216"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_217"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_218"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_219"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_221"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_223"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_224"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_225"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_226"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_227"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_228"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_229"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_231"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_232"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_233"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_234"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_235"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_236"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_237"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_238"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_239"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_241"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_242"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_243"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_244"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_245"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_246"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_247"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_248"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_249"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_251"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_252"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_253"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_254"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_255"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_256"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_257"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_258"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_259"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_261"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_262"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_263"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_264"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_265"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_266"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_267"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_268"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_269"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_272"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_273"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_274"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_275"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_276"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_277"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_278"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_279"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:label="loc_us-gaap_InterestAndOtherIncomeTableTextBlock_285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:label="loc_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="loc_us-gaap_PropertyLeaseGuaranteeMember_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_413"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AccruedMilestonePayment_0" xml:lang="en-US">Represents the amount of accrued milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AccruedMilestonePayment_1" xml:lang="en-US">Accrued Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AccruedMilestonePayment_2" xml:lang="en-US">Accrued milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementMember_0" xml:lang="en-US">Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementMember_1" xml:lang="en-US">Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementStartDate_0" xml:lang="en-US">Start date of the agreement, in CCYY-MM-DD format.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementStartDate_1" xml:lang="en-US">Agreement, start date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementTerminationDescription_0" xml:lang="en-US">Agreement termination description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementTerminationDescription_1" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AgreementTerminationDescription_2" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AmountIncurredMilestonePayments_0" xml:lang="en-US">Amount incurred milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmountIncurredMilestonePayments_1" xml:lang="en-US">Amount incurred milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AtMarketOfferingProgramMember_0" xml:lang="en-US">At The Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AtMarketOfferingProgramMember_1" xml:lang="en-US">At Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AtMarketOfferingProgramMember_2" xml:lang="en-US">At The Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_0" xml:lang="en-US">Expiration period of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_1" xml:lang="en-US">Class Of Warrant Or Righst Period From Which Warrants Or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_2" xml:lang="en-US">Expiration period of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_0" xml:lang="en-US">Collaboration Agreement With U.S. Antibody Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_1" xml:lang="en-US">Collaboration Agreement With U.S. Antibody Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsMember_0" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsMember_1" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_0" xml:lang="en-US">Collaborative Arrangements Two Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_1" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CommercialLicenseAgreementMember_0" xml:lang="en-US">Commercial License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CommercialLicenseAgreementMember_1" xml:lang="en-US">Commercial License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ContingentFees_0" xml:lang="en-US">Contingent fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ContingentFees_1" xml:lang="en-US">Contingent fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ContingentFees_2" xml:lang="en-US">Contingent fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredParticipationOfBmsInRdExpenses_0" xml:lang="en-US">Deferred participation of BMS in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredParticipationOfBmsInRdExpenses_1" xml:lang="en-US">Deferred Participation Of Bms In Rd Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredParticipationOfBmsInRdExpenses_2" xml:lang="en-US">Deferred participation of BMS in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_0" xml:lang="en-US">Development, regulatory and commercial milestones compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_1" xml:lang="en-US">Development, regulatory and commercial milestones compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DocumentAndEntityInformationAbstract_0" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DocumentAndEntityInformationAbstract_1" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_FinancialIncomeExpenseNet_0" xml:lang="en-US">The aggregate of financial and other income net of expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_1" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_FinancialIncomeExpenseNet_2" xml:lang="en-US">Financial Income Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_3" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_4" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_0" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_1" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsLineItems_0" xml:lang="en-US">Government And Other Grants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsLineItems_1" xml:lang="en-US">Government and Other Grants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsMember_0" xml:lang="en-US">Government and Other Grants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsMember_1" xml:lang="en-US">Government and Other Grants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsTable_0" xml:lang="en-US">Government And Other Grants [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsTable_1" xml:lang="en-US">Government and Other Grants [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Increase (decrease) in deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Increase Decrease In Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Decrease in deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Decrease in operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Decrease in operating lease right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_0" xml:lang="en-US">Long term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_1" xml:lang="en-US">Long Term Deferred Participationin Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_2" xml:lang="en-US">Long-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementMember_0" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementMember_1" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Maximum authorized proceeds from issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Maximum Authorized Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0" xml:lang="en-US">Maximum Royalty Repaid As Percentage Of Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1" xml:lang="en-US">Maximum royalty repaid as percentage of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2" xml:lang="en-US">Maximum royalty repaid as percentage of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_May2012AgreementMember_0" xml:lang="en-US">Information pertaining to the May 2012 Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_May2012AgreementMember_1" xml:lang="en-US">May 2012 Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_May2012AgreementMember_2" xml:lang="en-US">May 2012 Agreement With Advisor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted, that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_1" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_2" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NumberOfWarrantsExercised_0" xml:lang="en-US">Number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NumberOfWarrantsExercised_1" xml:lang="en-US">Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_NumberOfWarrantsExercised_2" xml:lang="en-US">Warrants exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ParticipationRights_0" xml:lang="en-US">Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to advisor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ParticipationRights_1" xml:lang="en-US">Participation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfClosingPrice_0" xml:lang="en-US">Percentage of closing price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfClosingPrice_1" xml:lang="en-US">Percentage of closing price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfRoyaltiesOnNetSales_0" xml:lang="en-US">Percentage of royalties on net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfRoyaltiesOnNetSales_1" xml:lang="en-US">Percentage of royalties on net sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_0" xml:lang="en-US">The amount of purchase property and equipment as non cash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_1" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_2" xml:lang="en-US">Purchase Of Property And Equipment As Non Cash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_3" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_0" xml:lang="en-US">Receivables on account of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_1" xml:lang="en-US">Receivables On Account Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_2" xml:lang="en-US">Receivables on account of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RegisteredDirectOfferingMember_0" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RegisteredDirectOfferingMember_1" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RelativeFairValueOfDeferredParticipation_0" xml:lang="en-US">Relative fair value of deferred participation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RelativeFairValueOfDeferredParticipation_1" xml:lang="en-US">Relative Fair Value Of Deferred Participation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RelativeFairValueOfDeferredParticipation_2" xml:lang="en-US">Relative fair value of deferred participation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_0" xml:lang="en-US">Addition Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Additional Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2" xml:lang="en-US">Potential milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0" xml:lang="en-US">Potential milestone compensation company is now eligible for.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable On Remaining Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2" xml:lang="en-US">Potential milestone compensation company is now eligible for</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Preclinical Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2" xml:lang="en-US">Preclinical milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_0" xml:lang="en-US">Represents Research and development grant one member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_1" xml:lang="en-US">Research And Development Grant One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_2" xml:lang="en-US">Research And Development Grant One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RetainerFee_0" xml:lang="en-US">Retainer fee per month.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RetainerFee_1" xml:lang="en-US">Retainer Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RetainerFee_2" xml:lang="en-US">Retainer fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyContingentObligations_0" xml:lang="en-US">The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyContingentObligations_1" xml:lang="en-US">Royalty Contingent Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RoyaltyContingentObligations_2" xml:lang="en-US">Contingent royalty obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0" xml:lang="en-US">Royalty Percentage Based On Future Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1" xml:lang="en-US">Royalty percentage based on future revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2" xml:lang="en-US">Royalty percentage based on future revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayFundNonCurrent_0" xml:lang="en-US">Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayFundNonCurrent_1" xml:lang="en-US">Severance Pay Fund Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SeverancePayFundNonCurrent_2" xml:lang="en-US">Severance pay fund</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayNet_0" xml:lang="en-US">Severance pay, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayNet_1" xml:lang="en-US">Severance Pay Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SeverancePayNet_2" xml:lang="en-US">Decrease in severance pay, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Short term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Short Term Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Short-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_0" xml:lang="en-US">Stock-based compensation relating to options issued to employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_1" xml:lang="en-US">Stock Based Compensation Relating To Options Issued To Employees And Directors Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_2" xml:lang="en-US">Stock-based compensation issued to employees, directors and non-employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_3" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1" xml:lang="en-US">Svb Leerink Llc And Stifel Nicolaus And Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_0" xml:lang="en-US">The entire disclosure of unaudited interim consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1" xml:lang="en-US">Unaudited Interim Consolidated Financial Statements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_2" xml:lang="en-US">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_UnderwritersMember_0" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnderwritersMember_1" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessDevelopment_0" xml:lang="en-US">Marketing and business development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDevelopment_1" xml:lang="en-US">Marketing and business development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0" xml:lang="en-US">Gain from property and equipment disposal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0" xml:lang="en-US">Decrease in trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0" xml:lang="en-US">Decrease in other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_0" xml:lang="en-US">Decrease (increase) in interest receivables from short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_1" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Decrease (increase) in long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0" xml:lang="en-US">Decrease (increase) in long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_2" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_3" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_0" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_1" xml:lang="en-US">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and development expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0" xml:lang="en-US">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2" xml:lang="en-US">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsDomain_0" xml:lang="en-US">Government And Other Grants [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RelatedPartyBalancesAndTransactionsAbstract_0" xml:lang="en-US">Related Party Balances And Transactions Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0" xml:lang="en-US">Unaudited Interim Consolidated Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine3_0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeAxis_1" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis_0" xml:lang="en-US">Statement Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_StatementGeographicalAxis_1" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis_0" xml:lang="en-US">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_1" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_0" xml:lang="en-US">Trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">Stock-based compensation issued to employees, directors and non-employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Warrants purchase to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Warrants purchase to ordinary shares remain outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Ordinary shares, par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Ordinary shares, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Ordinary shares, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Ordinary shares of NIS 0.01 par value per share: 200,000,000 shares authorized on June 30, 2021 and December 31, 2020; 83,917,929 and 83,675,856 shares issued and outstanding on June 30, 2021 and December 31, 2020, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized on June 30, 2022, and December 31, 2021; 86,624,643 and 86,433,432 shares issued and outstanding on June 30, 2022, and December 31, 2021, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration of credit risks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_0" xml:lang="en-US">Related parties' expenses amounts charged to research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0" xml:lang="en-US">Trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0" xml:lang="en-US">Unrecognized compensation cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Period over which compensation expense will be recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US">Unrecognized estimated compensation cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember_0" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_0" xml:lang="en-US">Share based compensation ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_0" xml:lang="en-US">Equity investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_0" xml:lang="en-US">Gain Contingencies, Nature [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis_0" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure_0" xml:lang="en-US">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure_1" xml:lang="en-US">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">TAXES ON INCOME [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">TAXES ON INCOME</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Increase in other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0" xml:lang="en-US">Increase in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0" xml:lang="en-US">Decrease in operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndOtherIncomeTableTextBlock_0" xml:lang="en-US">Schedule of Financial And Other Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest_0" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest_1" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest_2" xml:lang="en-US">Interest Income, Deposits with Financial Institutions, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0" xml:lang="en-US">Amount of investment in Compugen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">NON- CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recently adopted accounting pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Current maturity of operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Long term operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right to use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">GENERAL [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0" xml:lang="en-US">GENERAL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_0" xml:lang="en-US">FINANCIAL AND OTHER INCOME, NET [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_1" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" xml:lang="en-US">FINANCIAL AND OTHER INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1" xml:lang="en-US">Exchange rate differences and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherShortTermInvestments_0" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0" xml:lang="en-US">Accrued severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0" xml:lang="en-US">Proceeds from ordinary shares in offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from issuance of ordinary shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_0" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_2" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_1" xml:lang="en-US">Proceeds from equity investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0" xml:lang="en-US">Proceeds from sales of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Proceeds from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from warrant exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyLeaseGuaranteeMember_0" xml:lang="en-US">Office leases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_1" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0" xml:lang="en-US">Upfront payment received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_0" xml:lang="en-US">Percentage of workforce reduction from restructuring activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0" xml:lang="en-US">Revenue recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" xml:lang="en-US">Schedule of financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of related party balances and transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Weighted-average Assumptions Used to Estimate Fair Value of Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of weighted-average assumptions used to estimate fair value of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Expected dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0" xml:lang="en-US">Expected volatility, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0" xml:lang="en-US">Expected volatility, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0" xml:lang="en-US">Expected risk free interest rate range, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0" xml:lang="en-US">Expected risk free interest rates range, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xml:lang="en-US">Ordinary shares available for issuance | shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average fair value of options granted during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1" xml:lang="en-US">Number of shares purchased for ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Stock options granted, exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_0" xml:lang="en-US">Stock options granted, exercise price, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0" xml:lang="en-US">Stock options granted, exercise price, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0" xml:lang="en-US">SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Offering price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">SHAREHOLDERS' EQUITY:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">SHAREHOLDERS' EQUITY [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0" xml:lang="en-US">Issuance of ordinary shares pursuant to the ESPP, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1" xml:lang="en-US">Issuance of ESPP shares, (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Issuance of shares, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Options exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0" xml:lang="en-US">Issuance of ordinary shares pursuant to the ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1" xml:lang="en-US">Issuance of ESPP shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Value of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionPlanExpense_0" xml:lang="en-US">Share based compensation stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplyCommitmentAxis_0" xml:lang="en-US">Supply Commitment [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_1" xlink:to="lab_cgen_AccruedMilestonePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_2" xlink:to="lab_cgen_AccruedMilestonePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_3" xlink:to="lab_cgen_AccruedMilestonePayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementMember_4" xlink:to="lab_cgen_AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementMember_5" xlink:to="lab_cgen_AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_6" xlink:to="lab_cgen_AgreementStartDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_7" xlink:to="lab_cgen_AgreementStartDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_8" xlink:to="lab_cgen_AgreementTerminationDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_9" xlink:to="lab_cgen_AgreementTerminationDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_10" xlink:to="lab_cgen_AgreementTerminationDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmountIncurredMilestonePayments_11" xlink:to="lab_cgen_AmountIncurredMilestonePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmountIncurredMilestonePayments_12" xlink:to="lab_cgen_AmountIncurredMilestonePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_13" xlink:to="lab_cgen_AtMarketOfferingProgramMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_14" xlink:to="lab_cgen_AtMarketOfferingProgramMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_15" xlink:to="lab_cgen_AtMarketOfferingProgramMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_16" xlink:to="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_17" xlink:to="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_18" xlink:to="lab_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_19" xlink:to="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_20" xlink:to="lab_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_21" xlink:to="lab_cgen_CollaborativeArrangementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_22" xlink:to="lab_cgen_CollaborativeArrangementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_23" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_24" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CommercialLicenseAgreementMember_25" xlink:to="lab_cgen_CommercialLicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CommercialLicenseAgreementMember_26" xlink:to="lab_cgen_CommercialLicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_27" xlink:to="lab_cgen_ContingentFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_28" xlink:to="lab_cgen_ContingentFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_29" xlink:to="lab_cgen_ContingentFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBmsInRdExpenses_30" xlink:to="lab_cgen_DeferredParticipationOfBmsInRdExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBmsInRdExpenses_31" xlink:to="lab_cgen_DeferredParticipationOfBmsInRdExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBmsInRdExpenses_32" xlink:to="lab_cgen_DeferredParticipationOfBmsInRdExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_33" xlink:to="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_34" xlink:to="lab_cgen_DevelopmentRegulatoryAndCommercialMilestonesCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DocumentAndEntityInformationAbstract_35" xlink:to="lab_cgen_DocumentAndEntityInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DocumentAndEntityInformationAbstract_36" xlink:to="lab_cgen_DocumentAndEntityInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_37" xlink:to="lab_cgen_FinancialIncomeExpenseNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_38" xlink:to="lab_cgen_FinancialIncomeExpenseNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_39" xlink:to="lab_cgen_FinancialIncomeExpenseNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_40" xlink:to="lab_cgen_FinancialIncomeExpenseNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_41" xlink:to="lab_cgen_FinancialIncomeExpenseNet_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_42" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_43" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_44" xlink:to="lab_cgen_GovernmentAndOtherGrantsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_45" xlink:to="lab_cgen_GovernmentAndOtherGrantsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsMember_46" xlink:to="lab_cgen_GovernmentAndOtherGrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsMember_47" xlink:to="lab_cgen_GovernmentAndOtherGrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_48" xlink:to="lab_cgen_GovernmentAndOtherGrantsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_49" xlink:to="lab_cgen_GovernmentAndOtherGrantsTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_50" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_51" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_52" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_53" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_54" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_55" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_56" xlink:to="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_57" xlink:to="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_58" xlink:to="lab_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_59" xlink:to="lab_cgen_MasterClinicalAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_60" xlink:to="lab_cgen_MasterClinicalAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_61" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_62" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_63" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_64" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_65" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_66" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_67" xlink:to="lab_cgen_May2012AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_68" xlink:to="lab_cgen_May2012AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_69" xlink:to="lab_cgen_May2012AgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_70" xlink:to="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_71" xlink:to="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_72" xlink:to="lab_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_73" xlink:to="lab_cgen_NumberOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_74" xlink:to="lab_cgen_NumberOfWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_75" xlink:to="lab_cgen_NumberOfWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_76" xlink:to="lab_cgen_ParticipationRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_77" xlink:to="lab_cgen_ParticipationRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_78" xlink:to="lab_cgen_PercentageOfClosingPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_79" xlink:to="lab_cgen_PercentageOfClosingPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfRoyaltiesOnNetSales_80" xlink:to="lab_cgen_PercentageOfRoyaltiesOnNetSales_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfRoyaltiesOnNetSales_81" xlink:to="lab_cgen_PercentageOfRoyaltiesOnNetSales_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_82" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_83" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_84" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_85" xlink:to="lab_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_86" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_87" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_88" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_89" xlink:to="lab_cgen_RegisteredDirectOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_90" xlink:to="lab_cgen_RegisteredDirectOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelativeFairValueOfDeferredParticipation_91" xlink:to="lab_cgen_RelativeFairValueOfDeferredParticipation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelativeFairValueOfDeferredParticipation_92" xlink:to="lab_cgen_RelativeFairValueOfDeferredParticipation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelativeFairValueOfDeferredParticipation_93" xlink:to="lab_cgen_RelativeFairValueOfDeferredParticipation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_94" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_95" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementAdditionalPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_96" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_97" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_98" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_99" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_100" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_101" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_102" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_103" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_104" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_105" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_106" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_107" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_108" xlink:to="lab_cgen_RetainerFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_109" xlink:to="lab_cgen_RetainerFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_110" xlink:to="lab_cgen_RetainerFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_111" xlink:to="lab_cgen_RoyaltyContingentObligations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_112" xlink:to="lab_cgen_RoyaltyContingentObligations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_113" xlink:to="lab_cgen_RoyaltyContingentObligations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_114" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_115" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_116" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNonCurrent_117" xlink:to="lab_cgen_SeverancePayFundNonCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNonCurrent_118" xlink:to="lab_cgen_SeverancePayFundNonCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNonCurrent_119" xlink:to="lab_cgen_SeverancePayFundNonCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_120" xlink:to="lab_cgen_SeverancePayNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_121" xlink:to="lab_cgen_SeverancePayNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_122" xlink:to="lab_cgen_SeverancePayNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_123" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_124" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_125" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_126" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_127" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_128" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_129" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_130" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_131" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_132" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_133" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_134" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_135" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_136" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_137" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_138" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_139" xlink:to="lab_cgen_UnderwritersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_140" xlink:to="lab_cgen_UnderwritersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment_141" xlink:to="lab_us-gaap_BusinessDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment_142" xlink:to="lab_us-gaap_BusinessDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_143" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_144" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_145" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_146" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_147" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_148" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_149" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_150" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_151" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_152" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_153" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_154" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_155" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_156" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_157" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_158" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_159" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_160" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_161" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_162" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_163" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_164" xlink:to="lab_us-gaap_OperatingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_165" xlink:to="lab_us-gaap_OperatingExpenses_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_166" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_167" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_168" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_169" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_170" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_171" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_172" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_173" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_174" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_175" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_176" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_177" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_178" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_179" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_180" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_181" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_182" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_183" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_184" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_185" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_186" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_187" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_188" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_189" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_190" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_191" xlink:to="lab_cgen_GovernmentAndOtherGrantsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_192" xlink:to="lab_cgen_RelatedPartyBalancesAndTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_193" xlink:to="lab_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_194" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_195" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_196" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_197" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_198" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_199" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_200" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_201" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_202" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_203" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3_204" xlink:to="lab_dei_EntityAddressAddressLine3_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_205" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_206" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_207" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_208" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_209" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_210" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_211" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_212" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_213" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_214" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_215" xlink:to="lab_srt_RangeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_216" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_217" xlink:to="lab_srt_StatementGeographicalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_218" xlink:to="lab_srt_StatementGeographicalAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_219" xlink:to="lab_srt_StatementScenarioAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_220" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_221" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_222" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_223" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_224" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_225" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_226" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_227" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_228" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_229" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_230" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_231" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_232" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_233" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_234" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_235" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_236" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_237" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_238" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_239" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_240" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_241" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_242" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_243" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_244" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_245" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_246" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_247" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_248" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_249" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_250" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_251" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_252" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_253" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_254" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_255" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_256" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_257" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_258" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_259" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_260" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_261" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_262" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_263" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_264" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_265" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_266" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_267" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_268" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_269" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_270" xlink:to="lab_us-gaap_EmployeeStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_271" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost_272" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired_273" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_274" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_275" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure_276" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure_277" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_278" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_279" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_280" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_281" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_282" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_283" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_284" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncomeTableTextBlock_285" xlink:to="lab_us-gaap_InterestAndOtherIncomeTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_286" xlink:to="lab_us-gaap_InterestIncomeDepositsWithFinancialInstitutions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_287" xlink:to="lab_us-gaap_InvestmentIncomeInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_288" xlink:to="lab_us-gaap_InvestmentIncomeInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_289" xlink:to="lab_us-gaap_InvestmentIncomeInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_290" xlink:to="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_291" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_292" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_293" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_294" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_295" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_296" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_297" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_298" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_299" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_300" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_301" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_302" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_303" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_304" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_305" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_306" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_307" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_308" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_310" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_311" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_312" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_313" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_314" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_315" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_316" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_317" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_318" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_319" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_320" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_321" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_322" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_323" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_324" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments_325" xlink:to="lab_us-gaap_OtherShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_326" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_327" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_328" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_329" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_330" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_331" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_332" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_333" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_334" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_335" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_336" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_337" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_338" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_339" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_340" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_341" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_342" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyLeaseGuaranteeMember_343" xlink:to="lab_us-gaap_PropertyLeaseGuaranteeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_344" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_345" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_346" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_347" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_348" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_349" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_350" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_351" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_352" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_353" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_354" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_355" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_356" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_357" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_358" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_360" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_361" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_362" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_363" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_364" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_365" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_366" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_367" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_368" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_369" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_370" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_371" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_372" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_373" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_374" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_375" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_376" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_377" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_378" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_379" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_380" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_381" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_382" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_383" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_384" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_385" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_386" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_387" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_388" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_389" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_390" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_391" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_392" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_393" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_394" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_395" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_396" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_397" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_398" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_399" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_400" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense_401" xlink:to="lab_us-gaap_StockOptionPlanExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_402" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_403" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_404" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_405" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis_406" xlink:to="lab_us-gaap_SupplyCommitmentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_407" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_408" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_409" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_410" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_411" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_412" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_413" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cgen-20220630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-daei1" roleURI="http://cgen.com/role/cgen-daei1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-cbs" roleURI="http://cgen.com/role/cgen-cbs"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-cbsp" roleURI="http://cgen.com/role/cgen-cbsp"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-socise1" roleURI="http://cgen.com/role/cgen-socise1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-g" roleURI="http://cgen.com/role/cgen-g"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-sap1" roleURI="http://cgen.com/role/cgen-sap1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#UnauditedInterimConsolidatedFinancialStatements" roleURI="http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-cac" roleURI="http://cgen.com/role/cgen-cac"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-se1" roleURI="http://cgen.com/role/cgen-se1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#TaxesOnIncome" roleURI="http://cgen.com/role/TaxesOnIncome"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-fin" roleURI="http://cgen.com/role/cgen-fin"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-rpbat" roleURI="http://cgen.com/role/cgen-rpbat"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-set" roleURI="http://cgen.com/role/cgen-set"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-fint" roleURI="http://cgen.com/role/cgen-fint"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#RelatedPartyBalancesAndTransactionsTables" roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-gd1" roleURI="http://cgen.com/role/cgen-gd1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#ShareholdersEquityIssuanceOfSharesDetails" roleURI="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#ShareholdersEquityScheduleOfStock-basedCompensationDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-find" roleURI="http://cgen.com/role/cgen-find"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#cgen-rpbatd" roleURI="http://cgen.com/role/cgen-rpbatd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20220630.xsd#SUBSEQUENTEVENTS" roleURI="http://cgen.com/role/SUBSEQUENTEVENTS"/>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentType_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AmendmentFlag_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityFileNumber_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine1_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine2_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine3_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCityOrTown_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCountry_15" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressPostalZipCode_16" order="150" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbs">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SeverancePayFundNonCurrent" xlink:label="loc_cgen_SeverancePayFundNonCurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_cgen_SeverancePayFundNonCurrent_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_us-gaap_AssetsNoncurrent_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_AccountsPayableCurrent_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_18" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_19" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_LiabilitiesCurrent_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_22" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_22" xlink:to="loc_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_22" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_23" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_22" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_24" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_22" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_CommitmentsAndContingencies_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_StockholdersEquityAbstract_28" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_CommonStockValue_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_29" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_30" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_StockholdersEquity_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbsp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_BusinessDevelopment_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-socise1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_NumberOfWarrantsExercised_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_NetIncomeLoss_15" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_17" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction" xlink:label="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_SeverancePayNet_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_12" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_13" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_14" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_21" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_24" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_25" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_26" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" xlink:to="loc_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" xlink:to="loc_cgen_ReceivablesOnAccountOfShares_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-g">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sap1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements">
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock" xlink:label="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract_0" xlink:to="loc_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cac">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-se1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/TaxesOnIncome">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-fin">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-rpbat">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_6" order="50" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-set">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_EmployeeStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-fint">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RelatedPartyBalancesAndTransactionsAbstract" xlink:label="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_RelatedPartyBalancesAndTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-gd1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_AccruedMilestonePayment_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_7" order="60" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsTable" xlink:label="loc_cgen_GovernmentAndOtherGrantsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyLeaseGuaranteeMember" xlink:label="loc_us-gaap_PropertyLeaseGuaranteeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsMember" xlink:label="loc_cgen_GovernmentAndOtherGrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CommercialLicenseAgreementMember" xlink:label="loc_cgen_CommercialLicenseAgreementMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborationAgreementWithUSAntibodyCompanyMember" xlink:label="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_GovernmentAndOtherGrantsLineItems" xlink:label="loc_cgen_GovernmentAndOtherGrantsLineItems_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PercentageOfRoyaltiesOnNetSales" xlink:label="loc_cgen_PercentageOfRoyaltiesOnNetSales_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AmountIncurredMilestonePayments" xlink:label="loc_cgen_AmountIncurredMilestonePayments_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_cgen_GovernmentAndOtherGrantsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_1" xlink:to="loc_us-gaap_PropertyLeaseGuaranteeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_StatementGeographicalAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4" xlink:to="loc_srt_SegmentGeographicalDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_IL_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_7" xlink:to="loc_cgen_GovernmentAndOtherGrantsMember_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_srt_RangeAxis_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_10" xlink:to="loc_srt_RangeMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MinimumMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MaximumMember_11" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_14" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_14" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_14" xlink:to="loc_cgen_May2012AgreementMember_14" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_14" xlink:to="loc_cgen_CommercialLicenseAgreementMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_us-gaap_SupplyCommitmentAxis_18" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_18" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_18" xlink:to="loc_cgen_CollaborationAgreementWithUSAntibodyCompanyMember_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsLineItems_21" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_RoyaltyContingentObligations_24" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_ContingentFees_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_ParticipationRights_26" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_RetainerFee_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_AgreementStartDate_29" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_AgreementTerminationDescription_30" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_PercentageOfRoyaltiesOnNetSales_31" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsLineItems_21" xlink:to="loc_cgen_AmountIncurredMilestonePayments_32" order="110" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="loc_cgen_DeferredParticipationOfBmsInRdExpenses_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_RelativeFairValueOfDeferredParticipation" xlink:label="loc_cgen_RelativeFairValueOfDeferredParticipation_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_47"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AtMarketOfferingProgramMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_AgreementMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_cgen_RegisteredDirectOfferingMember_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_cgen_UnderwritersMember_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_WarrantMember_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" xlink:to="loc_us-gaap_EmployeeStockMember_14" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_17" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_19" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_21" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_22" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_23" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_24" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_25" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_27" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_cgen_PercentageOfClosingPrice_28" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_cgen_DeferredParticipationOfBmsInRdExpenses_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_cgen_RelativeFairValueOfDeferredParticipation_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_31" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_32" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_33" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_34" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_35" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_36" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_37" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_38" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_StockOptionPlanExpense_40" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_41" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_42" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_43" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_44" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_45" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_46" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_47" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_us-gaap_EmployeeStockMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="50" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-find">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20220630.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-rpbatd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image00001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ =P!2  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !O 1L# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8 %/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQEC7MU% 'Q3_ ,*V\:_]"OJG_@.U?8F@:>ND>'=-TY5VBUM8X< =U4 UI44
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291245910016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COMPUGEN LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001119774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Harokmim Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291245309904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,008<span></span>
</td>
<td class="nump">$ 7,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term bank deposits</a></td>
<td class="nump">88,917<span></span>
</td>
<td class="nump">109,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">4,696<span></span>
</td>
<td class="nump">5,460<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">101,984<span></span>
</td>
<td class="nump">123,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">1,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SeverancePayFundNonCurrent', window );">Severance pay fund</a></td>
<td class="nump">2,866<span></span>
</td>
<td class="nump">3,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right to use asset</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">2,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,658<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">8,328<span></span>
</td>
<td class="nump">8,941<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">110,312<span></span>
</td>
<td class="nump">132,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses', window );">Short-term deferred participation in R&amp;D expenses</a></td>
<td class="nump">2,906<span></span>
</td>
<td class="nump">3,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">8,320<span></span>
</td>
<td class="nump">8,078<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,995<span></span>
</td>
<td class="nump">17,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON- CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses', window );">Long-term deferred participation in R&amp;D expenses</a></td>
<td class="nump">1,051<span></span>
</td>
<td class="nump">2,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term operating lease liability</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent', window );">Accrued severance pay</a></td>
<td class="nump">3,394<span></span>
</td>
<td class="nump">3,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">5,936<span></span>
</td>
<td class="nump">8,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized on June 30, 2022, and December 31, 2021; 86,624,643 and 86,433,432 shares issued and outstanding on June 30, 2022, and December 31, 2021, respectively</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">531,074<span></span>
</td>
<td class="nump">528,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(440,933)<span></span>
</td>
<td class="num">(422,079)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">90,381<span></span>
</td>
<td class="nump">106,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 110,312<span></span>
</td>
<td class="nump">$ 132,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayFundNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayFundNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short term deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79708-111665<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291245766448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value per share</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="nump">86,433,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="nump">86,433,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291245907440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 14,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Marketing and business development expenses</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">5,173<span></span>
</td>
<td class="nump">5,373<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,633<span></span>
</td>
<td class="nump">19,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="nump">18,854<span></span>
</td>
<td class="nump">19,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 18,854<span></span>
</td>
<td class="nump">$ 19,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="nump">$ 18,854<span></span>
</td>
<td class="nump">$ 19,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">86,486,612<span></span>
</td>
<td class="nump">83,739,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">86,486,612<span></span>
</td>
<td class="nump">83,739,983<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate of financial and other income net of expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291245474608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 507,427<span></span>
</td>
<td class="num">$ (387,876)<span></span>
</td>
<td class="nump">$ 119,782<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">83,675,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">461<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">115,877<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">425<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_NumberOfWarrantsExercised', window );">Warrants exercised, shares</a></td>
<td class="nump">89,557<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ESPP shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">239<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ESPP shares, (in shares)</a></td>
<td class="nump">36,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue', window );">Stock-based compensation issued to employees, directors and non-employees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,916<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,402)<span></span>
</td>
<td class="num">(19,402)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">510,468<span></span>
</td>
<td class="num">(407,278)<span></span>
</td>
<td class="nump">103,421<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Jun. 30, 2021</a></td>
<td class="nump">83,917,929<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">528,533<span></span>
</td>
<td class="num">(422,079)<span></span>
</td>
<td class="nump">$ 106,693<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">86,433,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,433,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">104<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">33,186<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ESPP shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">248<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ESPP shares, (in shares)</a></td>
<td class="nump">158,025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue', window );">Stock-based compensation issued to employees, directors and non-employees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,854)<span></span>
</td>
<td class="num">(18,854)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 531,074<span></span>
</td>
<td class="num">$ (440,933)<span></span>
</td>
<td class="nump">$ 90,381<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,624,643<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount lower than $ 1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation relating to options issued to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291245730560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,854)<span></span>
</td>
<td class="num">$ (19,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,189<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SeverancePayNet', window );">Decrease in severance pay, net</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain from property and equipment disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Decrease in operating lease right of use asset</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Decrease (increase) in interest receivables from short-term bank deposits</a></td>
<td class="num">(114)<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Decrease in trade receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease in other accounts receivable and prepaid expenses</a></td>
<td class="nump">764<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in long-term prepaid expenses</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in trade payables</a></td>
<td class="num">(2,387)<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in other accounts payable and accrued expenses</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in operating lease liability</a></td>
<td class="num">(644)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses', window );">Decrease in deferred participation in R&amp;D expenses</a></td>
<td class="num">(2,387)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,683)<span></span>
</td>
<td class="num">(13,629)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturity of short-term bank deposits</a></td>
<td class="nump">58,945<span></span>
</td>
<td class="nump">71,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Investment in short-term bank deposits</a></td>
<td class="num">(38,500)<span></span>
</td>
<td class="num">(57,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(258)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">20,187<span></span>
</td>
<td class="nump">13,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(143)<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">8,514<span></span>
</td>
<td class="nump">7,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">8,371<span></span>
</td>
<td class="nump">8,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction', window );">Purchase of property and equipment</a></td>
<td class="num">(80)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ReceivablesOnAccountOfShares', window );">Receivables on account of shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchase property and equipment as non cash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ReceivablesOnAccountOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables on account of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ReceivablesOnAccountOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Severance pay, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291250568256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>GENERAL [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 1:-</span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">GENERAL</span></span></strong></p>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:26.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">a.</span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div>
                    <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Compugen (the &#8220;Company&#8221;) is a clinical-stage, therapeutic discovery and development company utilizing its proprietary computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company&#8217;s innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the Company discovered computationally, COM701, COM902, bapotulimab (formerly known as BAY 1905254) and AZD2936. The Company&#8217;s therapeutic pipeline also includes early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The innovative immuno-oncology pipeline, the strategic collaborations and the Company&#8217;s computational discovery engine serves as the three key corporate building blocks.</span></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25">&#160;</div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">b.</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Company is headquartered in Holon, Israel. Its clinical development activities operate from its U.S. subsidiary in South San Francisco, California.</span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">c.</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint regulators.</span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $10,000, and, following the return of the CGEN 15022 program in 2017 to the Company, the Company is eligible to receive an aggregate of over $250,000 in potential milestone payments, not including aggregate milestone payments of approximately $23,000 received to date. Additionally, the Company is eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.</span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Pursuant to the terms of Bayer Agreement, bapotulimab program was transferred to Bayer&#8217;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing licenses from Compugen.</span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.8pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">d.</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development and commercial activities under the agreement. Compugen received a $10,000 upfront payment and $8,000 milestone payment out of up to $200,000 that the Company is eligible to receive in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></div>
              </td>
            </tr>

        </table>
        <div/>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">e.</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol-Myers Squibb Company (&#8220;Bristol-Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. Pursuant to the Master Clinical Agreement, Compugen is responsible for and will continue sponsoring the ongoing two-part Phase 1 trial, which includes the evaluation of the combination of COM701 and Opdivo&#174;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplies its own compound(s) for the studies, and otherwise each party is responsible for all costs associated with the study that it is conducting.<br/>&#160;<br/>In conjunction with the signing of the Master Clinical Agreement, Bristol-Myers Squibb made a $12,000 investment in Compugen, see Note 5a.</span></div>
              </td>
            </tr>
            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
            </tr>
            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On February 14, 2020, the Master Clinical Agreement with Bristol-Myers Squibb was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol-Myers Squibb&#8217;s antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#174;.</span></div>
                <div style="margin:0pt">&#160;</div>
                <div style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Pursuant to the Master Clinical Agreement, as amended, the Company sponsors the two-part Phase 1/2 trial, which includes the evaluation of the triple combination of COM701, Opdivo&#174; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provides Opdivo&#174; and BMS-986207 at no cost to the Company.</span></div>
                <div style="margin:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">As part of the said amendment, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo&#174; under the Phase 1 study and will not continue the expansion cohorts of the dual combination.</span></div>
                <div style="margin:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On February 19, 2021, the Master Clinical Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced solid tumors, where Compugen is responsible for and sponsors the expansion cohort and Bristol-Myers Squibb provides Opdivo&#174; at no cost to us for this study.</span></div>
                <div style="margin:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration.</span></div>
                <div style="margin:0pt">&#160;</div>
                <div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $20,000 investment in Compugen, see Note 5a.</span></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291249477072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 2:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNIFICANT ACCOUNTING POLICIES</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
            </tr>
            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2021. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2021, are applied consistently in these interim consolidated financial statements.</span></p>
              </td>
            </tr>

        </table>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291250359776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract', window );"><strong>Unaudited Interim Consolidated Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock', window );">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Operating results for the six-month period ended June 30, 2022, are not necessarily indicative of the results that may be expected for the year ended December 31, 2022.</span></span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of unaudited interim consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291249493840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS AND CONTINGENCIES</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company provided bank guarantees in the amount of $320 in favor of its offices in Israel, car leases in Israel and credit card security for its U.S. subsidiary.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company received in the past grants from the office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist, (&#8220;IIA&#8221;). The Company is not obligated to repay any amounts received from the IIA if it does not generate any income from products which incorporate technologies which were funded by such research program(s).</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If income is generated from products which incorporate technologies which were funded by a research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue generated from products that incorporate technologies that were funded by such research program(s), up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum amount to be repaid is 100% plus interest at LIBOR).</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2022, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled $9,867.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
          <div style="line-height:1.25">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div>
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company is entitled to certain royalties that could be eliminated upon payment of certain one-time fees (all milestone and royalties payments referred together as &#8220;Contingent Fees&#8221;). For the six-month periods ended June 30, 2022 and 2021, the Company did not incur Contingent Fees.</span></span></div>
                  </div>
                </td>
              </tr>

          </table>
        </div>
        <div/>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 9, 2012, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates. Under the agreement the Advisor shall be entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months ended June 30, 2022 and 2021, the Company had not paid nor accrued any expenses related to this agreement.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;line-height:1.25">
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify">
                  <div style="font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (&#8220;CLA&#8221;) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the six-month periods ended June 30, 2022 and 2021, the Company did not incur milestone payments.<br/>&#160;</span></span></span></div>
                </td>
              </tr>

          </table>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the six-month periods ended June 30, 2022 and 2021 the Company incurred milestone payments in the amounts of $0 and $150.</span></span></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291249493552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>SHAREHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text">
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 5:-</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS' EQUITY</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of Shares:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 14, 2018, the Company entered into agreements in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of 5,316,457 Ordinary Shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional Ordinary Shares (the &#8220;Warrants&#8221;). The Warrants are exercisable at a price of $4.74 per Ordinary Share and have a term of five years from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $19,767 (net of $1,233 issuance expenses).</span></span></div>
        <div/>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six-month periods ended June 30, 2022 and 2021, warrants to purchase an aggregate of 0 and 89,557 Ordinary Shares were exercised with proceeds of approximately $0 and $425, respectively, and warrants to purchase up to 297,469 Ordinary Shares remain outstanding as of June 30, 2022.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $12,000 equity investment in the Company.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $4.95 per share. The share price represents a 33% premium over the average closing price of Compugen&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $4,121 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses which are amortized over the period of the clinical trial based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221; and $7,788 (net of $91 issuance expenses) were considered equity investment.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $8.57333 per share. The share price represented a 33% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $5,000 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;) and $14,958 (net of $42 issuance expenses) were considered equity investment.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp; Company, Incorporated, as representatives of the several underwriters relating to the issuance and sale in a public offering of 8,333,334 of the Company&#8217;s ordinary shares at a price to the public of $9.00 per share (and a price of $8.46 per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement an additional 483,005 ordinary shares pursuant to the underwriters&#8217; option specified above. The Company sold a total of 8,816,339 ordinary shares in the offering with proceeds of $74,147 (net of $5,200 issuance expenses).</span></span></div>
        <div/>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock option plan:</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six-month period ended June 30, 2022, the Company&#8217;s Board of Directors granted 1,497,500 options to purchase ordinary shares of the Company to employees, directors and non-employees. The exercise prices for such options range from $1.90 to $5.00 per share, with vesting to occur in up to four years.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents the assumptions used to estimate the fair value of the options granted in the periods presented:</span></span></div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:84.45pt">

            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69%-72</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">66%-67</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.5%-3.0</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.5%-0.8</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.0-5.4</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.1</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
      </div>
    </div>
    <div>
      <div>
        <div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average fair value of options granted during the six-month periods ended June 30, 2022 and 2021 were $1.94 and $5.54, respectively.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six-month periods ended June 30, 2022 and 2021, the Company recorded share based compensation related to stock options in a total amount of $2,092 and $1,805, respectively.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2022, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $11,614 which is expected to be recognized over a weighted average period of approximately<span style="font-weight:bold">&#160;</span>2.85 years.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months ended June 30, 2022 and 2021, the total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 8,504,958 and 6,242,283, respectively.</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee Stock Purchase Plan:</span></span></div>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its stock-option awards and Employee Stock Purchase Plan (&#8220;ESPP&#8221;).</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2022 and since its adoption, 275,854 Ordinary Shares had been purchased under the ESPP and 324,146 Ordinary Shares were available for future issuance under the ESPP.</span></span></div>
          <div/>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div>
            <div style="margin-left:56.7pt">

                <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">65%-70</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">64%-70</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.1%-1.7</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.0%-0.1</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.5</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.4-0.5</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>

                </table>

            </div>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six-month periods ended June 30, 2022 and 2021, the Company recorded ESPP compensation in a total amount of $97 and $111.</span></span></div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291249493840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>FINANCIAL AND OTHER INCOME, NET [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">FINANCIAL AND OTHER INCOME, NET</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 6:-</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">FINANCIAL AND OTHER INCOME, NET</span></p>
                </td>
              </tr>

          </table>
          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
          <div>
            <div style="margin-left:56.7pt">

                <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>463</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>528</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences and other</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">316</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">31</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>779</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>559</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>

                </table>

            </div>
          </div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291250324576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY BALANCES AND TRANSACTIONS</a></td>
<td class="text">
            <div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 7:-</span></span></td>
                    <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>RELATED PARTY BALANCES AND TRANSACTIONS</strong></span></p>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>

                <div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Balances with related parties:</span></span></span></div>
                  <div>
                    <div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>June 30,</span></strong></span></span></div>
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2022</span></strong></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>December&#160;31,<br/>2021</span></strong></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
                                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                              </td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;Trade and other payables (a)</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>141</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>94</span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                            </tr>

                        </table>
                      </div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                      <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Related parties' expenses:</span></span></span></div>
                      <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <div>
                          <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Six months ended</span></strong></span></span></div>
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>June 30,</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2022</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2021</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Amounts charged to:</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development expenses (a)</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>114</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>110</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              </tr>

                          </table>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;width:56.7pt">&#160;</td>
                        <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:32pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(a)</span></span></span></td>
                        <td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif">
                          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</span></span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>

            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291328706992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>NOTE 8:-</span></span></span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>SUBSEQUENT EVENTS</span></span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>On August 3, 2022, the Company and Bristol-Myers Squibb entered into a letter agreement pursuant to which the Master Clinical Agreement, as amended thereafter, is terminated as of such date. Such termination also includes termination of the right of first negotiation and the exclusivity right granted to BMS thereunder.</span></span></span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:56.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The parties shall use reasonable efforts to wind down activities under the Master Clinical Agreement with respect to the dual combination study of COM701 with nivolumab and the triple combination study of COM701 with nivolumab and BMS- 986207 and will create a sub-team of the parties to oversee such wind-down activities.</span></span></span></span></span></div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291245879552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to estimate fair value of options granted</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69%-72</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">66%-67</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.5%-3.0</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.5%-0.8</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                    <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.0-5.4</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.1</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to estimate fair value of options granted</a></td>
<td class="text">
                <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">65%-70</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">64%-70</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.1%-1.7</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.0%-0.1</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom">
                        <div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life (years)</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.5</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.4-0.5</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>

                </table>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291250573520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>FINANCIAL AND OTHER INCOME, NET [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of financial and other income, net</a></td>
<td class="text">
                <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                      <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest income</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>463</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>528</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange rate differences and other</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">316</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">31</span></span></div>
                      </td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom">&#160;</td>
                      <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:76%" valign="bottom">
                        <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>779</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>559</span></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                    </tr>

                </table>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291249529840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_RelatedPartyBalancesAndTransactionsAbstract', window );"><strong>Related Party Balances And Transactions Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party balances and transactions</a></td>
<td class="text">
                <div>
                  <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Balances with related parties:</span></span></span></div>
                  <div>
                    <div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>June 30,</span></strong></span></span></div>
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2022</span></strong></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                                <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>December&#160;31,<br/>2021</span></strong></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
                                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                              </td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                              <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                            </tr>
                            <tr>
                              <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;Trade and other payables (a)</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>141</span></span></span></div>
                              </td>
                              <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                              <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                <div style="line-height:1.25;font-family:Arial"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>94</span></span></span></div>
                              </td>
                              <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                            </tr>

                        </table>
                      </div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                      <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;margin-left:56.7pt"><span style="font-family:Times New Roman,Times,serif"><span>Related parties' expenses:</span></span></span></div>
                      <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
                      <div style="margin-left:56.7pt">
                        <div>
                          <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%">

                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Six months ended</span></strong></span></span></div>
                                  <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>June 30,</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2022</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>2021</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                                <td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                                  <div style="text-align:center;line-height:1.25;text-indent:2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Unaudited</span></strong></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Amounts charged to:</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                                <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                              </tr>
                              <tr>
                                <td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom">
                                  <div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research and development expenses (a)</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>114</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom">
                                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>110</span></span></span></div>
                                </td>
                                <td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom">&#160;</td>
                              </tr>

                          </table>
                        </div>
                      </div>
                    </div>
                  </div>
                  <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="font-family:Times New Roman, Times, serif;width:56.7pt">&#160;</td>
                        <td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:32pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(a)</span></span></span></td>
                        <td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif">
                          <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</span></span></span></div>
                        </td>
                      </tr>

                  </table>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RelatedPartyBalancesAndTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RelatedPartyBalancesAndTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291246108928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2013</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>GENERAL [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AccruedMilestonePayment', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Potential milestone compensation</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable', window );">Preclinical milestone compensation</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue', window );">Amount of investment in Compugen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccruedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccruedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount on the investment owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 10<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6438156&amp;loc=d3e57880-113973<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 10<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6431724&amp;loc=d3e32938-113948<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291246041376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 05, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=cgen_CollaborationAgreementWithUSAntibodyCompanyMember', window );">Collaboration Agreement With U.S. Antibody Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AmountIncurredMilestonePayments', window );">Amount incurred milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AgreementStartDate', window );">Agreement, start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  09,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AgreementTerminationDescription', window );">Agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_CommercialLicenseAgreementMember', window );">Commercial License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | May 2012 Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ParticipationRights', window );">Participation Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember', window );">Government and Other Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived', window );">Maximum royalty repaid as percentage of grant received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_RoyaltyContingentObligations', window );">Royalty Contingent Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember', window );">Government and Other Grants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember', window );">Government and Other Grants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsLineItems', window );"><strong>Government and Other Grants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Start date of the agreement, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AmountIncurredMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount incurred milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AmountIncurredMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government And Other Grants [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Royalty Repaid As Percentage Of Grant Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ParticipationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to advisor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ParticipationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyContingentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyContingentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentageBasedOnFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage Based On Future Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentageBasedOnFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=cgen_CollaborationAgreementWithUSAntibodyCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=cgen_CollaborationAgreementWithUSAntibodyCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_CommercialLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_CommercialLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=cgen_GovernmentAndOtherGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291241158000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Detail Textuals)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 14, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 14, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock options granted, exercise price, minimum | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock options granted, exercise price, maximum | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted during period | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 5.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Share based compensation stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,092<span></span>
</td>
<td class="nump">$ 1,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized estimated compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation expense will be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,504,958<span></span>
</td>
<td class="nump">6,242,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of shares purchased for ESPP | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for issuance | shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Share based compensation ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase to ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants purchase to ordinary shares remain outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_AgreementMember', window );">Agreement [Member] | Registered direct offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,316,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase to ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,253,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable', window );">Expiration period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_MasterClinicalAgreementMember', window );">Master Clinical Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,424,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,332,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.57333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_PercentageOfClosingPrice', window );">Percentage of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsMember', window );">Collaborative Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_RelativeFairValueOfDeferredParticipation', window );">Relative fair value of deferred participation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsTwoMember', window );">Collaborative Arrangements Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_RelativeFairValueOfDeferredParticipation', window );">Relative fair value of deferred participation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember', window );">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,334<span></span>
</td>
<td class="nump">8,816,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from ordinary shares in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember', window );">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares | shares</a></td>
<td class="nump">483,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration period of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum authorized proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of closing price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RelativeFairValueOfDeferredParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Relative fair value of deferred participation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RelativeFairValueOfDeferredParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_MasterClinicalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_MasterClinicalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_CollaborativeArrangementsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291241053808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Expected risk free interest rates range, minimum</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Expected risk free interest rate range, maximum</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Expected risk free interest rates range, minimum</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Expected risk free interest rate range, maximum</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291242422816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>FINANCIAL AND OTHER INCOME, NET [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Exchange rate differences and other</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate of financial and other income net of expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140291250864256">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Trade and other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related parties' expenses amounts charged to research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>zk2228202_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgen="http://cgen.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgen-20220630.xsd" xlink:type="simple"/>
    <context id="C_20220101to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20210101to20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_20210101to20210630_usgaapSupplyCommitmentAxis_cgenCollaborationAgreementWithUSAntibodyCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">cgen:CollaborationAgreementWithUSAntibodyCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapSupplyCommitmentAxis_cgenCollaborationAgreementWithUSAntibodyCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">cgen:CollaborationAgreementWithUSAntibodyCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cgen:GovernmentAndOtherGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220101to20220630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:CommercialLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-05</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-14</endDate>
        </period>
    </context>
    <context id="C_20210630_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20210101to20210630_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20220630_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-10</endDate>
        </period>
    </context>
    <context id="C_20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20210101to20210630_srtRangeAxis_srtMinimumMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20210101to20210630_srtRangeAxis_srtMaximumMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20130801to20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2013-08-01</startDate>
            <endDate>2013-08-05</endDate>
        </period>
    </context>
    <context id="C_20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2013-08-05</instant>
        </period>
    </context>
    <context id="C_20180301to20180330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-30</endDate>
        </period>
    </context>
    <context id="C_20180330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2018-03-30</instant>
        </period>
    </context>
    <context id="C_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <unit id="ILSPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_20220101to20220630" id="FFact_306">0001119774</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_20220101to20220630" id="FFact_307">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="C_20220101to20220630" id="FFact_309">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_20220101to20220630"
      id="Fdei_DocumentFiscalPeriodFocus20220803133013452">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentPeriodEndDate
      contextRef="C_20220101to20220630"
      id="Fdei_DocumentPeriodEndDate20220803135349061">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentType
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220803132217335">6-K</dei:DocumentType>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220803135229207">2022</dei:DocumentFiscalYearFocus>
    <dei:EntityFileNumber
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220803132624667">000-30902</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220803132653437">COMPUGEN LTD.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220803132710165">26 Harokmim Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220803132729395">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220803132743972">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220803132757086">IL</dei:EntityAddressCountry>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220727222920490"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220727223630806"
      unitRef="usd"
      xsi:nil="true"/>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220727223653597"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220727223710614"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_1"
      unitRef="usd">8008000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_2"
      unitRef="usd">7801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_3"
      unitRef="usd">363000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_4"
      unitRef="usd">713000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_5"
      unitRef="usd">88917000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_6"
      unitRef="usd">109248000</us-gaap:OtherShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_9"
      unitRef="usd">4696000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_10"
      unitRef="usd">5460000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_11"
      unitRef="usd">101984000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_12"
      unitRef="usd">123222000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_13"
      unitRef="usd">1906000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_14"
      unitRef="usd">1911000</us-gaap:PrepaidExpenseNoncurrent>
    <cgen:SeverancePayFundNonCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_15"
      unitRef="usd">2866000</cgen:SeverancePayFundNonCurrent>
    <cgen:SeverancePayFundNonCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_16"
      unitRef="usd">3125000</cgen:SeverancePayFundNonCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_17"
      unitRef="usd">1952000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_18"
      unitRef="usd">2247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_19"
      unitRef="usd">1604000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_20"
      unitRef="usd">1658000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_21"
      unitRef="usd">8328000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_22"
      unitRef="usd">8941000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_23"
      unitRef="usd">110312000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_24"
      unitRef="usd">132163000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713620_0"
      unitRef="usd">2154000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713621_1"
      unitRef="usd">4621000</us-gaap:AccountsPayableCurrent>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713621_2"
      unitRef="usd">2906000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713622_3"
      unitRef="usd">3629000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713622_4"
      unitRef="usd">615000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713622_5"
      unitRef="usd">768000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713623_6"
      unitRef="usd">8320000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713623_7"
      unitRef="usd">8078000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713623_8"
      unitRef="usd">13995000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713623_9"
      unitRef="usd">17096000</us-gaap:LiabilitiesCurrent>
    <cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713624_10"
      unitRef="usd">1051000</cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses>
    <cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713624_11"
      unitRef="usd">2715000</cgen:LongTermDeferredParticipationinResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713624_12"
      unitRef="usd">1491000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713625_13"
      unitRef="usd">1982000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713625_14"
      unitRef="usd">3394000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713625_15"
      unitRef="usd">3677000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713627_16"
      unitRef="usd">5936000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713627_17"
      unitRef="usd">8374000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20220630"
      id="Fxbrl_20220720111940687_20220719213713627_16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20211231"
      id="Fxbrl_20220720111940687_20220719213713627_17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220719214834949"
      unitRef="ILSPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20220630"
      decimals="INF"
      id="F20220719213713628_18"
      unitRef="ILSPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220719214917721"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20220630"
      decimals="INF"
      id="F20220719213713628_20"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20220630"
      decimals="INF"
      id="Fxbrl_20220719215055193"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20220630"
      decimals="INF"
      id="F20220719213713629_22"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20220719215111705"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20211231"
      decimals="INF"
      id="F20220719213713629_24"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713630_26"
      unitRef="usd">240000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713630_27"
      unitRef="usd">239000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713630_28"
      unitRef="usd">531074000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713631_29"
      unitRef="usd">528533000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713631_30"
      unitRef="usd">-440933000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713632_31"
      unitRef="usd">-422079000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713632_32"
      unitRef="usd">90381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713632_33"
      unitRef="usd">106693000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20220630"
      decimals="-3"
      id="F20220719213713633_34"
      unitRef="usd">110312000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="F20220719213713633_35"
      unitRef="usd">132163000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_61"
      unitRef="usd">13982000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_62"
      unitRef="usd">14123000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessDevelopment
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_63"
      unitRef="usd">478000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_64"
      unitRef="usd">465000</us-gaap:BusinessDevelopment>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_65"
      unitRef="usd">5173000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_66"
      unitRef="usd">5373000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_67"
      unitRef="usd">19633000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_68"
      unitRef="usd">19961000</us-gaap:OperatingExpenses>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_69"
      unitRef="usd">779000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_70"
      unitRef="usd">559000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_71"
      unitRef="usd">-18854000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_72"
      unitRef="usd">-19402000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719215810562_Fact_71"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719215810562_Fact_72"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_75"
      unitRef="usd">-18854000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_76"
      unitRef="usd">-19402000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20220719220126329"
      unitRef="USDPerShare">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="FFact_77"
      unitRef="USDPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20210101to20210630"
      decimals="INF"
      id="Fxbrl_20220719220147427"
      unitRef="USDPerShare">0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210101to20210630"
      decimals="INF"
      id="FFact_78"
      unitRef="USDPerShare">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_79"
      unitRef="usd">-18854000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_80"
      unitRef="usd">-19402000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20220720012025614"
      unitRef="Shares">86486612</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="FFact_81"
      unitRef="Shares">86486612</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20210630"
      decimals="INF"
      id="Fxbrl_20220720012118943"
      unitRef="Shares">83739983</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20210630"
      decimals="INF"
      id="FFact_82"
      unitRef="Shares">83739983</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823737_Fact_109"
      unitRef="Shares">83675856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727222823737_Fact_110"
      unitRef="usd">231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823737_Fact_111"
      unitRef="usd">507427000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823737_Fact_112"
      unitRef="usd">-387876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231"
      decimals="-3"
      id="Fxbrl_20220727222823737_Fact_113"
      unitRef="usd">119782000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823694_Fact_88"
      unitRef="Shares">115877</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823694_Fact_90"
      unitRef="usd">461000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823694_xbrl_20220720104827763"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220727222823694_Fact_91"
      unitRef="usd">461000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cgen:NumberOfWarrantsExercised
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823702_Fact_92"
      unitRef="Shares">89557</cgen:NumberOfWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823702_Fact_94"
      unitRef="usd">425000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823702_xbrl_20220720104840927"
      unitRef="usd">0</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220727222823702_Fact_95"
      unitRef="usd">425000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727223504334_Fact_96"
      unitRef="Shares">36639</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223504334_Fact_98"
      unitRef="usd">239000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223504334_xbrl_20220720104851290"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220727223504334_Fact_99"
      unitRef="usd">239000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727223514966_xbrl_20220720105139483"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223514966_Fact_100"
      unitRef="usd">1916000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223514966_xbrl_20220720104928823"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220727223514966_Fact_101"
      unitRef="usd">1916000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727222823722_xbrl_20220720105158469"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823722_xbrl_20220720105155026"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823722_Fact_102"
      unitRef="usd">-19402000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220727222823722_Fact_103"
      unitRef="usd">-19402000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823729_Fact_104"
      unitRef="Shares">83917929</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727222823729_Fact_105"
      unitRef="usd">231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823729_Fact_106"
      unitRef="usd">510468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20210630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823729_Fact_107"
      unitRef="usd">-407278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20210630"
      decimals="-3"
      id="Fxbrl_20220727222823729_Fact_108"
      unitRef="usd">103421000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727223132738_Fact_109"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_110"
      unitRef="usd">239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_111"
      unitRef="usd">528533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_112"
      unitRef="usd">-422079000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220727223132738_Fact_113"
      unitRef="usd">106693000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823749_Fact_114"
      unitRef="Shares">33186</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823749_Fact_116"
      unitRef="usd">104000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823749_xbrl_20220720104943489"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220727222823749_Fact_117"
      unitRef="usd">104000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727223329630_Fact_122"
      unitRef="Shares">158025</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727223329630_xbrl_20220719224804137"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223329630_Fact_124"
      unitRef="usd">248000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223329630_xbrl_20220720104955752"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220727223329630_Fact_125"
      unitRef="usd">249000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727223450181_xbrl_20220720105058426"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727223450181_Fact_126"
      unitRef="usd">2189000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727223450181_xbrl_20220720105006668"
      unitRef="usd">0</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220727223450181_Fact_127"
      unitRef="usd">2189000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_xbrl_20220720105044504"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_xbrl_20220720105025339"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823775_Fact_128"
      unitRef="usd">-18854000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220727222823775_Fact_129"
      unitRef="usd">-18854000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220727222823781_Fact_130"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_131"
      unitRef="usd">240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_132"
      unitRef="usd">531074000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_133"
      unitRef="usd">-440933000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20220727222823781_Fact_134"
      unitRef="usd">90381000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_135"
      unitRef="usd">-18854000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_136"
      unitRef="usd">-19402000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_137"
      unitRef="usd">2189000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_138"
      unitRef="usd">1916000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_139"
      unitRef="usd">232000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_140"
      unitRef="usd">240000</us-gaap:Depreciation>
    <cgen:SeverancePayNet
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_141"
      unitRef="usd">-24000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719231801817"
      unitRef="usd">-64000</cgen:SeverancePayNet>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_143"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220720144058011"
      unitRef="usd">1000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_145"
      unitRef="usd">-295000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_146"
      unitRef="usd">-357000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719231852648"
      unitRef="usd">114000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_148"
      unitRef="usd">-403000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_149"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719231907400"
      unitRef="usd">-2000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_151"
      unitRef="usd">-764000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_152"
      unitRef="usd">-212000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_153"
      unitRef="usd">-5000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_154"
      unitRef="usd">26000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719232044563"
      unitRef="usd">-2387000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_156"
      unitRef="usd">361000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_157"
      unitRef="usd">242000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_158"
      unitRef="usd">872000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_159"
      unitRef="usd">-644000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_160"
      unitRef="usd">-319000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_161"
      unitRef="usd">-2387000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_162"
      unitRef="usd">-178000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_163"
      unitRef="usd">-20683000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_164"
      unitRef="usd">-13629000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_165"
      unitRef="usd">58945000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_166"
      unitRef="usd">71100000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_167"
      unitRef="usd">38500000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_168"
      unitRef="usd">57445000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_169"
      unitRef="usd">258000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_170"
      unitRef="usd">218000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_171"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220719232155049"
      unitRef="usd">1000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_173"
      unitRef="usd">20187000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_174"
      unitRef="usd">13438000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_175"
      unitRef="usd">249000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_176"
      unitRef="usd">239000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_177"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_178"
      unitRef="usd">425000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_179"
      unitRef="usd">104000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_180"
      unitRef="usd">245000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_181"
      unitRef="usd">353000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_182"
      unitRef="usd">909000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220719232250681"
      unitRef="usd">-143000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_184"
      unitRef="usd">718000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_185"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_186"
      unitRef="usd">7810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_187"
      unitRef="usd">8371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20210630"
      decimals="-3"
      id="FFact_188"
      unitRef="usd">8528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220720191345976"
      unitRef="usd">-80000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="Fxbrl_20220720191351930"
      unitRef="usd">35000</cgen:PurchaseOfPropertyAndEquipmentAsNonCashTransaction>
    <cgen:ReceivablesOnAccountOfShares
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_191"
      unitRef="usd">0</cgen:ReceivablesOnAccountOfShares>
    <cgen:ReceivablesOnAccountOfShares
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_192"
      unitRef="usd">216000</cgen:ReceivablesOnAccountOfShares>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="C_20220101to20220630" id="FFact_200">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;NOTE 1:-&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;GENERAL&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:26.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;a.&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Compugen (the &#x201c;Company&#x201d;) is a clinical-stage, therapeutic discovery and development company utilizing its proprietary computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company&#x2019;s innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the Company discovered computationally, COM701, COM902, bapotulimab (formerly known as BAY 1905254) and AZD2936. The Company&#x2019;s therapeutic pipeline also includes early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The innovative immuno-oncology pipeline, the strategic collaborations and the Company&#x2019;s computational discovery engine serves as the three key corporate building blocks.&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;b.&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The Company is headquartered in Holon, Israel. Its clinical development activities operate from its U.S. subsidiary in South San Francisco, California.&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;c.&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&#x201c;Bayer Agreement&#x201d;) with Bayer Pharma AG (&#x201c;Bayer&#x201d;) for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint regulators.&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Under the terms of the Bayer Agreement, the Company received an upfront payment of $10,000, and, following the return of the CGEN 15022 program in 2017 to the Company, the Company is eligible to receive an aggregate of over $250,000 in potential milestone payments, not including aggregate milestone payments of approximately $23,000 received to date. Additionally, the Company is eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Pursuant to the terms of Bayer Agreement, bapotulimab program was transferred to Bayer&#x2019;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing licenses from Compugen.&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.8pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;d.&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#x201c;AstraZeneca&#x201d;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development and commercial activities under the agreement. Compugen received a $10,000 upfront payment and $8,000 milestone payment out of up to $200,000 that the Company is eligible to receive in development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div/&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;e.&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Master Clinical Agreement&#x201d;) with Bristol-Myers Squibb Company (&#x201c;Bristol-Myers Squibb&#x201d;) to evaluate the safety and tolerability of Compugen&#x2019;s COM701 in combination with Bristol-Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors. Pursuant to the Master Clinical Agreement, Compugen is responsible for and will continue sponsoring the ongoing two-part Phase 1 trial, which includes the evaluation of the combination of COM701 and Opdivo&#xae;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplies its own compound(s) for the studies, and otherwise each party is responsible for all costs associated with the study that it is conducting.&lt;br/&gt;&#160;&lt;br/&gt;In conjunction with the signing of the Master Clinical Agreement, Bristol-Myers Squibb made a $12,000 investment in Compugen, see Note 5a.&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On February 14, 2020, the Master Clinical Agreement with Bristol-Myers Squibb was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#xae; (nivolumab), and Bristol-Myers Squibb&#x2019;s antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#xae;.&lt;/span&gt;&lt;/div&gt;
                &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt;
                &lt;div style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Pursuant to the Master Clinical Agreement, as amended, the Company sponsors the two-part Phase 1/2 trial, which includes the evaluation of the triple combination of COM701, Opdivo&#xae; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provides Opdivo&#xae; and BMS-986207 at no cost to the Company.&lt;/span&gt;&lt;/div&gt;
                &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;As part of the said amendment, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo&#xae; under the Phase 1 study and will not continue the expansion cohorts of the dual combination.&lt;/span&gt;&lt;/div&gt;
                &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On February 19, 2021, the Master Clinical Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#xae; in patients with advanced solid tumors, where Compugen is responsible for and sponsors the expansion cohort and Bristol-Myers Squibb provides Opdivo&#xae; at no cost to us for this study.&lt;/span&gt;&lt;/div&gt;
                &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration.&lt;/span&gt;&lt;/div&gt;
                &lt;div style="margin:0pt"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $20,000 investment in Compugen, see Note 5a.&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20130801to20130805"
      decimals="-3"
      id="FFact_193"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20130805"
      decimals="-3"
      id="FFact_194"
      unitRef="usd">250000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable
      contextRef="C_20130805"
      decimals="-3"
      id="FFact_195"
      unitRef="usd">23000000</cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20180301to20180330"
      decimals="-3"
      id="FFact_196"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:AccruedMilestonePayment
      contextRef="C_20180301to20180330"
      decimals="-3"
      id="Fxbrl_20220720020744651"
      unitRef="usd">8000000</cgen:AccruedMilestonePayment>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20180330"
      decimals="-3"
      id="FFact_198"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_199"
      unitRef="usd">12000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20211130"
      decimals="-3"
      id="Fxbrl_20220728112859416"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_20220101to20220630" id="FFact_201">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 2:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2021. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2021, are applied consistently in these interim consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock contextRef="C_20220101to20220630" id="FFact_202">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 3:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Operating results for the six-month period ended June 30, 2022, are not necessarily indicative of the results that may be expected for the year ended December 31, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_20220101to20220630" id="FFact_217">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 4:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company provided bank guarantees in the amount of $320 in favor of its offices in Israel, car leases in Israel and credit card security for its U.S. subsidiary.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company received in the past grants from the office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly known as the Office of the Chief Scientist, (&#x201c;IIA&#x201d;). The Company is not obligated to repay any amounts received from the IIA if it does not generate any income from products which incorporate technologies which were funded by such research program(s).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;If income is generated from products which incorporate technologies which were funded by a research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue generated from products that incorporate technologies that were funded by such research program(s), up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum amount to be repaid is 100% plus interest at LIBOR).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2022, the Company&#x2019;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled $9,867.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 25, 2012, the Company entered into an Antibodies Discovery Collaboration Agreement (the &#x201c;Antibodies Discovery Agreement&#x201d;) with a U.S. antibody technology company (&#x201c;mAb Technology Company&#x201d;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company is entitled to certain royalties that could be eliminated upon payment of certain one-time fees (all milestone and royalties payments referred together as &#x201c;Contingent Fees&#x201d;). For the six-month periods ended June 30, 2022 and 2021, the Company did not incur Contingent Fees.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div/&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 9, 2012, the Company entered into agreement (the &#x201c;May 2012 Agreement&#x201d;) with a U.S. Business Development Strategic Advisor (&#x201c;Advisor&#x201d;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates. Under the agreement the Advisor shall be entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the six months ended June 30, 2022 and 2021, the Company had not paid nor accrued any expenses related to this agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                  &lt;div style="font-family:Arial"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (&#x201c;CLA&#x201d;) with a European cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#x2019;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the six-month periods ended June 30, 2022 and 2021, the Company did not incur milestone payments.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the six-month periods ended June 30, 2022 and 2021 the Company incurred milestone payments in the amounts of $0 and $150.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20220720103610231"
      unitRef="usd">320000</us-gaap:GuaranteeObligationsMaximumExposure>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20220101to20220630_srtRangeAxis_srtMinimumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062450451"
      unitRef="Pure">0.03</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20220101to20220630_srtRangeAxis_srtMaximumMember_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062556413"
      unitRef="Pure">0.05</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived
      contextRef="C_20220101to20220630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="2"
      id="Fxbrl_20220720062648820"
      unitRef="Pure">1</cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived>
    <cgen:RoyaltyContingentObligations
      contextRef="C_20220630_usgaapGainContingenciesByNatureAxis_cgenGovernmentAndOtherGrantsMember"
      decimals="-3"
      id="Fxbrl_20220720062746091"
      unitRef="usd">9867000</cgen:RoyaltyContingentObligations>
    <cgen:AgreementStartDate
      contextRef="C_20220101to20220630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="Fxbrl_20220720063011170">2012-05-09</cgen:AgreementStartDate>
    <cgen:ParticipationRights
      contextRef="C_20220101to20220630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="Fxbrl_20220727214951426"
      unitRef="Pure">0.04</cgen:ParticipationRights>
    <cgen:AgreementTerminationDescription
      contextRef="C_20220101to20220630_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="Fxbrl_20220720063144707">In 2014, the May 2012 Agreement was terminated, except with respect to certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</cgen:AgreementTerminationDescription>
    <cgen:PercentageOfRoyaltiesOnNetSales
      contextRef="C_20180101to20180105_cgenGovernmentAndOtherGrantsAxis_cgenCommercialLicenseAgreementMember"
      decimals="2"
      id="Fxbrl_20220720063310237"
      unitRef="Pure">0.01</cgen:PercentageOfRoyaltiesOnNetSales>
    <cgen:AmountIncurredMilestonePayments
      contextRef="C_20220101to20220630_usgaapSupplyCommitmentAxis_cgenCollaborationAgreementWithUSAntibodyCompanyMember"
      decimals="-3"
      id="Fxbrl_20220720025255942"
      unitRef="usd">0</cgen:AmountIncurredMilestonePayments>
    <cgen:AmountIncurredMilestonePayments
      contextRef="C_20210101to20210630_usgaapSupplyCommitmentAxis_cgenCollaborationAgreementWithUSAntibodyCompanyMember"
      decimals="-3"
      id="FFact_216"
      unitRef="usd">150000</cgen:AmountIncurredMilestonePayments>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="C_20220101to20220630" id="FFact_289">
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 5:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Issuance of Shares:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 14, 2018, the Company entered into agreements in connection with a registered direct offering (the &#x201c;Offering&#x201d;) of an aggregate of 5,316,457 Ordinary Shares (the &#x201c;RD Shares&#x201d;) of the Company at a purchase price of $3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional Ordinary Shares (the &#x201c;Warrants&#x201d;). The Warrants are exercisable at a price of $4.74 per Ordinary Share and have a term of five years from the date of issuance. The Offering was made pursuant to the Company&#x2019;s Registration Statement. Proceeds from the Offering were $19,767 (net of $1,233 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div/&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the six-month periods ended June 30, 2022 and 2021, warrants to purchase an aggregate of 0 and 89,557 Ordinary Shares were exercised with proceeds of approximately $0 and $425, respectively, and warrants to purchase up to 297,469 Ordinary Shares remain outstanding as of June 30, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#x2019;s COM701 in combination with Bristol-Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $12,000 equity investment in the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $4.95 per share. The share price represents a 33% premium over the average closing price of Compugen&#x2019;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The premium over the fair market value in the amount of $4,121 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses which are amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d; and $7,788 (net of $91 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $8.57333 per share. The share price represented a 33% premium over the closing price of Company&#x2019;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The premium over the fair market value in the amount of $5,000 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D, in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d;) and $14,958 (net of $42 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company, Incorporated, as representatives of the several underwriters relating to the issuance and sale in a public offering of 8,333,334 of the Company&#x2019;s ordinary shares at a price to the public of $9.00 per share (and a price of $8.46 per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement an additional 483,005 ordinary shares pursuant to the underwriters&#x2019; option specified above. The Company sold a total of 8,816,339 ordinary shares in the offering with proceeds of $74,147 (net of $5,200 issuance expenses).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div/&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock option plan:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the six-month period ended June 30, 2022, the Company&#x2019;s Board of Directors granted 1,497,500 options to purchase ordinary shares of the Company to employees, directors and non-employees. The exercise prices for such options range from $1.90 to $5.00 per share, with vesting to occur in up to four years.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table presents the assumptions used to estimate the fair value of the options granted in the periods presented:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:84.45pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;69%-72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;66%-67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.5%-3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.5%-0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.0-5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average fair value of options granted during the six-month periods ended June 30, 2022 and 2021 were $1.94 and $5.54, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the six-month periods ended June 30, 2022 and 2021, the Company recorded share based compensation related to stock options in a total amount of $2,092 and $1,805, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2022, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $11,614 which is expected to be recognized over a weighted average period of approximately&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;2.85 years.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the six months ended June 30, 2022 and 2021, the total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 8,504,958 and 6,242,283, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
                &lt;td style="width:27.75pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Employee Stock Purchase Plan:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its stock-option awards and Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:84.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2022 and since its adoption, 275,854 Ordinary Shares had been purchased under the ESPP and 324,146 Ordinary Shares were available for future issuance under the ESPP.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div/&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div&gt;
            &lt;div style="margin-left:56.7pt"&gt;

                &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                        &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;65%-70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;64%-70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                        &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.1%-1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.0%-0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                        &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                        &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.4-0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;

            &lt;/div&gt;
          &lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the six-month periods ended June 30, 2022 and 2021, the Company recorded ESPP compensation in a total amount of $97 and $111.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_223"
      unitRef="Shares">5316457</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_224"
      unitRef="USDPerShare">3.95</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_225"
      unitRef="Shares">4253165</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="INF"
      id="FFact_226"
      unitRef="USDPerShare">4.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable
      contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      id="FFact_227">P5Y</cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="-3"
      id="FFact_228"
      unitRef="usd">19767000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20180601to20180614_usgaapAwardTypeAxis_cgenRegisteredDirectOfferingMember_usgaapTypeOfArrangementAxis_cgenAgreementMember"
      decimals="-3"
      id="FFact_229"
      unitRef="usd">1233000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20220630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20220720033721852"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20210630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="FFact_230"
      unitRef="Shares">89557</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20220101to20220630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="-3"
      id="FFact_232"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20210101to20210630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="-3"
      id="FFact_233"
      unitRef="usd">425000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20220630_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="FFact_234"
      unitRef="Shares">297469</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_235"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_236"
      unitRef="usd">2424243000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_237"
      unitRef="USDPerShare">4.95</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20181001to20181010_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="FFact_238"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:RelativeFairValueOfDeferredParticipation
      contextRef="C_20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="FFact_239"
      unitRef="usd">4121000</cgen:RelativeFairValueOfDeferredParticipation>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="FFact_240"
      unitRef="usd">7788000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="FFact_241"
      unitRef="usd">91000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="Fxbrl_20220720034631668"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="Fxbrl_20220720034743180"
      unitRef="Shares">2332815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="5"
      id="Fxbrl_20220720034904580"
      unitRef="USDPerShare">8.57333</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20211101to20211130_usgaapTypeOfArrangementAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="Fxbrl_20220720034949299"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:RelativeFairValueOfDeferredParticipation
      contextRef="C_20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20220720035100582"
      unitRef="usd">5000000</cgen:RelativeFairValueOfDeferredParticipation>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20220720035407188"
      unitRef="usd">14958000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20220720035509163"
      unitRef="usd">42000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20200301to20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_242"
      unitRef="Shares">8333334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20200316_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="2"
      id="FFact_243"
      unitRef="USDPerShare">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20200316_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="2"
      id="FFact_244"
      unitRef="USDPerShare">8.46</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20200401to20200414_usgaapAwardTypeAxis_cgenUnderwritersMember_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_245"
      unitRef="Shares">483005</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_246"
      unitRef="Shares">8816339</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="-3"
      id="FFact_247"
      unitRef="usd">74147000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20220630_usgaapTypeOfArrangementAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="-3"
      id="FFact_248"
      unitRef="usd">5200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20220720040533152"
      unitRef="Shares">1497500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20220720040558485"
      unitRef="USDPerShare">1.9</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="FFact_251"
      unitRef="USDPerShare">5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="C_20220101to20220630" id="FFact_252">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220728002533924">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;69%-72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;66%-67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.5%-3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.5%-0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.0-5.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20220101to20220630"
      decimals="2"
      id="Fxbrl_20220727222002683"
      unitRef="Pure">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20220101to20220630"
      decimals="2"
      id="Fxbrl_20220727222015231"
      unitRef="Pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20210101to20210630"
      decimals="2"
      id="Fxbrl_20220727222026940"
      unitRef="Pure">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20210101to20210630"
      decimals="2"
      id="Fxbrl_20220727222103489"
      unitRef="Pure">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20220101to20220630"
      decimals="3"
      id="Fxbrl_20220727222244528"
      unitRef="Pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20220101to20220630"
      decimals="3"
      id="Fxbrl_20220727233307366"
      unitRef="Pure">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20210101to20210630"
      decimals="3"
      id="Fxbrl_20220727233317706"
      unitRef="Pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20210101to20210630"
      decimals="3"
      id="Fxbrl_20220727235651276"
      unitRef="Pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20220630"
      decimals="2"
      id="Fxbrl_20220727235701651"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20210101to20210630"
      decimals="2"
      id="Fxbrl_20220727235716123"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20220630_srtRangeAxis_srtMinimumMember"
      id="Fxbrl_20220727235725275">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20220630_srtRangeAxis_srtMaximumMember"
      id="Fxbrl_20220727235734670">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20210630"
      id="Fxbrl_20220727235745019">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="FFact_267"
      unitRef="USDPerShare">1.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20210101to20210630"
      decimals="INF"
      id="FFact_268"
      unitRef="USDPerShare">5.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockOptionPlanExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_269"
      unitRef="usd">2092000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_270"
      unitRef="usd">1805000</us-gaap:StockOptionPlanExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_271"
      unitRef="usd">11614000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_20220101to20220630" id="FFact_272">P2Y10M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20220720041818515"
      unitRef="Shares">8504958</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20210101to20210630"
      decimals="INF"
      id="FFact_274"
      unitRef="Shares">6242283</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="FFact_275"
      unitRef="Shares">275854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="FFact_276"
      unitRef="Shares">324146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      id="Fxbrl_20220728002557752">
                &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:middle;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                        &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;65%-70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;64%-70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                        &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.1%-1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.0%-0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                        &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;width:76%" valign="bottom"&gt;
                        &lt;div style="text-align:justify;text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.4-0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_277"
      unitRef="Pure">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_278"
      unitRef="Pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="Fxbrl_20220720042810087"
      unitRef="Pure">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="Fxbrl_20220720042816078"
      unitRef="Pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="3"
      id="FFact_280"
      unitRef="Pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="3"
      id="FFact_281"
      unitRef="Pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="3"
      id="Fxbrl_20220720042753766"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="3"
      id="Fxbrl_20220720042801271"
      unitRef="Pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_283"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="Fxbrl_20220720042946790"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      id="FFact_286">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20210630_srtRangeAxis_srtMinimumMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      id="Fxbrl_20220720042710462">P0Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20210630_srtRangeAxis_srtMaximumMember_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      id="Fxbrl_20220720042714542">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="C_20220101to20220630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="Fxbrl_20220720043008949"
      unitRef="usd">97000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="C_20210101to20210630_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="-3"
      id="FFact_288"
      unitRef="usd">111000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220727231501241">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 6:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold"&gt;FINANCIAL AND OTHER INCOME, NET&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div&gt;
            &lt;div style="margin-left:56.7pt"&gt;

                &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;463&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;528&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange rate differences and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;779&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;559&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220727231515518">
                &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unaudited&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest income&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;463&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;528&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:2px;width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exchange rate differences and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:bottom;font-family:Times New Roman, Times, serif;padding-bottom:4px;width:76%" valign="bottom"&gt;
                        &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Financial and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;779&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%" valign="bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;559&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_290"
      unitRef="usd">463000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_291"
      unitRef="usd">528000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220720002002984"
      unitRef="usd">316000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_293"
      unitRef="usd">31000</us-gaap:OtherNonoperatingIncomeExpense>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_294"
      unitRef="usd">779000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_295"
      unitRef="usd">559000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220727224715083">
            &lt;div&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 7:-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;RELATED PARTY BALANCES AND TRANSACTIONS&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;margin-left:56.7pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Balances with related parties:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div&gt;
                    &lt;div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="margin-left:56.7pt"&gt;
                        &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&#160;Trade and other payables (a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25;font-family:Arial"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25;font-family:Arial"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;

                        &lt;/table&gt;
                      &lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;margin-left:56.7pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Related parties' expenses:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="margin-left:56.7pt"&gt;
                        &lt;div&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Research and development expenses (a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;

                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;width:56.7pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:32pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                        &lt;td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif"&gt;
                          &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220728112628625">
                &lt;div&gt;
                  &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;margin-left:56.7pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Balances with related parties:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;div&gt;
                    &lt;div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="margin-left:56.7pt"&gt;
                        &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td rowspan="1" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;
                                &lt;div style="text-align:center;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" rowspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&#160;Trade and other payables (a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25;font-family:Arial"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                &lt;div style="line-height:1.25;font-family:Arial"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                            &lt;/tr&gt;

                        &lt;/table&gt;
                      &lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt;margin-left:56.7pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Related parties' expenses:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
                      &lt;div style="margin-left:56.7pt"&gt;
                        &lt;div&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%" width="90%"&gt;

                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Six months ended&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                  &lt;div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;June 30,&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="6" style="vertical-align:top;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                                  &lt;div style="text-align:center;line-height:1.25;text-indent:2pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;Unaudited&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;
                              &lt;tr&gt;
                                &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;padding-bottom:4px;background-color:rgb(204, 238, 255);width:76%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25;text-indent:-8.5pt;margin-left:11.35pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Research and development expenses (a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%" valign="bottom"&gt;
                                  &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                                &lt;/td&gt;
                                &lt;td colspan="1" style="font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                              &lt;/tr&gt;

                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                  &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                      &lt;tr&gt;
                        &lt;td style="font-family:Times New Roman, Times, serif;width:56.7pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="vertical-align:top;font-family:Times New Roman, Times, serif;width:32pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(a)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                        &lt;td style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, serif"&gt;
                          &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_20220630"
      decimals="-3"
      id="FFact_298"
      unitRef="usd">141000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_299"
      unitRef="usd">94000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="FFact_300"
      unitRef="usd">114000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20210101to20210630"
      decimals="-3"
      id="FFact_301"
      unitRef="usd">110000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20220101to20220630"
      id="Fxbrl_20220728193545297">
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;NOTE 8:-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div style="font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On August 3, 2022, the Company and Bristol-Myers Squibb entered into a letter agreement pursuant to which the Master Clinical Agreement, as amended thereafter, is terminated as of such date. Such termination also includes termination of the right of first negotiation and the exclusivity right granted to BMS thereunder.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.9pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The parties shall use reasonable efforts to wind down activities under the Master Clinical Agreement with respect to the dual combination study of COM701 with nivolumab and the triple combination study of COM701 with nivolumab and BMS- 986207 and will create a sub-team of the parties to oversee such wind-down activities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20220727222920490"
          xlink:label="Fxbrl_20220727222920490"
          xlink:type="locator"/>
        <link:footnote id="FN20220727223934071" xlink:label="FN20220727223934071" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount lower than $ 1.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220727222920490"
          xlink:to="FN20220727223934071"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220727223630806"
          xlink:label="Fxbrl_20220727223630806"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220727223630806"
          xlink:to="FN20220727223934071"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220727223653597"
          xlink:label="Fxbrl_20220727223653597"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220727223653597"
          xlink:to="FN20220727223934071"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220727223710614"
          xlink:label="Fxbrl_20220727223710614"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220727223710614"
          xlink:to="FN20220727223934071"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_298"
          xlink:label="FFact_298"
          xlink:type="locator"/>
        <link:footnote id="FN20220720121444312" xlink:label="FN20220720121444312" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company incurred expenses for research and development services provided by related party for cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_298"
          xlink:to="FN20220720121444312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_299"
          xlink:label="FFact_299"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_299"
          xlink:to="FN20220720121444312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_300"
          xlink:label="FFact_300"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_300"
          xlink:to="FN20220720121444312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_301"
          xlink:label="FFact_301"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_301"
          xlink:to="FN20220720121444312"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>35
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MFB9/EV*;4$?'6R115OQ%3UM;W$*+/%/)>NL,"-9AO/G/?VPG8L^!. T.=.M
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M</\^2=3+B?[<L?N\U?T?4$L#!!0    ( !4X!%4XT*62H@(  $<'   8
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK55=3]LP%/TK5I#0)K$F3=* H(U4
MVB) #"K*MH=I#VYZVU@D=F8[+>S7[]H)4<L"8VA]J+_N.3[GVKGN;X2\5RF
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MC774=E-\Z4": %Q?"J&?!J:8-F]G_!M02P,$%     @ %3@$570N/Y\>!
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M'PZ>C=F0/3\JM4N(>.K+C72S*?^6$JYN&U <[>WW$?B$>;A<M'-M!'[H<91
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M$\NHB8(P@\J-'=8,,D+WJ!?P*B[GT^W0*>77OA!Q9&W-'D#[A6"B:5,F?SP
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M1]!D?/4VZDZU-ZQJ0C?,E*7>&H85/6:HO0.M[Y2RO>$W&)['^3]02P,$%
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MF-;T,T'C'6A_J[4[&1Z@_SW-_@-02P,$%     @ %3@$54,Q:7$U P  ^PP
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MUS6D5_H:I^;SBVU69XZ@E0RHID,U"M4,J&9*[5[&;-+<3+7O(TE2\U *VKB
M:BY*XZ-1ERXD\4G[/ZMRN?"H"5J\@&HZ5*-0S8!J)E2SH)H-U1RHYJ(T_HVV
M=2M#?J65L9\ W!\ME;.%C7T^T3Z=V.^;/JBF0S4*U0RH9D(UJ]*XV<*9IC4V
M;C9T4*=CT.8[FE #\EFI>Q>RN'?Q'>][$HN]TP$M7$ U"M4,J&96FN"E9<GM
MMD7[[4_0M7*@FHO2^&S490M97+8X:SN2L.+B,MS)*.&F!5K"@&HZ5*-0S8!J
M)E2SH)H-U9Q*X^8>9Q-U/&MNAOZ.%H9<MS!D\3GY-XN$L14[.BK*4_21+8(T
M8TG1G T2YF<D?GIB9856=.PD'JIWQ* E#*A&H9H!U4RH9D$U&ZHY4,U%:7P0
MZQZ&+.YA?-EWU_=79$K3S8G=0&@) JKIE<9-4<TFX\;./H4.:D U$ZI94,V&
M:@Y4<U$:GY^Z)R&+>Q+V_N1151SLW@F$=B*@FBZWKYD@R8K23 ZTZP#53*AF
M034;JCE0S45I?'+JKH/\RA4G?NQ:16*]=Z:@50>Y70#0%&FL-F>?*'18 ZJ9
M4,V":C94<Z":B]+X6-5=!UG<=?CQR7!HP0&JZ7+[9+@J%]'2FL&"=A>@F@G5
M+*AF0S4'JKDHC0]6W7"0Q0V'/_9S$>6E)[CFN/A]O6*W=Z"@38=*.WX?JW(Y
M:Z4)VF" :B94LZ":#=4<J.:B-#Y-=2E"%I<B*'<AEV("XO VCE?S!.U*0#6]
MTH[SI%Y.U&:>H!T(J&9"-0NJV5#-@6HN2N.OC%QW(!1Q!X*^K(-DU[BK+C=Q
M%*FN%(F]OBF":OHKCU4[>144"ET/ ZJ94,V":C94<Z":B]+X9-6-"47<F'CO
M%>>DR%U^>^![(6F?NNJ,%[0T =5TJ$:AF@'53*AF034;JCE0S45I?.3J(H8B
M+F+P):7#^S/R+9H?KU;[B\1TQ@Y:MU#:5S20U>*_QO2X#AV60C4#JIE0S8)J
M-E1SH)J+TOA$'7URAKAO81]E:#_?'K'LXIP)03'=.U/8S\W ?G"&TB[/*(H\
ME1H3(@9T6!.J65#-AFH.5'-1&I^INCJAB*L3WSTA*'9[!TKMF')H3N'IT#%I
MI4G2T:#32VVB-$\<&]!Q3:AF034;JCE0S45I?%+JDH3RRL4D_MH$V3<21,\L
MS8I#I\Y40$L22E>MH?7Y(CIT4-HQJ-S^4!,#.J@)U2RH9D,U!ZJY*(W/1%U_
M4,3UAWN6^'D2BHL>%<<U89P>-B6=Z8#6'2IM=O1"'5TV?W?KT#'I66,:T#%-
MJ&9!-1NJ.5#-16E\-NH.@R+N,-S%8>@]QL5\]C,C;XI)[$4YY9:*Y]R@S06H
MID,U"M4,J&9"-0NJV5#-@6HN2N,S5]<;%'&]X:PBJ]CHG3!HE0&J4:AF0#6S
MTHZG*6:-ZS%8T!%MJ.9 -1>E\;FIBPR*N,CPL;A 9;&9XC\*8,Z>6%*\DVGM
M)5G@!^ORW&QGIJ!U!JBF0S4*U0RH9D(U"ZK94,VI-.Y=PI+<^/WAHL;D/\:V
MKC.HXE/\_!D@UIP_Z/[T6FBC :KI4(U"-0.JF6K[$@B3R;1YB5;HF#94<Z":
MB]+X(-7M!57<7A <2GW:QL+#*;'<.T_0"@-4HU#-@&HF5+.@F@W5'*CFHC0^
M=W6%0157&,XZG!(;O1,&O3@$5*-0S8!JIMJ^9(+:_" ;Z(@V5'.@FHO2^-S4
M10557%3XX<,IL=\[4]"V E2C4,V :B94LZ":#=6<2N,^V;1URL]%C<FGJJXJ
MJ.*JPG<=3D%;"E!-AVH4JAE0S:PT[CQVQT=>0 >UH9H#U5R4QB>IKC*HXBK#
MPY>WY!TK>C]?R;MW=^4'T#QDP1,++\B'P(]#;Y.27[S5^G=R%Z_67O1-?(P%
M+3U -1VJ4:AF0#43JEE0S89J#E1S41J?Q;I"H8HK%#]2:A73O8,'O7P$5*-0
MS5#;E[:8*L6?QGL<S:X[3J6QHLR:FRYHJP*J.5#-16E\7.I6A2IN59PW)0'M
M4$ U':I1J&9 -;/2N(,*N7E084''M*&: ]5<E,8GI^Y&J'_3I1_$;N\T0?L2
M4(U"-4/M^%B*YO8%>MT'J&9#-0>JN2B-CU)=EU#%=0E^)J)Y7:+BPLI5UCKC
M!*U*0#4=JE&H9D U4VT7"":JI#8_-@8ZJ W5'*CFHC0N4EK=E=#$78D?F)+(
M-V"?HSE+MDF0L43<KA6O1=_P034=JE&H9D U$ZI94,V&:@Y4<U$:G]&ZAJ&)
M:Q@_,E6AM3_Y09TJHU'C+7YWXE7H'2EHPP*J&5#-A&H65+.AF@/57)3&1ZIN
M6&CBAL5W'Y2)W=X;,FCK JI1J&94VO$;C:>7ZGAT]*?1(C6A*V!!-1NJ.5#-
M16F[: W3)6.9[F7>[?6*)0MVQ\(P)7Z\B;)BD*-;2<*>BD\TO'HC#X:MVZET
M94@=MYO2E=5UNRU=.>7MPWK8V^NUMV#OO6011"D)V5.^"J/+27XTD02+Y>&;
M+%[?#/)?,(]QEL6K\LLE\_)=U>(.^;\_Q7&V_Z888!LG7\N'>?M_4$L#!!0
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M/#WQ2F\D6R:'1@],2A8EEPL@ 7#=0'T_8TP^W^@.\G/'X?]02P,$%     @
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M4)@$O3[G7&T#LT'U_D5_ %!+ P04    "  5. 15;2(SKF<#  #H"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RM5F&3VC80_2L:-]/>S:1G&PRD
M%#SCPW2:3G*Y =).)],/PEZP)K;D2#(<_[XKV>< ,31M\P6L];ZWNT]K:2=[
M(3^J#$"3IR+G:NID6I=CUU5)!@55=Z($CF\V0A94XU)N755*H*D%%;G;\[RA
M6U#&G7!B;8\RG(A*YXS#HR2J*@HJ#_>0B_W4\9UGPX)M,VT,;C@IZ1:6H-^7
MCQ)7;LN2L@*X8H(3"9NI$_GC^<CX6X??&>S5T3,QE:R%^&@6K].IXYF$((=$
M&P:*?SN809X;(DSC4\/IM"$-\/CYF?T76SO6LJ8*9B+_@Z4ZFSJO')+"AE:Y
M7HC]K]#4,S!\B<B5_27[QM=S2%(I+8H&C!D4C-?_]*G1X0C@]R\ >@V@=PX8
M7 #T&T#_'!!<  0-(/A:P* !V-+=NG8K7$PU#2=2[(DTWLAF'JSZ%HUZ,6[Z
M9*DEOF6(T^%B_B9:S6/R&"U6?Y+[Z$WT,)LO2?00D]4B>EA&L]7K=P]+<A.#
MIBQ7M^1'\GX9DYL7M^0%89RL,E$IRE,U<37F8UC=I(D]JV/W+L0>DK>"ZTR1
M.4\A/<6[6$=;3.^YF%GO*N%O%;\C?>\EZ7F]7D<^\=?#_0[X_#H\A@3A?A?\
MI)I^NS5]R]?_GUOS(5HK+?&+^ZMK"^H807<,<PJ-54D3F#IXS"B0.W#"[[_S
MA][/7?I]2[+Y-R([T39HM0VNL8<K25,@V+9$Z PD*>F!KG/H:N+[ZTP?_$[9
M:]# @LQ9O0O] )MB=ZSF5>)_J^:7 7\*VG@G&@U:C097*UM 3C6DJ(W4#-0/
M!)[P=E*@""U$Q;4B24;E%CVT("9#*I/,:IK"#B^@$J\3W8*ZE+T>_X*R@R^5
M]8,S9;M\O%.?^=7@_[']ALZ98=1J/?JG6E<9D)DH2LH/>*XFE92H;"LY3@27
M-3;IL02]2BEV#,]2LCZ@]^?M.UA\0GF"O:YTE>)^FL.;<E;0G!0BA5R]M+QK
M"9 ROK4+,VAHX 9'Q*9Q5^2FP&BW9MM5599"8@85IM40WW4)Y!Y=405@UYC9
M #O(-%+]V;;6=ORXM[?NF7WFCV._PQX-Q_&PRSX:QW:,<3^'K6>@M]B\C"N2
MPP93\.Y&V!&RGBOJA1:EO3C70N,U;!\S',5 &@=\OQ%"/R],@':X"_\&4$L#
M!!0    ( !4X!%6!2FOT5P,  % 4   -    >&PO<W1Y;&5S+GAM;-U846_:
M,!#^*U':3:TT-4#60%9 VI J3=JF2NW#WBI#'+#D.)EC.NCC?LY^UG[)?'9(
M O4AUH>M#-3&=Y_ON^_L2^)V6*HUI[<+2I6WRK@H1_Y"J>)=$)2S!<U(>9$7
M5&@DS65&E#;E/"@+24E20E#&@UZG$P498<(?#\4RN\Y4Z<WRI5 COU^[/'OY
MF(S\;O36]RS=)$_HR+\_>_UMF:NK4\]>3]Z<G'3NSZ]V_6<&./<#)^FEF_37
MCY]MVHM.F[D!SS8H1A\=H'F;_/10ZOXVM9G^2A/9P%=8V. @17L$8<3Q8:5V
M]E?;00ON=QP%ZXBF9C!,<% UU'B8YJ+IJ]"W#LU.,NH]$#[R)X2SJ600E9*,
M\;5U]\ QRWDN/:4;6J?K@J=\M'#76M#K%4_&1"Y-;IO!_IY6TW> C04"&>>U
MP)YO'>-A092B4EQKPTPVSB>05XWOUH56.)=DW>U=^DV N>@DTUPF5-9INO[&
M-1YRFH(<R>8+N*J\" !4*L_T(&%DG@MB-&PBJH&FG5'.;^%!\#7=XEZEK7TS
MNR;JH194#2V--8"_S6:YV[3ALWB]@CWDZL-2ER.,#<U&;R1-V<K8J[06@+%W
M<792%'S]GK.YR*@M_N"$XR'9Q'F+7+)'G0U:9:8=5/K> Y6*S=J>[Y(4=W2E
M-NVT2G'-O2/4_'?7>4X%E82W1>O>?\FK_&S%U9OS7V@VCY5=Q4Z18?_E:ZQ.
M"R]=9'0,(H]BNP?'(#(^ I']?_;4W"LRJ$X9K:/,UD&F]GIP8!SY7^#XR9ND
MWG3)N&*BLA8L2:AX<I[1](I,]9]+6_QZ?D)3LN3JK@9'?C/^3!.VS.)ZU@TL
M1#6K&7^"\KI1?5K5N9A(Z(HFD\J4\ZD9>GJ@LU8?"-A%KLW'C6 Q%G,C@&%Y
M, 58C(W"\OQ/]0S0>BR&:1LXD0$:,T!C;)0+F9@OEL<=$^N/N](X#L,HPE9T
M,G$JF&#K%D7PXV;#M$$$E@<R_=E:X[N-=\C^/L#V=%^'8)7BG8A5BJ\U(.YU
M@X@X=N\VE@<BL%W >@?RN_- 3[ECPA!V%=.&W<$X$L<8 KWH[M$H0E8G@J][
M?["[) SCV(T YE80AA@"=R..8 I  X:$H7D/[KR/@LU[*FC^ASC^#5!+ P04
M    "  5. 15EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_
MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+
MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D
M5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@
M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/
M['X 4$L#!!0    ( !4X!%5U5)9;X (  #\0   /    >&PO=V]R:V)O;VLN
M>&ULQ9=;;YLP%(#_BL7+,FD:@;;I14TE"DYBB9@,2*4^520XC56P(^.T6W_]
M#"R:LU767KP\$5]D/I]SX@_?OG'QLN+\!7RO*]:,G:V4NQO7;=9;4A?-5[XC
M3(ULN*@+J9KBV6UV@A1ELR5$UI7K#X<CMRXH<^YN#VLMA*LWN"1K23E3G6W'
M R5OS>_QM@E>:4-7M*+RQ]CI?E?$ 35EM*;OI!P[0P<T6_XVXX*^<R:+*EL+
M7E5CQ^L''HB0=/U7=]9"YL6JZ7IDL4H+!3)V1D.UX(:*1G8SNO4+Q?A*U.2^
MM9=\0BM)1%1(,A5\OZ/LN5U&[<+5MM'%X?#L@W@C_B6,?+.A:Q+Q];XF3/9Q
M%*1J 5FSI;O& :RHR=@Y3 $%*P%D4@4)(-8OI>:V.U6O1F6_:ZEPM1B*&ZH&
M!"H[<'N088*S)$91D,,(W =Q@$,(LAF$>:8!^@9 _V2 8+ H-,@S ^39?X3,
M<O680ZP DPD(D_E"@SPW0)Z?#G(68 WRP@!Y<3K(()MID",#Y,@NY!1BF :Q
M!G-I@+FT"Y.A*483% 8X!T$8)DN<(SP%"Q7%$$']7WQE@+RR"[G$P3)";4X1
MSF&*YN HT1KDM0'RVG;MS><H[^LMP%&+V(82XC_BZ U-Y_70<KIG00IG21S!
M-/L$X+<ERA]U-J-++,MD@K ZGE$0=^%+\AE,5;Y56.$7@&&N8YJ,XEE62@KC
MKNH609H_'IS2ISQ/CPY"S^04S[)4LN5]IO*KRA' A[8H=3"31SS+(OFH!,%
M?8%5I/FL0YH\XED6B;$6GWP=TV02S[)*C+5XC&ERC&=9,K^,!P81D06MCM-L
M\HIG62S&,QL,=$R363S+:OGX+],'$^1$_]0VR<4_@5S (%,KE_N*Z)KV39[Q
M3^F9IS,=TWAS.:5GCC%-GO$[S[B'"VM)-I21$JM7-*I?79[7"P':1R_6\XNV
MTC?[J@I57\)B7I2'^^_A[G[W$U!+ P04    "  5. 1598M'TS(!  ",#@
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M   3    6T-O;G1E;G1?5'EP97-=+GAM;,V7RT[#,!!%?R7*MFI<!R@/M=T
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M4$L! A0#%     @ %3@$5=SS'7[M    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %3@$59E<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  5. 15(GQS3%D#  "H"P  &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ %3@$57GLD&"&!@  ZAH
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M965T-BYX;6Q02P$"% ,4    "  5. 152)@D14T*  !G'   &
M    @('@)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M%3@$51&1<+F[ @  :@8  !@              ("!8S$  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !4X!%7YY^F,>@,  .P'   8
M          " @50T  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  5. 15PSYH-T8(   O%0  &0              @($$.   >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !4X!%7$4 Z;7PH  !$=
M   9              " @8%   !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ %3@$566-)IYZ @  E04  !D              ("!%TL
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  5. 15&PR>
M7 D#  #(!@  &0              @('(30  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( !4X!%5\CVC81P,  "H'   9
M  " @0A1  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M%3@$5?U"QUOX @  00<  !D              ("!AE0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  5. 15:0OUTX "  "!!0  &0
M            @(&U5P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( !4X!%48%V6 (@,  *H&   9              " @6Q:  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ %3@$54,Q:7$U P
M^PP  !D              ("!Q5T  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  5. 15V2_9X/L%   =)0  &0              @($Q
M80  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !4X!%4.
MWY[*4PX  $.N   9              " @6-G  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ %3@$51)!W&W>!   @QP  !D
M     ("![74  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M"  5. 15[AT[N[,"   +!P  &0              @($">P  >&PO=V]R:W-H
M965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !4X!%5M(C.N9P,  .@)   9
M              " @>Q]  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L!
M A0#%     @ %3@$58%*:_17 P  4!0   T              ( !BH$  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  5. 15EXJ[',     3 @  "P
M        @ $,A0  7W)E;',O+G)E;'-02P$"% ,4    "  5. 15=5266^ "
M   _$   #P              @ 'UA0  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ %3@$566+1],R 0  C X  !H              ( ! HD  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ %3@$5;7'I45K 0
MC0\  !,              ( !;(H  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     !\ 'P!0"   "(P

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>64</ContextCount>
  <ElementCount>151</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-daei1</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cbs</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cbsp</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-csocl</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-socise1</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-g</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sap1</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements</Role>
      <ShortName>UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cac</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-se1</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0013 - Disclosure - FINANCIAL AND OTHER INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-fin</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0014 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-rpbat</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0015 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0017 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-set</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-se1</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0018 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-fint</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-fin</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0019 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-rpbat</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0020 - Disclosure - GENERAL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-gd1</Role>
      <ShortName>GENERAL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-g</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-cac</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0022 - Disclosure - SHAREHOLDERS' EQUITY (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0023 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0024 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-find</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-fint</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2228202.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0025 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-rpbatd</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cgen-20220630.xsd</File>
    <File>cgen-20220630_cal.xml</File>
    <File>cgen-20220630_def.xml</File>
    <File>cgen-20220630_lab.xml</File>
    <File>cgen-20220630_pre.xml</File>
    <File doctype="6-K" isDefinitelyFs="true" isUsgaap="true" original="zk2228202.htm">zk2228202.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isUsgaap="true" original="exhibit_99-2.htm">exhibit_99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="267">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>40
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zk2228202.htm exhibit_99-2.htm": {
   "nsprefix": "cgen",
   "nsuri": "http://cgen.com/20220630",
   "dts": {
    "schema": {
     "local": [
      "cgen-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cgen-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cgen-20220630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cgen-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgen-20220630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "exhibit_99-2.htm",
      "zk2228202.htm"
     ]
    }
   },
   "keyStandard": 123,
   "keyCustom": 28,
   "axisStandard": 7,
   "axisCustom": 1,
   "memberStandard": 7,
   "memberCustom": 11,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/dei/2022": 5,
    "http://fasb.org/us-gaap/2022": 3,
    "http://cgen.com/20220630": 1
   },
   "contextCount": 64,
   "entityCount": 1,
   "segmentCount": 18,
   "elementCount": 243,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 267,
    "http://xbrl.sec.gov/dei/2022": 13
   },
   "report": {
    "R1": {
     "role": "http://cgen.com/role/cgen-daei1",
     "longName": "0001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2228202.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2228202.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cgen.com/role/cgen-cbs",
     "longName": "0002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20220630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://cgen.com/role/cgen-cbsp",
     "longName": "0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20220630",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "ILSPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220630",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://cgen.com/role/cgen-csocl",
     "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://cgen.com/role/cgen-socise1",
     "longName": "0005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cgen.com/role/cgen-g",
     "longName": "0007 - Disclosure - GENERAL",
     "shortName": "GENERAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cgen.com/role/cgen-sap1",
     "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements",
     "longName": "0009 - Disclosure - UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS",
     "shortName": "UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "cgen:UnauditedInterimConsolidatedFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cgen.com/role/cgen-cac",
     "longName": "0010 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cgen.com/role/cgen-se1",
     "longName": "0011 - Disclosure - SHAREHOLDERS' EQUITY",
     "shortName": "SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cgen.com/role/cgen-fin",
     "longName": "0013 - Disclosure - FINANCIAL AND OTHER INCOME, NET",
     "shortName": "FINANCIAL AND OTHER INCOME, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cgen.com/role/cgen-rpbat",
     "longName": "0014 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cgen.com/role/SUBSEQUENTEVENTS",
     "longName": "0015 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cgen.com/role/cgen-set",
     "longName": "0017 - Disclosure - SHAREHOLDERS' EQUITY (Tables)",
     "shortName": "SHAREHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cgen.com/role/cgen-fint",
     "longName": "0018 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables",
     "longName": "0019 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cgen.com/role/cgen-gd1",
     "longName": "0020 - Disclosure - GENERAL (Details)",
     "shortName": "GENERAL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20130801to20130805",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20130801to20130805",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cgen.com/role/CommitmentsAndContingenciesDetails",
     "longName": "0021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20220630",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220630",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
     "longName": "0022 - Disclosure - SHAREHOLDERS' EQUITY (Detail Textuals)",
     "shortName": "SHAREHOLDERS' EQUITY (Detail Textuals)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20220630",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "ILSPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R21": {
     "role": "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
     "longName": "0023 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule of fair value assumptions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cgen.com/role/cgen-find",
     "longName": "0024 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Details)",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220101to20220630",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cgen.com/role/cgen-rpbatd",
     "longName": "0025 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20220630",
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20220630",
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES [Abstract]",
        "verboseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r282"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146"
     ]
    },
    "cgen_AccruedMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "AccruedMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of accrued milestone payment.",
        "label": "Accrued Milestone Payment",
        "terseLabel": "Accrued milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r292",
      "r293",
      "r294",
      "r309"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "AgreementMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement [Member]",
        "label": "Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "AgreementStartDate",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of the agreement, in CCYY-MM-DD format.",
        "label": "Agreement, start date"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AgreementTerminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "AgreementTerminationDescription",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination description.",
        "label": "Agreement termination description",
        "terseLabel": "Agreement termination description"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AmountIncurredMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "AmountIncurredMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount incurred milestone payments.",
        "label": "Amount incurred milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r79",
      "r95",
      "r108",
      "r137",
      "r139",
      "r141",
      "r147",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r220",
      "r222",
      "r227",
      "r282",
      "r299",
      "r300",
      "r311"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r96",
      "r108",
      "r147",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r220",
      "r222",
      "r227",
      "r282",
      "r299",
      "r300",
      "r311"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r147",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r220",
      "r222",
      "r227",
      "r299",
      "r300",
      "r311"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_AtMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "AtMarketOfferingProgramMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Program [Member]",
        "label": "At Market Offering Program [Member]",
        "terseLabel": "At The Market Offering Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200"
     ]
    },
    "us-gaap_BusinessDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "BusinessDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Marketing and business development expenses",
        "label": "Marketing and business development expenses",
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r94",
      "r273"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r39",
      "r40"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r68"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period of warrants.",
        "label": "Class Of Warrant Or Righst Period From Which Warrants Or Rights Exercisable",
        "terseLabel": "Expiration period of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase to ordinary shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase to ordinary shares remain outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborationAgreementWithUSAntibodyCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "CollaborationAgreementWithUSAntibodyCompanyMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement With U.S. Antibody Company [Member]",
        "label": "Collaboration Agreement With U.S. Antibody Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborativeArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "CollaborativeArrangementsMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Member]",
        "label": "Collaborative Arrangements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CollaborativeArrangementsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "CollaborativeArrangementsTwoMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements Two Member.",
        "label": "Collaborative Arrangements Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_CommercialLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "CommercialLicenseAgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial License Agreement [Member]",
        "label": "Commercial License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4)",
        "verboseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 4)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r74",
      "r84"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-cac"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r149",
      "r150",
      "r261",
      "r298"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r309"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, par value per share",
        "verboseLabel": "Ordinary shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "label": "Ordinary shares, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares of NIS 0.01 par value per share: 200,000,000 shares authorized on June 30, 2021 and December 31, 2020; 83,917,929 and 83,675,856 shares issued and outstanding on June 30, 2021 and December 31, 2020, respectively",
        "terseLabel": "Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized on June 30, 2022, and December 31, 2021; 86,624,643 and 86,433,432 shares issued and outstanding on June 30, 2022, and December 31, 2021, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r282"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r98",
      "r100",
      "r104",
      "r247",
      "r251"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of credit risks",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r134"
     ]
    },
    "cgen_ContingentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "ContingentFees",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent fees.",
        "label": "Contingent fees",
        "terseLabel": "Contingent fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-rpbatd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties' expenses amounts charged to research and development expenses",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_DeferredParticipationOfBmsInRdExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "DeferredParticipationOfBmsInRdExpenses",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred participation of BMS in R&amp;amp;D expenses.",
        "label": "Deferred Participation Of Bms In Rd Expenses",
        "terseLabel": "Deferred participation of BMS in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r45"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-rpbatd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables",
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r86",
      "r157",
      "r158",
      "r159",
      "r163",
      "r164",
      "r165",
      "r239",
      "r291"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per share",
        "terseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r124",
      "r126",
      "r128",
      "r129",
      "r130",
      "r132",
      "r225",
      "r226",
      "r248",
      "r252",
      "r276"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r126",
      "r128",
      "r129",
      "r130",
      "r132",
      "r225",
      "r226",
      "r248",
      "r252",
      "r276"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period over which compensation expense will be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized estimated compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation ESPP",
        "documentation": "The amount of plan compensation cost recognized during the period."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r90",
      "r101",
      "r102",
      "r103",
      "r111",
      "r112",
      "r113",
      "r115",
      "r121",
      "r123",
      "r133",
      "r148",
      "r167",
      "r202",
      "r203",
      "r204",
      "r211",
      "r212",
      "r224",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r236",
      "r255",
      "r256",
      "r257"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity investment",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "cgen_FinancialIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "FinancialIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      },
      "http://cgen.com/role/cgen-find": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl",
      "http://cgen.com/role/cgen-find"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate of financial and other income net of expense.",
        "negatedLabel": "Financial and other income, net",
        "label": "Financial Income Expense Net",
        "totalLabel": "Financial and other income, net",
        "verboseLabel": "Financial and other income, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "GainContingenciesByNatureAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Contingencies, Nature [Axis]",
        "documentation": "Information by nature of gain contingency."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_GainContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "GainContingencyNatureDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain from property and equipment disposal",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "cgen_GovernmentAndOtherGrantsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "GovernmentAndOtherGrantsAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Other Grants [Axis]",
        "label": "Government and Other Grants [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "GovernmentAndOtherGrantsDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government And Other Grants [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "GovernmentAndOtherGrantsLineItems",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government And Other Grants [Line Items]",
        "label": "Government and Other Grants [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "GovernmentAndOtherGrantsMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Other Grants [Member]",
        "label": "Government and Other Grants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_GovernmentAndOtherGrantsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "GovernmentAndOtherGrantsTable",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government And Other Grants [Table]",
        "label": "Government and Other Grants [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "GuaranteeObligationsMaximumExposure",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security",
        "terseLabel": "Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security",
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "localname": "IL",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before taxes on income",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes on income",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r69",
      "r76",
      "r88",
      "r137",
      "r138",
      "r140",
      "r142",
      "r249",
      "r277"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/TaxesOnIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r208",
      "r209",
      "r210",
      "r213",
      "r215",
      "r217",
      "r218",
      "r219"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes on income",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122",
      "r123",
      "r136",
      "r207",
      "r214",
      "r216",
      "r253"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 130.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in trade receivables",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in other accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 120.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in trade payables",
        "terseLabel": "Increase (decrease) in trade payables",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in other accounts receivable and prepaid expenses",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in interest receivables from short-term bank deposits",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred participation in R&amp;amp;D expenses.",
        "label": "Increase Decrease In Deferred Participation In Research And Development Expenses",
        "terseLabel": "Decrease in deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 110.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in operating lease right of use asset.",
        "negatedLabel": "Decrease in operating lease right of use asset",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in operating lease liability",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in long-term prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-find": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-find"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "totalLabel": "Interest Income, Deposits with Financial Institutions, Total",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r135"
     ]
    },
    "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of investment in Compugen",
        "documentation": "Nominal or face amount on the investment owned."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72",
      "r82",
      "r282",
      "r290",
      "r295",
      "r310"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r93",
      "r108",
      "r147",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r221",
      "r222",
      "r223",
      "r227",
      "r282",
      "r299",
      "r311",
      "r312"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r108",
      "r147",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r221",
      "r222",
      "r223",
      "r227",
      "r299",
      "r311",
      "r312"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON- CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_LongTermDeferredParticipationinResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "LongTermDeferredParticipationinResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term deferred participation in R&amp;amp;D expenses.",
        "label": "Long Term Deferred Participationin Research And Development Expenses",
        "verboseLabel": "Long-term deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MasterClinicalAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "MasterClinicalAgreementMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement [Member]",
        "label": "Master Clinical Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "MaximumAuthorizedProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum authorized proceeds from issuance of common stock.",
        "label": "Maximum Authorized Proceeds From Issuance Of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "MaximumMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r169",
      "r245",
      "r254",
      "r271",
      "r272",
      "r278",
      "r280",
      "r284",
      "r301",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "MaximumRoyaltyRepaidAsPercentageOfGrantReceived",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Royalty Repaid As Percentage Of Grant Received",
        "label": "Maximum royalty repaid as percentage of grant received",
        "terseLabel": "Maximum royalty repaid as percentage of grant received"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_May2012AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "May2012AgreementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the May 2012 Agreement.",
        "label": "May 2012 Agreement [Member]",
        "terseLabel": "May 2012 Agreement With Advisor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "MinimumMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r169",
      "r245",
      "r254",
      "r271",
      "r272",
      "r278",
      "r280",
      "r284",
      "r301",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r38"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-csocl",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net loss",
        "label": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r38",
      "r77",
      "r87",
      "r91",
      "r97",
      "r99",
      "r103",
      "r108",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r122",
      "r123",
      "r127",
      "r137",
      "r138",
      "r140",
      "r142",
      "r147",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r226",
      "r227",
      "r277",
      "r299"
     ]
    },
    "cgen_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted, that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements, not yet adopted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "verboseLabel": "Warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total operating expenses",
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current maturity of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right to use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL [Abstract]",
        "verboseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-g"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r65"
     ]
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable and accrued expenses",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL AND OTHER INCOME, NET [Abstract]",
        "verboseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-fin"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "FINANCIAL AND OTHER INCOME, NET",
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r61"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-find": {
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-find"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Exchange rate differences and other",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_OtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term bank deposits",
        "documentation": "Amount of short-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r85",
      "r287"
     ]
    },
    "cgen_ParticipationRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "ParticipationRights",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to advisor.",
        "label": "Participation Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance expenses",
        "verboseLabel": "Issuance expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in short-term bank deposits",
        "label": "Payments to Acquire Short-term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "cgen_PercentageOfClosingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "PercentageOfClosingPrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing price.",
        "label": "Percentage of closing price"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_PercentageOfRoyaltiesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "PercentageOfRoyaltiesOnNetSales",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties on net sales.",
        "label": "Percentage of royalties on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PostemploymentBenefitsLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance pay",
        "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts receivable and prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term prepaid expenses",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from ordinary shares in offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of ordinary shares, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturity of short-term bank deposits",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Equity Method Investments",
        "verboseLabel": "Proceeds from equity investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sales of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r58"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from warrant exercised",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_PropertyLeaseGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PropertyLeaseGuaranteeMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office leases [Member]",
        "documentation": "A guarantee of performance by a third party lessee under terms of a lease agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r83",
      "r250",
      "r282"
     ]
    },
    "cgen_PurchaseOfPropertyAndEquipmentAsNonCashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "PurchaseOfPropertyAndEquipmentAsNonCashTransaction",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchase property and equipment as non cash transaction.",
        "negatedLabel": "Purchase of property and equipment",
        "label": "Purchase Of Property And Equipment As Non Cash Transaction",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "RangeAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "verboseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r168",
      "r169",
      "r197",
      "r198",
      "r199",
      "r244",
      "r245",
      "r254",
      "r271",
      "r272",
      "r278",
      "r280",
      "r284",
      "r296",
      "r301",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "RangeMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r168",
      "r169",
      "r197",
      "r198",
      "r199",
      "r244",
      "r245",
      "r254",
      "r271",
      "r272",
      "r278",
      "r280",
      "r284",
      "r296",
      "r301",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "cgen_ReceivablesOnAccountOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "ReceivablesOnAccountOfShares",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables on account of shares.",
        "label": "Receivables On Account Of Shares",
        "terseLabel": "Receivables on account of shares"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered direct offering [Member]",
        "label": "Registered direct offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RelatedPartyBalancesAndTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "RelatedPartyBalancesAndTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances And Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS [Abstract]",
        "verboseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-rpbat"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241"
     ]
    },
    "cgen_RelativeFairValueOfDeferredParticipation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "RelativeFairValueOfDeferredParticipation",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relative fair value of deferred participation.",
        "label": "Relative Fair Value Of Deferred Participation",
        "verboseLabel": "Relative fair value of deferred participation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront payment received",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Payments Receivable",
        "terseLabel": "Potential milestone compensation"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone compensation company is now eligible for.",
        "label": "Research And Development Arrangement Payments Receivable On Remaining Program",
        "verboseLabel": "Potential milestone compensation company is now eligible for"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Preclinical Payments Receivable",
        "terseLabel": "Preclinical milestone compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses, net",
        "label": "Research and development expenses, net",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r89",
      "r319"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r94"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://cgen.com/role/cgen-gd1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of workforce reduction from restructuring activities",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r81",
      "r258",
      "r259",
      "r282"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit [Member]",
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r111",
      "r112",
      "r113",
      "r115",
      "r121",
      "r123",
      "r148",
      "r202",
      "r203",
      "r204",
      "r211",
      "r212",
      "r224",
      "r255",
      "r257"
     ]
    },
    "cgen_RetainerFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "RetainerFee",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retainer fee per month.",
        "label": "Retainer Fee",
        "terseLabel": "Retainer fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275"
     ]
    },
    "cgen_RoyaltyContingentObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "RoyaltyContingentObligations",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.",
        "label": "Royalty Contingent Obligations",
        "terseLabel": "Contingent royalty obligations"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_RoyaltyPercentageBasedOnFutureRevenues": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "RoyaltyPercentageBasedOnFutureRevenues",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Percentage Based On Future Revenues",
        "label": "Royalty percentage based on future revenues",
        "terseLabel": "Royalty percentage based on future revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-fint"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of financial and other income, net",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party balances and transactions",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted-average Assumptions Used to Estimate Fair Value of Options Granted",
        "terseLabel": "Schedule of weighted-average assumptions used to estimate fair value of options granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "auth_ref": [
      "r143",
      "r144",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r279",
      "r283",
      "r302"
     ]
    },
    "cgen_SeverancePayFundNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "SeverancePayFundNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.",
        "label": "Severance Pay Fund Non Current",
        "terseLabel": "Severance pay fund"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_SeverancePayNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "SeverancePayNet",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance pay, net.",
        "label": "Severance Pay Net",
        "terseLabel": "Decrease in severance pay, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected risk free interest rate range, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected risk free interest rates range, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares available for issuance | shares",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of options granted during period",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "verboseLabel": "Number of shares purchased for ESPP",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted, exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cgen.com/role/Disclosure-SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r205",
      "r206"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted, exercise price, minimum",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted, exercise price, maximum",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-se1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r60"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "ShortTermDeferredParticipationInResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term deferred participation in R&amp;amp;D expenses.",
        "label": "Short Term Deferred Participation In Research And Development Expenses",
        "verboseLabel": "Short-term deferred participation in R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cgen.com/role/cgen-sap1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r107"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r51",
      "r90",
      "r101",
      "r102",
      "r103",
      "r111",
      "r112",
      "r113",
      "r115",
      "r121",
      "r123",
      "r133",
      "r148",
      "r167",
      "r202",
      "r203",
      "r204",
      "r211",
      "r212",
      "r224",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r236",
      "r255",
      "r256",
      "r257"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "verboseLabel": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r279",
      "r283",
      "r302"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-set",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementTable",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/cgen-set",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r133",
      "r246"
     ]
    },
    "cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "StockBasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation relating to options issued to employees and directors.",
        "label": "Stock Based Compensation Relating To Options Issued To Employees And Directors Value",
        "terseLabel": "Stock-based compensation issued to employees, directors and non-employees",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares pursuant to the ESPP, shares",
        "terseLabel": "Issuance of ESPP shares, (in shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r51",
      "r52"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares, net, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r51",
      "r52"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r51",
      "r52",
      "r181"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares pursuant to the ESPP",
        "terseLabel": "Issuance of ESPP shares",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r51",
      "r52"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Value of shares issued",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r51",
      "r52"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r51",
      "r52"
     ]
    },
    "cgen_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation stock options",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cgen.com/role/cgen-cbs": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cgen.com/role/cgen-cbs",
      "http://cgen.com/role/cgen-socise1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders' equity",
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r44",
      "r282",
      "r290",
      "r295",
      "r310"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cgen.com/role/cgen-cbs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails",
      "http://cgen.com/role/ShareholdersEquityScheduleOfStock-basedCompensationDetails",
      "http://cgen.com/role/cgen-set"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SupplyCommitmentArrangementMember",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r71",
      "r80"
     ]
    },
    "us-gaap_SupplyCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SupplyCommitmentAxis",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Commitment [Axis]",
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r71",
      "r80"
     ]
    },
    "cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "SvbLeerinkLlcAndStifelNicolausAndCompanyMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]",
        "label": "Svb Leerink Llc And Stifel Nicolaus And Company [Member]",
        "terseLabel": "SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "cgen_UnauditedInterimConsolidatedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "UnauditedInterimConsolidatedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Interim Consolidated Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_UnauditedInterimConsolidatedFinancialStatementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "UnauditedInterimConsolidatedFinancialStatementsTextBlock",
     "presentation": [
      "http://cgen.com/role/UnauditedInterimConsolidatedFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of unaudited interim consolidated financial statements.",
        "label": "Unaudited Interim Consolidated Financial Statements [Text Block]",
        "verboseLabel": "UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "cgen_UnderwritersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cgen.com/20220630",
     "localname": "UnderwritersMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters [Member]",
        "label": "Underwriters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "WarrantMember",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityIssuanceOfSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r130"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in computing basic and diluted net loss per share",
        "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r130"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.12)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "730",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "730",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "730",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "10",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6431724&loc=d3e32938-113948"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "20",
   "Section": "10",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6438156&loc=d3e57880-113973"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "230",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "940",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.5)",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03.17)",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "105",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "7",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "7",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "15",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "272",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "9",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "440",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "440",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "80",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "1D",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "14",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "270",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "17",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "848",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "910",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "924",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "235",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "360",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "948",
   "SubTopic": "310",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "954",
   "SubTopic": "440",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "976",
   "SubTopic": "310",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "978",
   "SubTopic": "310",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "80",
   "Section": "55",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "852",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "55",
   "Paragraph": "29F",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "410",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "712",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665"
  },
  "r304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "712",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665"
  },
  "r305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "852",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "852",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "912",
   "SubTopic": "730",
   "Section": "25",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>41
<FILENAME>0001178913-22-002918-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-22-002918-xbrl.zip
M4$L#!!0    ( !4X!%46OZ&%*@P  *QJ   1    8V=E;BTR,#(R,#8S,"YX
M<V3M7-USVS82?^]?P?/+Y69.ENTTN<;CI$-+E*,96?1)<I,^=2 2DC A018
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M?RECP Q&&O+'_6283ZE4E)"MCHLP 0D))/E:.^67<G3Q@E"BYCV#4LOH&/W
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M)XIQ1<BQ;MZ_(KTB@=N KC6+?D8&,()G#^K5;P?7K5OHLPT#Y>!P+;16B*X
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MPP@"AA+/JJH%+3$<IA[)JJJ<EGOH(Y4AW-P )"8R=$R%OJY:K\9#HE8?P+!
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MM/-,PKY+-1OM%)#,2+CB5%(< Y:/TMYSE?F"@ZP^Y#RC$,"PP!GT7\Z5TFO
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M27FHQ9U+97M_5Q: KN/F^<K0==Q=7QFZCMOOP>@^N32\C9)D&J+7>N'.>Q>
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M:,T%, YO 96D*X7\9DDI=7&/C;3S\\$SQ99E$GD7,W':JN$N&: P:?GTA\*
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MS(29%5E^KG+(E#8FBE7'(QBC)B@==\5SA8)E'R^SI[>&G#8F(%^1=4P\RH9
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MN!+U#'ZAZ5,N[#B$8U^Z49^X\T)1)M-C9V<&#D2;VKM4TR'K_:-FJ&ZW&"@
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MNABX23)=B'SKT_B>+I_2+.OZ'8P[R?^8B+\FI] 9ZDB#O1C:U@/\F76Z*,Z
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M45:$;)FE8$"=IQR+BSB$;[LP+(%"@;UAM'*=Y2OPX!%PD>?(WC@>+AL;.<^
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M3-092RIW3J'S'V: .@I3$1!?1-@?2X \TX:YH21.4.]FI1%LBC,107+*;^/
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MVZT6MR^MRH<>5Y&335-S ;15!.E0$S#ERA8X+'[,AW(SO0BY"=KR5=X#WYC
MH*W&3P"W&3?.U 999UR'TAQ"=.J02B&M?M;HB,;(8FC(SM!7;$C MYZU0>8=
M;^5HL%)"M*O+VY6[-B6-:%?[JAV2W5-&M*M*V>[ZT])*R-6MQH1BZ_02[6I7
MB6L!,K)0R 6MQF_=XSD_G)DM^E7!$C\NM$P95LFK,>#'GVN38WL U5#%Z222
MY9-3Z@TKAB)I0SF].KN<#H)>34E).8DZ.Y1&2R*>=*><3.-6085RH'*<QZV3
MRL]YR@E3UU9':=/M3DUYJ5 Y;3NKP&^<M@T94H45[9VV71.I<EJ.NTF.!AR5
M*YDJ)_>!^5*YS<:-F5HY53J_!\9'%65Y6SF1W^XC0GT.5T[TSL^2\9UL:1E?
M.1$[MY<8'Q'[2 K+Z7D0+2C4DI4C;2PG[QM\5K5*/,L)]OY6ZCL!K?#(2R2U
M\LX5]]83L.,\@NOX<9]^[ZTLNN!14+?UX61VP9"UAYQ6%&$0E2@#_U50I=+D
MNP&CO2;@JJ A%E"NM<)6 %&E/S@!IKT>XBJ@*K?[)D%5:0FNNN:"W!+ERHM8
M]5RA?- $_%8%RO4H(\:AQ>::">T+=5[<&$V=IMQ&-PG#>),H5DA!M5"0L(\<
MVRZ4RG=0KTO96!]T$P;B(.F;,.2!Z9L H5^S%A'4[ISP^W4 P,Q#R6!A-,#I
MI8"@OFU)_YBI/;H4$ 9HMM+'I;QRGAT;OA(19JH90GEOXU2Y8HC@K;UJZR@]
MBJ"$^H\R:S3VLJEQ>CZ\4:9EZ1N)#U5M$\1DXE@EX_[K6#<2U. C@"^]5,R@
MELH&M.IX[S_8M?UT5"3VWO?ZIGCW=P=Y+ ?ZTH4&- %/'M/"0=QC,8PY/#:U
M&C?:'0<%UT2&W4/?1$\IV$FF7!O+A[8G=.0$SDT?^HJ$L5"88?YXYQ$]FT#T
M+5TQ%@*3K"'ZIJWW3=G>[".,)/F>8RQPZZ^5X]EJ0R86T1,(9AX$ Q6HRI(I
M.4(FZ!.5ATP4^7H)3!E#HF! FB+'-2[Z#>:^YV\!JGOIK1-XV$7&Z1-%G>F$
MYG/7CF=ZEF.ZE<7GH(FT] G&X#9(YJ$E,![*43F\RL5MB<0\C=+J%(V75LP+
M(JW27X2BYF^4A0ABYA%L'\U(L0##6>])AONN7"R70X2QIBH78E<Q6/HEJ% Q
MFSA YS"I"VPE_Z"@Q+F"<A&'RRV5;DB9]!1T:--*XFV@R\]Q?@BLDO\SZ6ID
M:8\[XYLRC!Y]1SH_7-Q/__TPG2^GO\,_[A7'+\>/(?A/#!&9/B/[*4_D,F&*
M^ICE/4"6D.H7<*OO L#G<TK\:4"O!X&N%.<."9F^E,2FV_#+"0(//8%_^W]0
M2P,$%     @ %3@$5:0&>Y4>)   @N<! !    !E>&AI8FET7SDY+3$N:'1M
M[5U9<]M(DG[?B/T/M>J9;G<,2/,^)-NQLB3W:%>6/*)Z)W;>"D"1Q H'&X=D
M]J_?S*S"P4,'+1Z@5(H9-PGBJ,K\\LXJ?!C'GOOIW_^-L0]CP6WZ!)]C)W;%
MIP_OY7_5P?^H5-B%8PD_$C:+@T/VK__^3?Y$?Z>!E7C"CYD5"A[#*4GD^"/V
M.0RX'3KV2+!OUU=#QQ6LT:AVJXUJN]9I%JX_"2;3T!F-8U;O]]NLPAJU1J-X
M>:4B!_I>C?2#&=A39HZLP W"CP<_#>GO@$7QU!4?#X:!'U>&W'/<Z2'[Y<;Q
M1,0NQ3V[#CSN_V(P.F*P2(3.\(C1V9'SISAD]=HD/F*Q^!Y7N.N,_$/FBB$<
MH><<LI]J]'=T($=C.W<I@<8AHPL^'@"18A%F0S&#T!9PJ1_XXHC);Q4SB./
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M_8[5LX15MUKMAM5OU>N\S1OVD-=JG5Y+ WX%>)44\ !J6]P)-YA0I#5QN0\
M)4<#E#LCG )>+3C+<B) +"+X'M0^LT&7LV]C'@E6!VZ,$>D@*-RGLZ(XL1U@
MN+P7&@"X6SP6B\-D<+%ON0E=!A($C'4Y1"PD'_ H$)K/(8 K<-G7J0C!-_HC
M<4RSU)(#=L&L=VIM;@D!%D+ ER'OF7:SW^4MRVIKR5D!I^63G*\!*'YNWW'?
M OF9A,*"L_#&: U&(?<D;(=.&,45B'V)V6P2Q"!B#IQ%D07*!%Q:.;\\A0/
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MQ)"=?1=6$CM ^*OAT,$IPB!2::XRQ<=S=A\DK@W8N17(AGC,_=NE@R)IP$G
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MNUT&=3KIL0FI[G6,=KUG=.L;J#+KC-I;!U?3Z/9Q^UL-+@VN#6BN%OR_4]^
M#Z_!]=;!!9JKV3?ZO9UL+KJ>FD+Z"0YSTQ79+T_-_8,9/O9S?MLB88HWM5S!
M0YK7^(AY/!PY?B4.)G"'VB3.CJ0=)G3P@#GVQX/3P;<OW\!E_1P*?GL,_Q09
M5WS"!$ZJF'A6A0\!YH>,N_=\&BV[SRSS/XQ#X OXL;9 QM"'/!:1G4**$37L
M[5HR%]E"1+^F+*O5(,Y-Z40[E*M8YJ<:_2T+@M.?@."SE)S]1KQCR'< A 4^
M^L>#V@%]5ZTZ]!UG_6>CW^KR?M?NMMJMEFB:O&G5.I9IU]N-EFWVVMD\J0-G
MR#W'G1ZR7VX<#V*!2W'/K@./^[\8C(X8+!*A,U3].I'SIT@9.#/KHERZ8A@O
M3/U@"23ES)9%2FJ$,X]X0& >E^KBN"SA TB.V#.;D4ZNOG[[_;>S2W9Q<UI=
M9QA8CLE=GIY=#LY.&7P:7%V<GQ[?P)?/QQ?'ER=G;/#WL[.; 8.#QWL\\X-/
M[WZO#JK,#ER7AP!E"'+C<9!$$-E&/Q39/Z9,46.^3'S7(Y=/BN*,Y*9*HVGV
MAZ)1'XIFIV75VKS5KG7-3FLX[/*6+:RB_:')K";/J_3B+=_88YU.1!E6PLZU
MHRK>J 6E<P-J;$P-L/]*?,&:-6-[_LVV%DEKYC_%_%-A"<H)-NO[R?\-- )K
MY;-%Y=.H;:+RIA5/V1D/?-] @X)6.!IWC^/N=Y\GMA,+>R_!MZ_,GV7M)MMQ
M2RWIFZ+I1EE( ]\6_[8H%YI^FX)ZIO&?U>ZS8D9^J58_'@S.;@8O;T=XV4RV
M;5!7'-2&->^+:+0)NU<JII&C]X8XMA&-LA9=D0YX0[KBM7I6VC)KR_P#TG:2
MA"%$: RF*^(U[(ZGE7T)E;WFV+YQ;#-J1145NYT?Z58^X='88!;\R\0?B0./
M!KV!-<YQ$,85X+8'%/%OF2TF0>3$$?4FAR**0\?"]F2\<G/Z1;=9;;;-JM\U
M&KW>'K58:125$$7U>M?H=O:I#73CBGAI1G0S#N#!IZMX+$+&+0ON#!HZ%)8
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MT"O'+"J6[#,OC:2,<N5_'!E"WKY53GMAR3$6P;!JV2,;MCP%FRNW0RF8RW]
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MI.LHF<&'FS]N[D:#/V]NAZ,1:<\/+T$NS+H;#6\'U_W'FVLP>L3_L/-7AE]
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M0.$[_AR5^7T)NBB2- #3F2$+:,;$G*,,*U.$B2],_ )-_)YOXD^>D7$12/B
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M%K:ZLM1J*]^WVI!8N[R([6=DH*F6D_TWU5Z16O\/LLRSRSKOZ\!A.LVOC2A
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M@\<1&#U]'@VN!_V'?\6XYMUB.Q=#7%I'W-"T[*'WV^,A82,D&5T\$1V;NIH
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MU>$E5\0(P*H,*[DBYB3DZA@>ADBTG8)_0,.%UA+(--56X=T-+E_PKFP$BR,
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MQA!QNU23ZFL6>*>BD+7*=F\7<,GAUBTG*P:OJP%O:ILJLPZ#4;/53F%$^E&
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M/.OF&'/'0 ZP(<US)>O$DDTV(0#_H[H3S $WP)R(J[L!]H\)VN'#04+!;MY
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M0^>)/%GO TSCWU33&2ONL9[;D0:;](#96_,%6>R5-M>2$D0W<^C@JB3YO)?
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MA2HF?L<?V./0GX2:Z#*.XWV+<WMH[5 LBKD:%.2<22IPY5*CR"04)"XG3F;
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M5<N1P2"%RFM*,4C#WN2B#5+342XKGS^CH';V:[/#I;,$K ]LE==7)-S:!GT
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MNO;V]67V?;J:/8#GZ<OJ)[B;?I_.[V=+ F^P>IG.E]/[U>-BOD0C[]P?!W%
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M,[Q[3C' +0N.'UM_-VC%/3ZALJU5],'XP2 -!7^X(AE1OT+BXM]CKT94>OM
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MAK*GTQ1["?U:WWZB7SMKKWX%_P=02P,$%     @ %3@$5=6/OFBX!P  _1\
M !    !E>&AI8FET7SDY+3,N:'1MW1G;<AI']GVK]A_.XMC>5 $")*SH8E5A
M)+O8E9!62 _)6\], UV>Z9YT]X#(U^><GCL@"7GCQ ZER]!S[O<S<SJW47CV
MSW\ G,XY"]P57EMA0WYVNI?^SP[_U6K!I?"Y-#P JX[AE_]^2F^YS[GRDXA+
M"[[FS")(8H2<P0>M6*!%,.-P<WL]%2&'7J]]V.ZU^YUW^Q7\H8I76LSF%KI'
M1WUH0:_3ZU716ZU4T+U,TE-/!2OP9KX*E7[?>#5UGP88NPKY^\942=N:LDB$
MJV-X>R<B;F#,EW"K(B;?-L&=-,%P+:8GX*"-^(T?0[<3VQ.P_,&V6"AF\AA"
M/L43Q^<87G7<YZ212A.(16Z@N0:'\+Z!1K)<%Z)X2@<<4:62_ 32;RU/6:LB
M9!<_@%&A", +F?^YN&]5? P'ZS?GG$SDA'PH14I51U2$F6F5R*"U?JNJ3RK>
M"41,SX1LD7K'P!*KBB.=<G%GC5R_4M7T2ZY>E;1#7"?3;^_WR::AD+Q5:-#N
M]3.[/^ZEU$E5'RTS=$^%P3:%]<S[=Z_?;T+^Y\?"3'2KTP3Z^3'W.&E CM$1
M"[.S!=."25N>.OVL9M),\21S8^/L-#F[>)@+3U@X.FKOG^XEF#&/V6A#]<;9
MFU?==YV3QU&V>>P/MV#C[&HP'GRZN+H8W[V=P/EH,KR?3$;78QB,S_%W</GS
M9#2!ZX]P>S&YO[QSE]<W%[>#.P2:.*B_7(6/H_%@/!P-+F%X/3X?D61_J">^
M@LA;K?D2"?X<J;/\$!:=Z&_79"(>(,+SN0$N ZS[_TDDAWW,,E? F0SHHOLM
MZ8:Y2]"U3E'7%!W$#6?:GSL%SOF"ARIV[>WB(:86:$[W".^L#37(H(1L@M)P
M^X9%\<EY$WB&AA#4(*F'>BM@<:S5@XBP888KZ+[&OEH_*QOD#]V#=@=0O5 H
MB=IJL',.4Z$-*E+Z0$U3NT^UBM;($X7N!@5?13'3S,/&'*-U5)"1Z+;A#F_G
MXH(P6-6%1#I!PDG..5J?8\N+E+;B-V:)**):AS3E6J.*2-D*7\3I72%S>Y3F
MF*HP5$N:% AQK!8\\I J"5#J_D$+8U4(5RNN#4Q^383G(;4%-];Y! FK1.,(
M@:K(E7,$JT@N2W;,&.4+-Y\LA9UCP;@Z['0=!EX>=7JHI$RFS+>)1J'0A].I
MX=;YBA0H2?H8@\)G(5AL%V&% S&O@]+ XF.3LKD%T7HFB6,TG-,:<;&Y5.Q'
M+4@EIC2 DC-%-JHS-;#DP#3Y4 :);Q&BO6'A)NJ,UD#?4@5F.$@1$X5Q#@H/
M&6%5@)<<Z1UB)#X;87EFM[^WU+YB^C-W:I,*'VA.Y<8\G>1U'"_'J:1[&0'.
MA&NIUVGWUS.O].Z3)MXA3U\@W)=$0^_O' R?N$2U0Z? ((@PO8PE,RSX9A!4
M85D==I?R?K!9WN&'?KN7!T8E(+ZDNO?;!_]/<6<6:XJ76 =<UJFL%"$EC?4*
M68'FH:N?N<H[V667N"OU+[%*<Z(LO7<[1*(S3>_P]0XV^-YB]:.03/HBL[2R
MU'Y'$O7C321KBSC=!B<R.,EM\Y$*]=/.TT7IJ=2X>3?=(/GNI1%9MLVUB$3W
M^PG.%-)?87CX<R8QA@(QQ4$#SS *O[8S&V>EUH^O^@4*K>=+$=@Y[>J=UQN/
M#[;MZOFM+]_5H?:HH?&2A?1/VBC6MH?+T?_N1[BR_>PVR>'@9G2':QQN1]?W
MM\.+;VHCVB5#,0MAR,P<[JEDX>AW7335 <YG"V$%%<PL4PG:)^@D@RY;,"N@
M84F5LYY8O4[[L,@LQ-N6JY7A,:N,3^9J=[^2K!G)9W(U6P!D38O S<U/EVC-
MIR'W;;%0V))82#,+ 3J*15?->PY5@6P$;L+P:MC,JENQ9F'!*Q4OY^Y';%0;
M7U*-0Y*L,HKW*DM7K'DQ@.,9;A^891 GVB0,F:!PA!&FSTB!S33G;OAR]AY0
M3_P%.Z7/X.9R6#74$W;^;A/@1JN%"-(Q:.0VM>>2(*Y@B *CD@B[A!8F2^G_
MS:PI9JUGD^'@!<DP=-W($&21#!5A4W#C-C6&#<NWJ9(N6&KQGK'*]UA<AG6-
MPG(N_#FUQH#'R@BB@VV5- @T6THW^Y3J>TQ^SB$-?J/TI$Z,+0<T$_1XWI21
M3_PEY\@%X]C!T$J]K2*UX?QY3S1W="I5MRSW+9KQ:5.G0Z3F)@DMG66(M5I1
MZO],TG]WX]_6W,IFO1?DUK3 6',#SFL;4;_%>*6!MW05I''TPC82JF6UBQ2B
M/E>S*0W2)U$I!43T7?QBE>:X>P3I*L ?<.<0QBT</(I#M>(<S)R24<54Z4VI
M0E;!GX@_3 NIJHM*2MQ)I1)K+$*0:9=,:^P)YF\9A)?BUT0$PJZ*0"M.J+?3
M,SKRBCO+PXV6$6,X6H0MF CSF=X5FDK->_/JIU[W\,243S&R"D1^(NO';.5V
M"<F9;N%D7*EWRL.1.05UD67XHS)$RE@L]#Z"XJY:U%]BD!831%NP$)MWNKDN
M>4BX&#=*6\>V7EW;V-Z)2NW9=[-6S.<LR!9>XM#<P@?K&BX\KCL4TJ0,89-C
M+1'7VM?187L_3\)O9"]Z\A7HQEO.ZBO0C?>C?\DKT*_\/@D9>'H7&U>)UJ[I
M$I#(QKW\ZG2/WI>[B^RE_^]02P,$%     @ %3@$58BLG@>I#   54T   T
M  !Z:S(R,C@R,#(N:'1M[1Q=<^(X\GU^A8ZIVTVJ8L 82""$K4Q"9G*;2;)
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M;;X:5@VE@#FU5X/"0!I0C-@:2!A)@S*QK")XN BT3IO)4&H"Z'B \6BE\N5
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M-C,P7V-A;"YX;6Q02P$"% ,4    "  5. 153&!*X9T0   :]   %0
M        @ %S%0  8V=E;BTR,#(R,#8S,%]D968N>&UL4$L! A0#%     @
M%3@$5:C'$H[T5P  O"$$ !4              ( !0R8  &-G96XM,C R,C V
M,S!?;&%B+GAM;%!+ 0(4 Q0    ( !4X!%4OY.ZT9B(  %X0 @ 5
M      "  6I^  !C9V5N+3(P,C(P-C,P7W!R92YX;6Q02P$"% ,4    "  5
M. 15I 9[E1XD  ""YP$ $               @ $#H0  97AH:6)I=%\Y.2TQ
M+FAT;5!+ 0(4 Q0    ( !4X!%4Z61B*17P  "_I"  0              "
M 4_%  !E>&AI8FET7SDY+3(N:'1M4$L! A0#%     @ %3@$5=6/OFBX!P
M_1\  !               ( !PD$! &5X:&EB:71?.3DM,RYH=&U02P$"% ,4
M    "  5. 15B*R>!ZD,  !530  #0              @ &H20$ >FLR,C(X
=,C R+FAT;5!+!08     "0 ) $ "  !\5@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
